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Chronic obstructive pulmonary disease (COPD) is a complex disorder classified as 3rd 
cause of the death worldwide1. The disease is progressive and so far there is no cure. It can be 
characterized as accelerated lung function decline, ultimately leading to death. But COPD is more 
than that, it involves inflammation in the lungs, muscle weakness and weight loss decreasing 
constantly the quality of life of patients2. Increased chances to develop COPD come with 
cigarette smoking mainly, but also air pollution plays an important role. However, only 10-15% 
of smokers develop COPD3. Main phenotypes of COPD are airway obstruction, emphysema 
and chronic bronchitis. In this thesis the focus is limited to airway obstruction and emphysema. 
Airway obstruction is a result of inflammation and remodeling of the airways, which leads to 
airway wall thickening and in consequence to airflow limitation4. The diagnosis is made based 
on spirometry, which measures forced expiratory volume in one second (FEV
1
) and forced 
vital capacity (FVC). The ratio between them is used for COPD diagnosis. According to GOLD 
criteria5 FEV
1
/FVC < 0.7 is a stage I COPD. Emphysema is a result of alveoli enlargement and 
air trapping resulting in serious tissue damage. It can be diagnosed using X-rays and nowadays 
mostly with computer tomography (CT) scan of the chest. Diagnosis based on spirometry 
parameters does not capture individuals with mild emphysema, who do not display decreased 
lung function yet. Using spirometry alone also does not allow distinguishing between COPD 
phenotypes, which are airway obstruction alone, emphysema alone and a mixed phenotype 
with both airway obstruction and emphysema present. 
Genetics of COPD – pre-GWAS era
 There is also genetic component involved in COPD, as shown in family studies6. 
Linkage analysis identified a locus on chromosome 2q7, that was later mapped to SERPINE2 
gene8. However, this finding was not confirmed by a subsequent larger study9. For many 
years the only genetic factor known to predispose to early-onset COPD was SERPINA1 gene10. 
Mutation in that gene leads to α-1 antitrypsin deficiency, which results in emphysema. However, 
the percentage of SERPINA1 caused COPD was very low (1-2% of COPD cases)10, therefore it 
was clear that other genes must be involved as well. For over two decades researchers were 
looking for these genes using a candidate gene approach. The principle of this method is to 
select a candidate for further investigation, based on what is already known, so the gene with 
a plausible function. In case of COPD three main pathways were targeted and most intensively 
studied: inflammatory, protease/anti protease and oxidative stress pathways. Despite many 
efforts candidate gene studies performed in COPD resulted in spurious results, making it 
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difficult to say which gene is associated with COPD and which one is not. Also, they mainly 
focused on airway obstruction; studies on genetics of emphysema were limited at the time. 
Studies on genetics of specific phenotypes of COPD, like for example mixed phenotype with 
airway obstruction and emphysema are lacking.
Genome-wide association studies
With the development of new technology enabling genome-wide association studies 
(GWAS) a real breakthrough in genetics of complex disorders came. The rationale behind 
GWAS is straight forward. Genome-wide genotyping is performed and given the presence of 
linkage disequilibrium (LD), not all the SNPs need to be typed. LD means that many SNPs are 
dependent on each other, so the genotype of SNP1 is sufficient to predict genotypes of SNP2 
and SNP3 (see Figure 1).
Figure 1. Genome-wide association study (GWAS) workflowLarge number of cases and controls are 
genotyped. Since there is linkage disequilibrium not all the SNPs need to be genotyped. Here four SNPs 
need to be genotyped to cover nearly entire gene. Next, genotype distributions are compared between 
cases and controls in the association test.
 If genetic component is involved in a disease, one can expect that patients will have 
different minor allele frequency (MAF) from controls for SNPs that tag loci related to the 
disease. Therefore genotyping of a large number of cases and controls is required in order to 
identify those differences (Figure 2). This number increases as the effect size, odds ratio (OR) 
decreases. Apart from large numbers needed to detect (small) genetic effects, appropriate 
and adequate phenotyping of the individuals included in the study is necessary. Mistakes in 
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determining case-control status can result in spurious and false findings. Once genotyping is 
done, another crucial and sensitive step is the quality control. It is very important to remove 
badly genotyped SNPs and samples of lower quality and confidence from the dataset prior 
to association testing. In studies combining different population factors like population 
stratification, presence of ethnic outliers, duplicates, relatives, and samples with mismatching 
gender should be carefully considered during the process of quality control2. This is in fact a 
crucial step and the more thoroughly it is performed, the better and more confident the results 
will be. Due to large number of tests performed in such a study the chances of false positive 
findings are high. There are two ways to minimize this risk: multiple testing correction and 
replication study. Multiple testing correction is usually done using Bonferroni correction, which 
determines the significance cut-off by simply dividing nominal level of significance (0.05) by 
number of tests performed. However, it has been proposed to use a fixed cut-off of 5*10e-08 
for GWA studies11. Replication study involves independent samples, in which genotyping of a 
subset of SNPs is performed. This step is very important, as it allows confirming the findings 
in other cohorts and/or populations. 
Figure 2. Relation between power of the GWA study and sample size.
COPD genetics – GWAS era
The first GWAS on COPD defined as airway obstruction was published in 200912 
and reported two loci as associated with the disease: CHRNA3/5 and HHIP. The CHRNA3/5 
locus became controversial, as it was found to be associated with lung cancer13, 14 and 
smoking addiction15 and debate on whether it is independently associated with COPD or acts 
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via cigarette smoking habits is still ongoing16. HHIP was previously identified in GWAS on 
pulmonary measures. It is an interesting finding, as hedgehog interaction protein is known to 
be involved in lung development. Second GWAS on COPD identified FAM13A gene17, which 
levels were shown to increase in hypoxia18. Same group performed one more GWAS study, 
in which locus on chromosome 19q13 was identified19. This locus contains four genes: RAB4B, 
EGLN2, MIA and CYP2A6. Same locus was also associated with smoking behavior20 and lung 
cancer21. Siedlinski studied smoking behavior of COPD patients and identified two candidate 
loci associated with age at smoking initiation: 2q21 and 6p2122. 
So far, only one GWAS on emphysema was published23 and reported BICD1 gene. This 
gene is involved in telomere length regulation24 which is an interesting finding supporting the 
hypothesis of COPD being a disease of prematurely and accelerated aging lung25. There are 
no GWA studies on COPD patients with airway obstruction and emphysema while we cannot 
exclude the possibility that different genetic factors underlie this phenotype when compared 
to pure airway obstruction.
Lung function level, decline and genetics
Lung function is simply a volume of air that can be inhaled and exhaled by the lungs. It 
is a trait that is heritable in 30-47%26, however, can be also predicted based on gender, height, 
weight, age and ethnicity. The lung development starts early in life and continues until the age 
of 20, when usually the maximal level is reached and plateau phase can be observed. Then 
around the age of 30-40 lung function level starts to drop, which is an aging related process 
known as lung function decline. However, in a disease state, like asthma or COPD, the observed 
decline is more rapid and progressive leading to premature lung function loss.
Multiple studies were conducted to investigate genetics of lung function level. The first 
GWAS on lung function measures was published in 2007 and used one of the first microarrays 
available, Affymetrix 80k27. Main findings included GSTO2 associated with mean FEV
1
 and mean 
FVC, ADARB1 associated with FEV
1
/FVC ratio and SNRPN associated with FEV
1
 decline. Two 
years later, the same group published results on pulmonary measures, where Affymetrix 550k 
platform was used, providing a better coverage of human genome28. In this study hedgehog-
interacting protein (HHIP) gene was associated with FEV
1
/FVC ratio. In 2009 another study was 
published by Repapi et al, confirming HHIP and identifying three new loci associated with FEV
1
 
(GSTCD, TNS1 and HTR4) and three with FEV
1
/FVC (AGER, THSD4 and DAAM2)29. Around the 
same time a meta-analysis was performed, including nearly 21,000 individuals in a discovery 
sample and over 16,000 in a replication set30. Three new loci were identified, GPR126 and 
ADAM19 were associated with FEV
1
/FVC ratio and INTS12 was associated with FEV
1
 level. In 
2011 a large GWAS on pulmonary measures was published, including over 48,000 individuals in 
copd.indd   12 9/2/2013   10:32:40 AM
chapter one introduction
13
a discovery set and over 46,000 in a follow up stage. This study reported 16 new loci (Figure 3)31. 
Only two studies investigated genetics of lung function decline so far. Imboden et al32 
performed a GWAS study on lung function decline in adults with and without asthma. No loci 
were identified on a genome-wide significant level. Moreover, SNPs previously associated with 
pulmonary function levels were not associated in this study with the decline. Another study 
by Hansel et al focused of determining genetic factors responsible for decline in smokers with 
mild COPD33. Two loci were identified with genome-wide significance level however, none of 
them was replicated. Locus on chromosome 10 contained TMEM26 and ANK3 genes and locus 
on chromosome 14 contained FOXA1 gene. TMEM26 and FOXA1 were shown to be expressed 
in airway epithelium and parenchyma and ANK3 in alveolar macrophages. Expression levels 
were dependent on both, COPD status and lung function.
Aim of the thesis
The general aim of this thesis is to identify genetics underlying chronic obstructive 
pulmonary disease and related phenotypes. Since COPD is a disease of accelerated lung 
function decline, we also studied genetics of it, as it could provide some answers. We also 
focused on specific subphenotypes of COPD, namely airway obstruction and emphysema, as 
frequently they co-occur. Last, but not least asthma was also a scope of our studies because 
of some resemblance to COPD. 
In Chapter 2 we tried to summarize the two decades of candidate gene studies and 
clarify the ambiguous results by performing meta-analyses on 20 polymorphisms in 12 genes 
that were studied in at least three independent publications. 
In Chapter 3 we describe a GWA study on COPD. We investigated the genetics of airway 
obstruction and emphysema, as well as an overlap between them, as in the study population we 
used – the NELSON cohort there are many individuals, who display features of both phenotypes. 
For replication we used European cohorts, gathered through COPACETIC consortium. 
Chapter 4 describes GWA study on lung function decline in a population of heavy 
smokers. For replication we used four population based cohorts: Doetinchem, Vlagtwedde/
Vlaardingen, British 1958 Birth cohort (B58C) and SAPALDIA. Additionally, we investigated 
gene-by environment interactions in Doetinchem and Vlagtwedde/Vlaardingen cohorts. We 
identified SNPs interacting with COPD status, smoking and gender.
In Chapter 5 we investigated shared genetics of asthma and COPD to check validity 
of the ‘Dutch hypothesis’ on a genome-wide level. Using the genome-wide genotyping data 
that was available for cohorts of asthma and COPD patients and controls we performed a 
meta-analysis. Subsequently, we performed two-staged replication and eQTL study on the 
most associated SNPs.
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In Chapter 6 we describe the first study aiming to identify gene-gene interactions in 
a genome-wide setup for COPD. We used the NELSON cohort for the discovery and LifeLines 
cohort for replication. 
Chapter 7 discusses the approaches taken in this thesis and future perspectives of 
genetics of COPD and complex disorders in general.
Study populations
The discovery cohort in all studies described in this thesis was the NELSON cohort. 
The NELSON cohort recruited Caucasian males of Dutch descent with smoking history of at 
least 20 pack-years to include them in lung cancer screening trial. University Medical Center 
Groningen and University Medical Center Utrecht were the study centers where patients were 
recruited and examined. Each participant underwent spirometry and computer tomography 
(CT) scan of the chest to enable diagnosis of COPD. Follow-up measurements were taken 3-4 
years later. Blood sample was obtained from each individual to enable DNA isolation.
Replication cohorts used included:
1. the Vlagtwedde/Vlaardingen cohort, a population-based cohort that recruited 
individuals from Vlagtwedde, a rural area, and Vlaardingen, an urban area in the 
Netherlands. Participants were followed for over 25 years with lung function 
measurements every 3 years. 
2. The Doetinchem cohort, a Dutch population-based cohort followed up for 10-15 years 
with lung function measurements taken every 5 years.
3. The Copenhagen City Heart Study (CCHS), is a Danish general population cohort. We 
used the third examination of the CCHs from 1991 through 1994, where 1,212 COPD 
cases were available and 3,656 controls have been matched randomly
4. Danish Lung Cancer Screening Trial (DLCST), is a cohort of heavy-smokers similar 
to the NELSON cohort, recruiting heavy-smokers. For this cohort no follow-up 
measurements were available.
5. Burden of Obstructive Lung Disease (BOLD) is a Polish cohort of 147 COPD patients 
and 355 matched healthy controls 
6. Rucphen is a cohort comprising 158 individuals, recruited from the genetic isolate in 
the Netherlands, a small village called Rucphen.
7. GLUCOLD (Groningen Leiden Universities Corticosteroids in Obstructive Lung 
Disease) study recruited 114 COPD cases with GOLD stage II or above.
8. LifeLines study consists of a population based sample of Northern part of the 
Netherlands including Caucasians of Dutch decent with detailed phenotyping 
information, including lung function measurements.
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Meta-analyses on suspected COPD genes - a summary of 20 years’ research
Joanna Smolonska1, Cisca Wijmenga1, Dirkje S Postma2, H Marike Boezen3
1 Department of Genetics, 2 Department of Pulmonology, 3 Department of 
Epidemiology University Medical Center Groningen, University of Groningen, 
Groningen, the Netherlands.
Am J Respir Crit Care Med. 2009 Oct 1;180(7):618-31
AT A GLANCE COMMENTARY
Scientific Knowledge on the Subject
For many years only one COPD gene was known. Searching for additional genes was 
based on candidate gene studies which often were impossible to replicate. Meta-
analyses can combine these studies to give them more power.
What This Study Adds to the Field
The choice of populations for a meta-analysis study or replication can strongly affect 
results, as at least some of the associations have opposite directions. 
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Abstract
Rationale: Chronic obstructive pulmonary disease (COPD) is a complex disorder with a high 
mortality worldwide. Studies on the role of candidate genes and their polymorphisms in COPD 
development have so far produced ambiguous results.
Objectives: The aim of this study was to reveal the role of COPD candidate genes using data 
collected in previous research.
Methods: We performed meta-analyses on 20 polymorphisms in 12 genes, after searching 
the PubMed and Embase databases for publications on COPD. These genes involve three 
main pathways associated with COPD development: the inflammatory, protease–anti-protease 
balance, and antioxidant pathways.
Measurements and Main Results: We obtained significant results for three TGFB1 polymorphisms 
although these were based only on a few studies. The IL1RN VNTR polymorphism increases 
the risk for COPD (OR 1.7, 95%CI 1.09-2.65), whereas the TNFA -308 G/A polymorphism does 
so only in Asian populations (OR 2.01, 95%CI 1.21-3.31). The GSTP1 I105V polymorphism was 
protective for COPD in Asian populations only (OR 0.69, 95%CI 0.56-0.85)
Conclusions: These results demonstrate the importance of ethnicity in identifying specific 
COPD genes.
Keywords: COPD, genes, polymorphism, SNP, meta-analysis, ethnicity
copd.indd   20 9/2/2013   10:33:00 AM
chapter two COPD CANDIDATE GENES META-ANALYSES
21
Introduction
 Chronic obstructive pulmonary disease (COPD) is a complex disorder characterized 
by expiratory airway obstruction and lung tissue destruction. In 2002 more than three million 
people died of COPD and, according to the World Health Organization (WHO), by 2030 COPD 
is expected to become the third leading cause of death worldwide.1 Smoking is the major risk 
factor for its development, but genetic susceptibility is thought to play a determining role in 
the development of the disease since only a relatively small proportion of smokers (10-15%)2 
develops symptomatic COPD and differences in cigarette smoke exposure account for only a 
small amount of the variation seen in lung function. Family-based and twin studies have shown 
that lung function is heritable and COPD clusters within families.
 A well-known example of a strong genetic factor predictive of the development of 
COPD is alpha-1-antitrypsin (AAT) deficiency carrier status. AAT deficiency is a very strong 
genetic trait that is related to severe, early onset COPD. The SERPINA1 gene (coding AAT – 
serine protease inhibitor, of which the main target is neutrophil elastase) was for many years 
the only genetic factor known to be associated with COPD development. However, only 1-2% 
of the COPD patients inherit this AAT deficiency,3 hence other genes are thought to play a role 
in most COPD cases. 
 Since only 10-15% of smokers develop COPD,2 the concept of the ‘genetically susceptible’ 
smoker has been proposed, i.e. a person who will develop COPD from smoking, whereas others 
will not. These susceptible smokers show a premature onset of decline in lung function and a 
more rapid rate of decline later in life compared to non-susceptible smokers. Smoking induces an 
inflammatory response and oxidative stress in the airways and lung tissue. This ultimately leads 
to increased numbers of goblet cells, airway remodeling and tissue destruction, phenotypes that 
accompany COPD. It is thus likely that genetic studies on candidate genes have initially focused 
on these typical COPD pathways induced by smoking, in addition to studying the enzymes that 
detoxify cigarette smoke products. Repair mechanisms are important as a response to lung 
tissue injury induced by cigarette smoke, so that genes involved in the protease/anti-protease 
balance are also considered to be candidate genes for COPD.
 The majority of genetic studies on COPD so far have been performed in relatively small 
samples of different ethnic populations, and resulted in unclear and sometimes contradictory 
results. Our aim was to summarize the current evidence for strong candidate genes and 
perform meta-analyses on published data in order to confirm or refute the genes’ importance 
in COPD. The genes we have studied can be grouped into three categories according to their 
function: (1) inflammatory genes, (2) genes involved in the protease/anti-protease balance, and 
(3) antioxidant genes. 
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Methods
Search strategy and selection criteria
 We performed a literature search in PubMed using “COPD [MeSH terms] and gene or 
polymorphism or pathway” for data to use in meta-analyses. We also searched PubMed and 
Embase querying for “COPD [MeSH] or pulmonary emphysema [MeSH] or COPD or chronic 
obstructive pulmonary disease [All fields] and genotype or allele or polymorphism or SNP or 
variant”, using MeSH/EMTREE terms and free text. There were no limitations of any type in our 
literature searches. Based on the literature found we selected genes and their polymorphisms for 
which we performed a second literature search, specifically looking for publications investigating 
their association with COPD. We also manually searched the references of relevant publications. 
For the meta-analyses we included only publications that described association of a particular 
polymorphism in a case-control or population-based study with clearly defined COPD with no 
other accompanying disease. The definition of COPD cases that were included had to follow 
the ATS/ERS guidelines4 or the GOLD criteria.5 Reviews and other publications like editorials and 
letters were excluded (unless containing original data). In the case of publications that reported 
only allele frequencies, but in which the authors had checked for Hardy-Weinberg equilibrium 
(HWE), we calculated genotype frequencies and used them for our meta-analyses. We further 
checked for HWE in controls among all publications reporting genotype frequencies found using 
the ‘genetics’ package for R which uses χ2 test to compare observed and expected genotype 
distributions. Publications deviating from HWE (p<0.05) were excluded. Information about the 69 
publications included in our meta-analyses can be found in Table S1 in the online supplementary 
information.
Meta-analyses
 We included only genes and polymorphisms that were described in at least three 
different studies in our meta-analyses. This led to 12 genes and 20 polymorphisms in the 
genes; these are described separately below. We investigated the following genes in relation 
to COPD: TNFA, TGFB1, IL-6, IL-1B, and IL1RN in the inflammatory pathways, MMP9 in the 
protease/anti-protease pathway, and GSTP1, GSTM1, GSTT1, EPHX1, SOD2 and SOD3 in the 
oxidative stress pathway. 
 Meta-analyses were performed using R (www.r-project.org) with the rmeta 
package. All odds ratios (ORs) for individual studies were calculated using this package from 
the contingency tables. For each meta-analysis a Woolf’s test for heterogeneity among 
publications was performed, and depending on the result, we used a fixed-effect model 
for non-heterogeneous studies (Mantel-Haenszel method) or a random-effect model for 
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heterogeneous studies (DerSimonian-Laird method). The model types are indicated in the 
relevant figures. For all meta-analyses a genetic model was also applied. A dominant model 
was used for all SNPs and a recessive model for null alleles.
Results
 We performed a two-stage literature search, as depicted in Figure 1. We started 
with a general search for publications on COPD genetics. 694 publications were found and 
their abstracts were read to determine their relevance. 188 publications passed our criteria 
and were used to select genes and their polymorphisms for a specific literature search. Of the 
selected genes, 12 had sufficient numbers of studies and we included them into meta-analyses. 
From a total of 314 publications we selected only those fulfilling our criteria described in the 
methods section. We determined genotype data from those publications and checked for 
HWE in controls. The whole process was performed independently by two investigators (JS 
and HMB). All discordances were discussed, brought to consensuses and studies were included 
or excluded unanimously. In the end 69 publications were included in our study.
Figure 1: Flow diagram showing literature search strategy 
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1. Inflammatory genes
 Inflammation is a continuous and ongoing process in the lungs of patients with COPD, 
and it is even more enhanced in severe and very severe cases.6 Epithelial cells are activated by 
cigarette smoking and their mediators further activate CD8+ cells and neutrophils, which play 
a crucial role in inflammation in COPD.7 Genes encoding these mediators have been studied for 
association with COPD.
Tumor necrosis factor alpha (TNFA)
 Many studies on this group of genes have concerned tumor necrosis factor α (TNFα), 
the key cytokine responsible for systemic inflammation, as it drives the production and secretion 
of many inflammatory mediators. TNFα plasma levels are raised in COPD and positively correlate 
with COPD severity. Thus polymorphisms in TNFA might contribute to COPD susceptibility, 
and indeed, some studies have shown associations between different TNFA polymorphisms and 
COPD,8-10 or emphysematous changes in the lungs in COPD cases.11 However, the majority of 
the studies found no associations in Caucasian12-17 or Asian18,19 populations. Our literature search 
identified 21 studies from 20 publications,8,10,14-16,18-32 including those recently published in a meta-
analysis by Gingo32 giving a total number of 3,552 cases and 3,659 controls with 1,028 cases and 
1,011 controls as carriers of the A allele. We found a non-significant increase of COPD risk with 
the -308 polymorphism known to increase promoter activity (OR 1.06, 95% CI 0.95-1.17 (figure 
2). After performing stratified analyses for Caucasians and Asians separately, the association 
remained non-significant, and became even weaker in the Caucasian populations (OR 1.02, 95% CI 
0.92-1.14). Remarkably, the association was significant in the Asian populations with an OR of 2.01 
(95% CI 1.21-3.31) (figure 2). The study by Hung resulted in an outstanding OR when compared to 
other studies. A sensitivity analysis showed that excluding the Hung study changed the result of 
this meta-analysis into non-significant (OR =1.42; 95% CI= 0.81-2.5). However, all estimates of the 
included studies were in the same direction. 
 Two other TNFA polymorphisms have been less well studied, one being a promoter 
polymorphism -238G/A, possibly increasing promoter activity. We included five publications 
reporting its genotype or allele frequencies10,15,29,30,32 in our meta-analysis, which showed an 
overall increased risk, yet non-significant risk of COPD (OR 1.10, 95% CI 0.87-1.38) (figure 3). 
The other polymorphism in the TNFα gene is located in the first intron at position +489, and 
its influence on TNFα expression is not known.33 We performed a meta-analysis on six studies 
from five publications10,18,19,30,32 and found a non-significant increase of COPD risk (OR 1.10, 95% 
CI 0.92-1.33) (figure 3). It thus seems unlikely that TNFα is associated with COPD susceptibility 
in Caucasians, although larger studies are needed to elucidate its role in Asians.
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Figure 2: Association of TNFA -308 G/A under dominant model. A fixed-effect model was used (n- 
number of cases, N- number of controls). Heterogeneity among publications: for Caucasians χ2(15)=12.48 
(p=0.64), for Asians χ2(44)=6.68 (p=0.15) and overall χ2(21)=23.31 (p=0.27).  Broekhuizen a- study with 
cachectic patients, b- study with non-cachectic patients.
Figure 3: Association of TNFA -238 and TNFA +489 with COPD under dominant model. For both analyses, 
a fixed-effect model was used. Test for heterogeneity resulted in χ2(4)=4.83 (p=0.31) and χ2(5)=6.51 
(p=0.26), respectively.
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Transforming growth factor β1 (TGF β1)
 Transforming growth factor β1 (TGF β1) is secreted by epithelial cells and macrophages 
and can cause fibrotic changes in lung tissue. A previous linkage analysis showed an association 
with chromosome 19 and identified that the association was located in the TGFB1 region 
after including additional short tandem repeat markers.34 Later studies showed inconsistent 
results and the majority failed to show significant associations. Our search resulted in seven 
publications describing associations of different TGFB1 polymorphisms with COPD, 34-40 four 
investigating associations in Caucasians, three in Asians. We performed meta-analyses on four 
TGFB1 polymorphisms (figure 4). The minor alleles of rs2241712 and rs1982073 were protective 
for COPD with OR 0.84; 95% CI 0.66-1.1 (non-significant) and OR 0.74; 95% CI 0.61-0.89, 
respectively. The third TGFB1 SNP, rs1800469, was also protective for COPD (OR 0.75; 95% 
CI 0.62-0.9). Meta-analysis of the fourth SNP, rs6957, provided a significant increased risk 
for COPD (OR 1.48, 95% CI 1.13-1.93). A summary of the significant results for TGFB1 SNPs 
regarding their putative function and direction of association is shown in Table 1. All these 
results should be considered with caution, due to the low number of appropriate studies 
available. In summary, there were too few studies reporting frequencies of TGFB1 SNPs in 
COPD patients and healthy controls. Hence it is not possible to draw any definitive conclusions 
as to their causative role in COPD development. 
Figure 4: Association of 
TGFB polymorphisms with 
COPD: rs2241712, rs1982073, 
rs1800469, and rs6957 
under dominant model. A 
random-effect model was 
used for rs1800469 (test 
for heterogeneity χ2(4)=11.65 
(p=0.02), τ2=0.1), and a fixed-
effect model was used 
for rs2241712 (χ2(2)=0.38, 
p=0.83), rs1982073 
(χ2(4)=2.19, p=0.7) and rs6957 
(χ2(2)=2.47, p=0.29).
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Interleukins (IL)
 The most frequently studied IL genes are IL10, IL6 and IL1. IL10 has been identified 
as a good candidate gene because of its anti-inflammatory potential and decreased levels in 
COPD. IL10 polymorphisms were studied in different contexts, but the number of case-control 
studies for each SNP was too low to perform an informative meta-analysis. 
 IL6 is a pro-inflammatory cytokine, hence SNPs in the gene may cause prolonged airway 
inflammation, which may contribute to COPD susceptibility. Promoter polymorphisms of IL6 
have been studied most frequently, as they can lead to altered protein levels. Because of its high 
levels in stable COPD patients, IL6 has been proposed as a marker of systemic inflammation in 
COPD. Its function as a predictor of COPD progression is not clear, since there are many sources 
of this cytokine in the human body besides the lungs41. We performed a meta-analysis on the 
-174G/C polymorphism including four publications studying Caucasian populations16,25,31,42 (figure 
5) and found no significant association with an OR 1.15 (95% CI 0.92-1.43).
Figure 5: Association of IL6 -174 G/C polymorphism under dominant model. A fixed-effect model was 
used (χ2(4)=4.83, p=0.31).
 Finally, another group of candidate genes, members of the proinflammatory interleukin 
1 (IL1) gene family (encoding two agonists IL1α and IL1β and antagonist receptor IL1RN), have 
been studied. We found eight relevant studies (four in Caucasians and four in Asians) from 
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seven publications.18,19,22,25,31,43,44 We included three IL1B polymorphisms into our meta-analyses, 
i.e. -511 C/T and -31 T/C, both suspected to alter the transcriptional activity and +3954 T/C, a 
silent substitution known to increase IL1β levels). The IL1RN VNTR (variable number of tandem 
repeats) polymorphism was also studied, always together with IL1B polymorphisms. This is 
not surprising as the IL1β /IL1RN ratio is known to be crucial in determining the severity of 
inflammatory responses45 and the IL1RN*2 allele (two repeats) has been shown to increase 
production of IL1β.46 We found a strong association between this polymorphism and risk for 
COPD in Asian populations (OR 1.70, 95% CI 1.09-2.65), as all the publications we could include 
had studied Asians (figure 6).
 We found no significant associations of SNPs in IL1B with COPD, i.e. position -511 with 
OR 1.12 (95% CI 0.74-1.7), position -31 with OR 1.3 (95% CI 0.99-1.71) and position +3954 with 
OR 0.82 (95% CI 0.63-1.07).
Figure 6: Association of polymorphisms within interleukin-1 gene family: IL1RN VNTR polymorphism, 
IL1B -511C/T, -31T/C and +3954T/C under dominant model. A random-effect model was used for IL1B 
-511C/T (χ2(6)=24.18, p=0.0001), a fixed-effect model was used for two other polymorphisms: -31T/C 
(χ2(3)=6.22, p=0.1) and +3954T/C (χ2(3)=2.19, p=0.53).
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2. Genes involved in protease–anti-protease balance
 Many proteases secreted by key inflammatory cells are involved in remodeling and 
progressive degradation of lung tissue. One of these is neutrophil elastase, which is released 
by neutrophils upon activation. Macrophages produce matrix metalloproteinases (MMPs) 
and cathepsins, which lead to elastolysis and emphysema. CD8+ cells secrete perforins and 
granzyme B which, together with TNFα, cause cytolysis and apoptosis of alveolar epithelial 
cells also contributing to emphysema.7 Although there is a broad spectrum of proteases 
involved in tissue damage in COPD, MMPs have been studied the most extensively, especially 
MMP9. We included five studies (three in Asians and two in Caucasians) on MMP9 in our meta-
analysis.47-51 The SNP at position -1562 causing a C to T transition, which is known to alter 
promoter activity,52 increased the risk for COPD, with an OR of 1.45, but the result was not 
significant (95% CI 0.84-2.50) (figure 7). More studies are needed to reveal its role. 
Figure 7: Association of MMP9 -1562C/T polymorphism under dominant model. A random-effect model 
was used (χ2(4)=14.32, p=0.0063, τ2=0.25).
 MMPs are inhibited by tissue inhibitors of metalloproteases (TIMP1-TIMP4). TIMP2 
polymorphisms have been studied and shown to be associated with COPD.53 TIMP1 also plays a 
role in COPD as its serum concentrations are elevated in COPD patients and correlate inversely 
with the level of FEV
1 
(forced expiratory volume in first second), which is a marker of COPD 
severity. It did not correlate with emphysema scores, suggesting it only plays a role in the 
development of airway obstruction.54 
 As mentioned, the SERPINA1 gene coding AAT was for many years the only known 
genetic factor associated with COPD. The SERPINA1 PI*ZZ genotype is known to cause the 
most severe AAT deficiency. Increased risk was also found for PI*MZ heterozygotes when 
compared with PI*MM individuals in a meta-analysis of 16 independent studies, although the 
level of FEV
1
 did not differ between these two groups.55 The S allele is also known to lower 
AAT levels. With a meta-analysis on SZ and MS carriers, the SZ carriers had an increased risk 
for COPD compared to normal allele carriers, PI*MM (OR 3.26, 1.24–8.57). The MS carriers had a 
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non-significant increased risk for COPD (OR 1.19, 1.02–1.38), while the number of individuals with 
a PI*SS genotype was not sufficient to perform a meta-analysis.56
3. Antioxidant genes 
 Because tobacco smoking is the main cause of COPD, genes involved in utilizing 
reactive oxygen/nitrogen species (ROS/RNS) delivered with cigarette smoke have also been 
studied. Two of the most studied genes in the antioxidant pathway are microsomal epoxide 
hydrolase (EPHX1) and glutathione S-transferase (GST) subunits P1, T1 and M1. 
Microsomal epoxide hydrolase (EPHX1)
 EPHX1 is the first line of defense against toxic epoxides provided with cigarette 
smoke and it has two polymorphisms that alter its function, Y113H and H139R, corresponding 
to slow and fast enzyme activity, respectively.57 A recent meta-analysis on EPHX58 including 
1,847 patients and 2,455 controls showed a significant increase in COPD risk (OR 1.59, 95% CI 
1.14-2.21) for the Y113H polymorphism and a non-significant reduction in COPD risk (OR 0.90, 
95% CI 0.65-1.24) for the H139R polymorphism. We included 18 studies 27,29,59-74 describing 
both polymorphisms in our meta-analyses, among them 11 in Caucasians and eight in Asians. 
The Y113H polymorphism was not associated with COPD (OR 1.02, 95% CI 0.91-1.14), also after 
stratification, in Caucasians (OR 1.02, 95% CI 0.9-1.15) and in Asians (OR 1.02, 95% CI 0.76-1.36) 
(figure 8). H139R provided a weakly protective role in COPD with a borderline significant OR 
0.91 (95% CI 0.83-1.01) (figure 9). Stratification for ethnicity confirmed there was no significant 
association in Caucasians (OR 0.96, 95% CI 0.85-1.07), but revealed a significant association in 
Asians (OR 0.76, 95% CI 0.61-0.96). 
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Figure 8: Association for EPHX Y113H polymorphism, overall and stratified analyses under dominant 
model. For all analyses a fixed-effect model was used. Heterogeneity among publications: for Caucasians 
(χ2(6)=4.08, p=0.67), for Asians (χ2(4)=6.62, p=0.16) and overall (χ2(11)=10.7, p=0.47).
Figure 9: Association for EPHX H139R polymorphism, overall and stratified analyses under dominant 
model. For all analyses a fixed-effect model was used. Heterogeneity among publications: for Caucasians 
(χ2(10)=18.2, p=0.052), for Asians (χ2(8)=5.73, p=0.45) and overall (χ2(17)=26.92, p=0.059).
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Glutathione S-transferase (GST)
 We performed meta-analyses on GSTM1 and GSTT1 null alleles (figures 10 and 11) under 
a recessive model, including 14 studies from 11 publications27,61,64,66,67,72,75-79 and one unpublished 
work (van Diemen et al) for GSTM1, with seven of the studies also covering GSTT1. Five 
of those studies investigated Asian populations and nine Caucasian populations. We found 
homozygotes for the GSTM1 null allele to have an increased risk of COPD (OR 1.3, 95% CI 
1.07-1.57). Stratified analysis confirmed this effect in Caucasian populations (OR 1.32, 95% CI 
1.04-1.68) but not in Asians (OR 1.24, 95% CI 0.85-1.8). For the GSTT1 null allele we found no 
significant associations in our overall analysis (OR 1, 95% CI 0.82-1.22) or stratified analyses 
(OR 1.2, 95%CI 0.63-2.29 and OR 0.93, 95% CI 0.73-1.19 for Caucasian and Asian populations, 
respectively).
Figure 10: Association of GSTM1 null allele overall and stratified analyses under recessive model. A 
random-effect model was used for all analyses. Heterogeneity among publications: for Caucasians 
(χ2(8)=19.8, p=0.01, τ2=0.08), for Asians (χ2(4)=9.94, p=0.0414, τ2=0.11) and overall (χ2(14)=29.81, p=0.005, 
τ2=0.07).* unpublished data
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Figure 11: Association of GSTT1 null allele overall and stratified analyses under recessive model. A random-
effect model was used in analysis for Caucasians (χ2(2)=6.81, p=0.033, τ2=0.23), and a fixed-effect model 
was used in analysis for Asians (χ2(3)=1.1, p=0.78) and overall (χ2(6)=8.74, p=0.19).
 The isoleucine to valine substitution polymorphism at position 105 of GSTP1 (I105V) 
increases both its catalytic activity for substrates and the metabolism of diol epoxides of 
polycyclic aromatic hydrocarbons.80 A second polymorphism, which has been less well studied, 
is located in exon 6 at position 114 and causes an alanine to valine substitution, which alters 
the protein function in the same way as the previous polymorphism. We combined 12 studies 
(including one unpublished, van Diemen et al) in our meta-analysis, six being conducted in 
Asians and six in Caucasians,27,64,67,71,75,78,79,81-84 which showed a non-significant protective effect 
for the I105V polymorphism (OR 0.89, 95% CI 0.73-1.1) (figure 12). However, stratified analysis 
showed a significant association in Asians (OR 0.69 95% CI 0.56-0.85), but not in Caucasians 
(OR 1.14 95% CI 0.96-1.35).
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Figure 12: Association of GSTP1 I105V polymorphism overall and stratified analyses under dominant 
model. A random-effect model was used in overall analysis (χ2(11)=23.85, p=0.013, τ2=0.07). In stratified 
analyses fixed-effect model was used for Caucasians (χ2(5)=3.82, p=0.57) and Asians (χ2(5)=7.48, p=0.19). 
* unpublished data.
Superoxide dismutases (SOD)
 Superoxide anion is delivered with cigarette smoke and is also generated in many 
resident and attracted inflammatory cells, for example in the defense processes against other 
ROS. The family of superoxide dismutases (SOD) changes this toxic anion into hydrogen peroxide. 
There are three members in this family: intracellular copper–zinc SOD (CuZnSOD), mitochondrial 
manganese SOD (MnSOD), and extracellular SOD (ECSOD), also known as SOD1, SOD2 and SOD3, 
respectively.85 Despite their important roles, genes of these enzymes have not yet been widely 
studied for associations with COPD. 
 We found four studies investigating the Ala16Val SOD2 polymorphism in COPD, three 
in Caucasians and one in Asians.86-89 Meta-analysis showed an increased risk for COPD (OR 1.07, 
95% CI 0.82-1.4) (figure 13). However, the result was non-significant, because the number of 
publications was low and the largest study,89 which influenced our meta-analysis the most, 
showed a non-significant result. More data for this polymorphism is required to reveal its role 
in COPD.
 We also found three publications reporting the association of the SOD3 R213G 
polymorphism with COPD in Caucasian populations.86,89,90 Our meta-analysis had an OR 
0.63 (95% CI 0.25-1.60) (figure 14), indicating a possible protective role by the 213G 
allele, but our result was not significant.
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Figure 13: Association of the SOD2 A16V polymorphism under dominant model. A fixed-effect model 
was used (χ2(3)=2.6, p=0.46).
Figure 14: Association of SOD3 R213G polymorphism under dominant model. A random-effect model was 
used (χ2(2)=9.45, p=0.0089, τ2=0.52).
 Recently Dahl et al91 performed a study on two newly identified SNPs in the SOD3 
(rs8192287 and rs8192288), which were found to be significantly associated with an increased 
risk for COPD hospitalization and mortality in the large, population-based, Copenhagen City 
Heart Study. They found a smaller effect in the second large cohort studied, the Copenhagen 
General Population Study. In both cohorts, associations of these SNPs were found with reduced 
FEV
1
% predicted and FVC% predicted (forced vital capacity). More recently, these results 
were partially confirmed by Siedlinski et al,89 who found an association of rs8192288 with 
reduced FVC, which was of borderline significance. They did not replicate the results for FEV
1
, 
possibly due to the low number of homozygous individuals.
Overlap with other diseases
 When considering the association between the polymorphisms in the genes and 
COPD, it appears that COPD shares some of its genetic background with other complex 
diseases. According to the HuGE database, up to 28 January 2009, 94 genes had been studied 
for association with COPD and these are involved in 89 pathways. For asthma 427 genes have 
been studied, which fall into 125 pathways, and 35 of them overlap with pathways involved 
in COPD. Table 2 shows the number of publications investigating associations for the genes 
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studied in the context of COPD with selected number of other complex diseases.
Table 2: Number of publications investigating specific genes for the various diseases.
Number of publications for each disease includes all studies ever published according to HuGe 
database. These numbers contain all types of studies, therefore not only in humans. 





TGFB1 9 24 22 94 8 9 4
TNFA 21 49 22 248 30 47 57
MMP9 7 3 - 39 3 4 2
GSTP1 13 34 - 379 4 2 1
EPHX1 16 2 - 98 - - 1
IL10 8 16 3 168 13 4 16
IL6 8 5 28 120 20 26 7
ADAM33 1 26 - 1 - - -
GSTT1 8 21 1 543 3 5 2
GSTM1 9 30 1 687 3 5 2
HMOX1 7 1 - 8 3 2 1
SOD2 2 4 - 83 3 7 -
SOD3 2 - - 3 1 2 -
 What can we infer from this? We can speculate that many diseases have a shared 
genetic background, but different (combinations of) polymorphisms in the shared genes 
determine which disease evolves. This has recently become evident for immune-related 
disorders92 but might in fact be true for other diseases as well. In addition, the type of disease 
that evolves from a shared genetic background can be determined by certain environmental 
factors, at specific windows of exposure. For example, a cigarette smoker with a -308A allele 
in TNFA gene can develop either COPD or Crohn’s disease depending on other environmental 
factors and other polymorphisms. Especially the latter are likely to be important, since complex 
disorders are determined by polymorphisms in many loci, underlying a specific genetic profile. 
So far little is known about these profiles, but new techniques like next generation sequencing 
might well be able to reveal them. 
Summary of results
 For this review we performed meta-analyses on 20 polymorphisms in 12 functional 
candidate genes that had previously been studied in at least 3 publications for association with 
COPD. Only five showed significant associations with COPD. Three of these were located in 
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TGFB1, two providing a protective effect of the minor allele (rs2241712 and rs1982073) and one 
(rs6957) gave an increased risk for COPD (OR 1.48). These results should be interpreted with 
caution as the number of studies was low. Two other polymorphisms showing a significant 
increase in COPD risk were the IL1RN VNTR polymorphism and the GSTM1 null allele (OR 1.7 
and OR 1.3, respectively). For all other polymorphisms we studied, the overall meta-analyses 
resulted in non-significant associations or had borderline significance, i.e. IL1B -31 polymorphism 
(OR 1.3, 95%CI 0.99-1.71) and H139R EPHX1 polymorphism (OR 0.91, 95% CI 0.83-1.01). Since 
ethnicity might influence the outcome of the results, we performed stratified analyses, for the 
six polymorphisms for which we had a sufficiently large number of studies, namely -308G/A in 
TNFA, Y113H and H139R in EPHX1, GSTM1 and GSTT1 null alleles, and I105V in GSTP1. 
Discussion
 The aim of this review was to reveal the roles of particular polymorphisms studied 
for association with COPD in a case-control design or in population-based studies and to 
summarize their sometimes conflicting results. The published candidate gene studies are all 
hypothesis-based. We took into account only those candidate genes that had been reported 
in a sufficient number of studies in relation to a well-defined, specific COPD phenotype. As 
shown, when critically evaluated in meta-analyses, some promising candidate genes do not 
seem to hold up at all. For example, the result of our meta-analysis on the TNFA -308G/A 
polymorphism: we included 21 studies and found a non-significant association, whereas after 
stratifying for ethnicity we did find it to be significant but only in Asians. These results are in 
contrast with those published by Gingo et al.32 This can be explained by the fact that all six 
studies included in our meta-analysis reported non-significant associations. Since Gingo et 
al did not perform analysis stratified by ethnicity, it cannot be ruled out that the association 
they observed was mostly due to a true association present in Asian populations, but not in 
Caucasian populations. 
 The result for the TNFA gene in Asian populations is based on five publications 
studying a total of 283 cases and 385 controls, with 43 and 38 carrying the A allele, respectively. 
This group is very small compared to the Caucasian population, where 3269 cases and 3274 
controls were present, 985 and 973 carrying the minor A allele, respectively. Is the effect 
really that strong in the Asian population or is there a publication bias? Results may well be 
biased, because all Asian studies reported an OR greater than 1. The Y113H polymorphism in 
EPHX was not associated with COPD in the overall analysis, and remained non-significant after 
analyses on Caucasians and Asians separately. For H139R in EPHX, as in our overall analysis, 
the association was non-significant in Caucasians but showed a significant protective effect 
in Asian populations, which is of interest because the total number of Caucasians included 
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was over four times that of Asians (2347 versus 679 cases and 4069 versus 808 controls). 
Stratified analysis for GSTM1 confirmed an increased risk for COPD, but only in Caucasians 
and, again, this group was much larger than the Asian group. The GSTT1 null allele was not 
associated with COPD in the overall analysis and this was also true in both Caucasian and 
Asian populations. By this we confirmed the results published by Hu et al93 on a GSTM1 and 
GSTT1 meta-analysis. They found significant increase in COPD risk for the GSTM1 null allele in 
overall (OR 1.46, 95% CI 1.16-1.83) and stratified analysis in non-Asians only (OR 1.57, 95% CI 
1.19-2.07). The GSTP1 I105V polymorphism was found to have a protective role in Asians, even 
for the relatively small numbers of subjects studied, suggesting its possible strong effect 
in this population. Interestingly, the same polymorphism seems to have an opposite effect 
in Caucasians (figure 12). These results show the importance of ethnicity in genetic studies, 
as some associations were present in one group but absent in another. Clearly, most of the 
polymorphisms we described were investigated in Caucasian populations. Thus combined 
analyses could yield diminished results or, on the contrary, indicate general associations which 
are in fact present in only one of the groups. We also showed that more studies are needed 
for most of the polymorphisms investigated here, especially in Asian populations, before more 
conclusive answers can be given.
 There are several limitations to our study. First, despite carefully selecting the studies, 
we cannot ensure homogeneity in either the case or control groups. Normally, COPD patients 
are or have been smokers, although this was not always an explicit criterion in the studies 
included in our meta-analyses (see table E1 in the online supplementary information). Controls 
should be matched for age, sex and, most of all, smoking history. Specifically the smoking 
habits, a crucial feature in studies on the etiology of COPD, are often not known, for example if 
the control groups are blood donors. Even more importantly, lung function measurements were 
not performed in this group, so individuals with low lung function may have been included. 
Some of the studies included blood donors as controls and this may have affected the outcome 
of the study strongly, for example it might have led to the discovery of strong associations, 
which would be observed due to bias in the participants’ smoking status. 
Secondly, the number of studies we used for the meta-analyses for each polymorphism is 
sometimes insufficient to draw reliable conclusions, e.g. on the TGFB1 polymorphisms. In some 
cases, when only allele frequencies were given, we calculated genotype frequencies based on 
HWE. This should not, however, influence the outcome of our analyses, as the number of such 
studies was relatively small, and the calculated genotype frequencies should not deviate from 
the actual genotype distributions. 
 We should mention also the importance of HWE. We excluded 19 studies from some 
of our meta-analyses due to the lack of HWE in control groups. The most affected was the 
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meta-analysis on the Y113H polymorphism (eight studies were excluded). This was because of a 
well-known problem with the first primer set used for genotyping: neighboring polymorphism 
caused an overestimation of the minor allele in this polymorphism. Including all these studies 
resulted in significant outcomes in the overall analysis and in the Caucasian populations (data 
not shown), similar to another recent meta-analysis.58 Half of the studies we excluded reported 
that HWE had been checked and that no deviations had been found. In the case of IL1RN, the 
only two studies investigating the role of its polymorphism in Caucasians were also excluded 
for the same reason, leaving only Asian populations in the meta-analysis.
 There are many single studies describing association of a particular gene with specific 
(related) phenotypic outcomes, like ADAM33 (a disintegrin and metalloprotease 33) that was 
first shown to be associated with asthma, then with COPD development in the general 
population,94 and later was linked to airway hyperresponsiveness in COPD patients.95 Such 
‘loose replications’ are sometimes interpreted as further proof for a role of that specific gene 
in the broader disease definitions, but functional studies are clearly necessary to pinpoint the 
exact role of such SNPs in genes. 
 It is worth mentioning recent findings from hypothesis-free genome-wide association 
(GWA) studies on lung cancer patients, which found an association with the nicotinic 
acetylcholine receptor subunit (CHRNA) gene polymorphisms.96 There is a debate on whether 
SNPs in that region have a direct effect on lung cancer or merely mediate smoking habits. 
Hung et al did not find any association of those SNPs with nicotine dependence,97 whereas 
Thorgeisson et al98 and Young et al99 investigated genotype frequencies of the most strongly 
associated SNP found in GWA studies, rs16969968 (which is in strong linkage disequilibrium 
with rs1051730), in lung cancer patients with and without COPD, and in smoking controls, 
to check whether this association could be confounded by COPD. They found an increased 
frequency of the AA genotype in both groups compared to controls, which means that 
the CHRNA gene polymorphism is associated with COPD and with lung cancer. Despite the 
interesting results, this study shows how important it is to select cases and controls carefully 
and to avoid possible confounders. The first GWA study on COPD was published recently100 
and identified associations of the same SNPs as in lung cancer, rs8034191 and rs1051730. 
Similarly, it still remains to be elucidated whether these SNPs are associated with COPD itself 
or whether this association is mainly seen because of nicotine addiction among COPD patients, 
although Pillai et al found no association with pack-years smoked in two cohorts. This might 
be because pack-years may not be the most appropriate indicator of addiction. To answer 
these questions, more studies are needed, especially studies with quantified addiction data. 
Clearly, none of the polymorphisms investigated here appeared in the GWA studies. This can 
be explained in part by the stringent criteria applied to select SNPs for replication and the 
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relatively small initial cohort. But we cannot rule out that some of these polymorphisms may 
not be associated with COPD at all.
 In summary, we showed that many candidate genes show no association with COPD 
after combining independent studies. For the majority of the genes more studies will be 
needed to reveal their role, especially in Asian populations. We show that ethnicity is very 
important in genetic studies, and therefore should always be taken into account, given that 
some associations show different directions for different populations.
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Chronic obstructive pulmonary disease (COPD) is a complex disorder comprising airway 
obstruction and emphysema. Very often they co-exist in COPD patients. Both phenotypes are 
known to have genetic components.
Methods
We performed genome-wide association studies (GWAS) and replication studies on airway 
obstruction and emphysema in the COPACETIC study. Since we wanted to identify the shared 
genetic component of the two phenotypes, we followed a two-staged approach to identify 
plausible genes. We used an independent cohort to replicate these findings.
Results
Although the GWA studies on airway obstruction and emphysema did not yield genome-wide 
significant findings, the overlap analysis using two different approaches pointed to the focal 
adhesion pathway, which is crucial in epithelial repair mechanisms.
Conclusion
Our results suggest the focal adhesion pathway to be involved in coexistence of airway 
obstruction and emphysema. Genes composing this pathway individually point towards so 
called systemic effects of COPD, justifying further attention in future studies. 
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Introduction
 The burden of COPD is increasing and it is expected to become the 3rd cause of 
death worldwide by 2030.1 Besides cigarette smoking, an established risk factor for COPD, 
air pollution and other environmental exposures can contribute to the onset of COPD. Genetic 
factors are also known to contribute to disease risk,2 and a large number of candidate gene 
studies have indicated several genes to be associated with COPD. However, these studies were 
not able to unequivocally point to causal genes or variants for COPD (reviewed in Smolonska 
et. al3). This might be due to the fact that COPD is a heterogeneous disorder comprising the 
presence of airway obstruction and emphysema as a single phenotype or both at the same 
time.4 Airway obstruction involves inflammation and remodeling of the airways resulting in 
airway wall thickening in bronchi and bronchioles, leading to airflow limitation. Emphysema is 
defined as destruction of lung tissue resulting in alveolar enlargement leading to air trapping.5 It 
is plausible that specific genetic features may underlie airway obstruction without emphysema 
and emphysema without airway obstruction, and potentially shared genes underlying the 
mixed phenotype of these two. Patients are usually diagnosed with COPD merely based on 
their lung function, according to the GOLD criteria (Global Initiative for Chronic Obstructive 
Lung Disease).6 However, this does not elucidate whether the airway obstruction is due to 
inflammation and remodeling of the airway wall or results from loss of elastic lung tissue as 
present in emphysema.7
 In the past few years, much effort has been put into unraveling the genetics of COPD 
defined based on lung function measurements. Genome-wide association studies (GWAS) 
have revealed HHIP, CHRNA3/5 and FAM13A loci to be associated with COPD defined as 
airway obstruction (FEV
1
/VC < 70%)8, 9 and BICD110 loci to be associated with the emphysema 
phenotype that is not captured by lung function alone. A few recent studies have confirmed 
that these genes in fact play a role in both COPD phenotypes. 11, 12 
 We have taken a hypothesis-free approach to investigatewhether there is shared 
genetics underlying airway obstruction and emphysema. If present, this might explain why 
some COPD patients display features of both sub-phenotypes.
Materials and methods
Study design
 Within the COPACETIC consortium framework we performed a genome-wide 
association (GWA) study on airway obstruction (case-control) and a GWA study on 
emphysema (quantitative trait) using the NELSON study (see Supplementary Material). Since 
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these datasets contained a significant proportion of overlapping individuals, a meta-analysis 
on shared genetics of both phenotypes could not be performed. We followed the analysis 
strategy shown in Figure 1. For details see Statistical analysis section.
Figure 1. Analytical strategy.
Discovery cohort
 We studied participants of the NELSON study which is a population-based cohort 
established as a lung cancer screening trial that included middle-aged, male, heavy smokers 
(>20 packyears) from two university medical centers in The Netherlands, Groningen and 
Utrecht. All participants performed spirometry and underwent computer tomography (CT) 
scanning to determine the presence of airway obstruction and emphysema respectively. A 
detailed description of this cohort can be found in van Iersel et al.13
Replication cohort
 The Multi-Ethnic Study of Atherosclerosis (MESA) was used as a separate replication 
cohort. MESA is a longitudinal study of subclinical cardiovascular disease and risk factors that 
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predict progression to clinically overt cardiovascular disease or progression of the subclinical 
disease.14 Between 2000 and 2002, MESA recruited 6,814 men and women 45 to 84 years of age 
from Forsyth County, North Carolina; New York City; Baltimore; St. Paul, Minnesota; Chicago; and 
Los Angeles. Exclusion criteria were clinical cardiovascular disease, weight exceeding 136 kg 
(300 lb.), pregnancy, and impediment to long-term participation. A small number of additional 
participants were included from the MESA Air Pollution Study, which recruited in Los Angeles 
and Rockland County, New York, under the MESA criteria except that participants were ages 
50 to 89 years.15 Given the race/ethnic distribution of NELSON, we limited the MESA sample 
for replication to Caucasians.
 
Phenotype definitions
 Airway obstruction cases were defined as having a (pre-bronchodilator) FEV
1
/FVC < 
0.7. Controls were defined as having FEV
1
/FVC > 0.7 and FEV1 > 90% predicted. 
 Firstly, emphysema was investigated as a quantitative trait based on CT scan 
measurements. We used the 15th percentile of density distribution (p15) in the lungs. To correct 
for scanner variations, density values in each scan were shifted to ensure that pure air located 
in the trachea had a density corresponding to -1000 HU. 
Secondly, presence and absence of emphysema was defined according to the lowest and 
highest quartile of the emphysema distribution, being P25<<-925HU and P75>-898HU respectively 
(see Statistical analysis for details on a second approach).
Emphysema measures were obtained on full-lung screening CT scans in NELSON and partial-
lung cardiac CT scans in MESA.16 The latter was adjusted for attenuation of air outside the 
body and has been previously validated compared to full-lung scans.17
Genotyping and quality control
 DNA samples were hybridized on Illumina Quad610 BeadChip containing over 
620,000 markers providing whole genome coverage. Genotypes were called with the 
standard algorithm provided by Illumina and implemented in GenomeStudio software. Quality 
control, as well as analysis, was performed with PLINK18. SNPs were excluded if a deviation 
from Hardy-Weinberg equilibrium was observed (p<0.0001) in controls only in the airway 
obstruction analysis (n=16,003) and in all subjects in the emphysema analysis (n=3,036). SNPs 
were excluded also in case of missing genotypes in more than 5% of samples (i.e. airway 
obstruction n=38,842, emphysema n=10,107) or if minor allele frequency was below 5% (i.e. 
airway obstruction n=53,681, emphysema n=64,251). Samples were excluded if more than 5% 
of genotype data was missing (i.e. airway obstruction n=24, emphysema n= 19) or in case of 
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duplicate samples (n= 29); detected as an ethnic outlier (based on genetic distance derived 
from principal components c1 and c2; n= 49); derived from a relative of another participant 
(based on IBS estimation, Phat > 0.5, n= 13); or had a diagnosis of lung cancer (n=16).
 Participants in the original MESA cohort who consented to genetic analyses were 
genotyped in 2009 using the Affymetrix Human SNP array 6.0. Data were filtered on SNP level 
call rate <95%, individual level call rate <95%, heterozygosity >53%, and all monomorphic SNPs 
were removed.
Statistical analysis
 To identify genetic overlap between airway obstruction and emphysema, we selected 
SNPs with p<0.001 from each GWA analysis and checked if the two resulting lists of top hits 
contained overlapping SNPs (supplementary data). Next, to check whether findings from this 
approach are not due to chance, we selected a subset of cases from NELSON participants that 
had both obstruction and emphysema (FEV
1





>90% predicted and p15>-898HU) as controls to perform case-
control analysis (second approach). We compared these groups using the Chi-squared test.
 For replication of the NELSON findings among Caucasians in MESA, we excluded 
individuals with top principal components (PCs) of ancestry > 3.5 SD. Based on our examination 
of principal components within each race/ethnic group, we used 3 PCs to account for 
population structure within the MESA.  Genetic analyses were performed as closely as possible 
to those performed in the NELSON cohort, with some modifications to account for study-
specific confounders in MESA.
To replicate findings of the NELSON study on airway obstruction and emphysema overlap the 
following analyses were performed in the MESA cohort: 
1) Linear regression on p15 adjusted for packyears, age, ex-/current smoking status 
and gender and logistic regression within cases with (AO+) and without (AO-) airway 
obstruction to replicate nine SNPs resulting from the top hits lists comparison
2) Logistic regression adjusting for gender within airway obstruction cases with 
emphysema (FEV
1
<0.7 and p15<-925HU; AO+E+) and without emphysema (FEV
1
<0.7 
and p15>-898 HU; AO+E-) to replicate SNPs found in case-control analysis (p<5*10-05).
Networks and pathways
 We used publicly available tools to identify networks of genes or proteins and 
checked if they represent an established pathway. For the first purpose, we used GeneMANIA19, 
a web-based tool that finds genes that interact in any way (physically, genetically, etc) with 
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query genes. We used application version 3.0.4 that was accessed on 26 May. For pathway 
identification, we used GATHER20, a web-based annotation tool, that among other functions 
looks for KEGG pathways and Gene Ontology (GO) terms.
Results
Genetic overlap between airway obstruction and emphysema
 We performed GWA studies for airway obstruction and emphysema separately 
(Supplementary Material). Comparing the top 661 SNPs from the airway obstruction association 
analysis and top 700 SNPs from the emphysema association analyses respectively (based on 
p cut-off < 0.001, Figure 1), we found nine SNPs showing moderate associations with both 
airway obstruction and emphysema (Table 1). These SNPs point to ABCB1, SLC30A10, ACOT11, 
KIAA1239, and ALPK2 genes that were subsequently investigated in GeneMANIA to identify 
potential protein networks. The resulting network (Figure 2) is enriched in proteins involved 
in response to drug (GO:0042493) and focal adhesion (hsa04510) pathways. Interestingly, the 
network includes IGLL1 and PARVA genes that, among others, were also identified amongst 
the genes close to the 25 most significant SNPs from our case-control study comparing 
575 airway obstruction cases with emphysema, to 178 airway obstruction cases without 
emphysema (Figure 1, Table 2) from the NELSON cohort. Although this study did not reveal 
genome-wide significant results, a pathway analysis including the ten most significant SNPs (p< 
2*10-5) again identified the focal adhesion pathway.
Table 1. 9 SNPs found to be moderately associated with airway obstruction and emphysema with the 
first approach (top hit lists comparisons).
CHR SNP A1 BETAp15 Pp15 Rank P15 ORao Pao Rank ao gene left_gene right_gene
1 rs300269 G 1.68 5.06E-04 365 0.83 6.45E-04 440 ACOT11 LOC645436 FAM151A
1 rs6700061 A -3.28 4.32E-04 322 1.43 7.19E-04 489 SLC30A10 LOC728518 LOC728528
1 rs17641611 A 2.74 1.60E-05 14 0.76 3.24E-04 221 NA LOC643779 LOC100129664
4 rs1469807 A -2.15 7.43E-05 60 1.23 7.91E-04 536 KIAA1239 LOC100130532 C4orf19
7 rs17064 T 3.19 5.75E-04 411 0.69 7.05E-04 476 ABCB1 ABCB4 RUNDC3B
13 rs1409255 C 1.76 3.28E-04 240 0.81 2.03E-04 143 NA LOC100129308 DIAPH3
18 rs9789183 G -2.52 2.50E-07 1 1.21 7.54E-04 512 NA LOC645355 TTMA
18 rs4271673 A 1.81 9.52E-04 654 0.81 8.28E-04 562 ALPK2 NEDD4L LOC100128163
20 rs6082843 A 1.62 7.97E-04 561 0.83 9.12E-04 609 NA KRT18P3 CYB5P4
BETA p15 is derived from linear regression performed on 15th percentile of density distribution, expressed 
in Hounsfield units, which has negative values. These estimates should be interpreted in the following 
way: BETA< 0 corresponds to more severe emphysema and BETA > 0 corresponds to a protective 
effect of the SNP.
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Figure 2. Network analysis for 4 genes found with first approach (comparison). In red genes predicted 
to be involved in the network and identified with the second approach (case-control analysis).
Table 2. 25 SNPs found to be associated in a second approach – case-control analysis, where cases 
suffered from airway obstruction and emphysema and controls had airway obstruction only.
CHR SNP A1 P OR gene left_gene right_gene
2 rs16863440 G 1.59E-06 0.34 NA LOC727982 SOX11
11 rs11022378 C 2.84E-06 1.79 PARVA MICALCL TEAD1
22 rs738781 G 9.03E-06 0.50 NA LOC388882 IGLL1
22 rs915583 A 9.03E-06 0.50 NA LOC388882 IGLL1
22 rs6003752 G 1.01E-05 0.50 NA LOC388882 IGLL1
22 rs5996566 C 1.21E-05 0.50 NA LOC388882 IGLL1
19 rs1613070 G 1.29E-05 0.59 KHSRP LOC390877 KHSRP
4 rs286451 A 1.39E-05 0.58 NA PAQR3 ARD1B
11 rs7110901 A 1.84E-05 2.76 LDLRAD3 LOC100128841 C11orf55
2 rs10865212 C 1.95E-05 0.57 PRKCE SRBD1 EPAS1
1 rs12403920 G 2.01E-05 2.41 NA RIMKLA ZMYND12
4 rs4975160 G 2.12E-05 0.58 NA PAQR3 ARD1B
23 rs2071583 C 2.13E-05 0.27 PHEX SMS ZNF645
16 rs7197966 A 2.68E-05 1.71 A2BP1 LOC100129334 LOC440337
4 rs6448032 G 3.26E-05 0.59 KCNIP4 PACRGL NCRNA00099
19 rs1290617 C 3.35E-05 1.72 CYP4F3 CYP4F8 LOC646575
4 rs6448033 A 3.54E-05 0.59 KCNIP4 PACRGL NCRNA00099
19 rs1290616 A 3.78E-05 1.71 CYP4F3 CYP4F8 CYP4F3
3 rs12494491 A 4.02E-05 0.59 NA SPSB4 ACPL2
5 rs17165388 A 4.15E-05 0.53 NA PPP2CA CDKL3
11 rs4755440 G 4.44E-05 2.07 LDLRAD3 LOC100128841 C11orf55
16 rs12445310 A 4.63E-05 0.55 NA CDH8 hCG_1642987
11 rs7107848 G 4.81E-05 0.51 PARVA MICALCL TEAD1
12 rs1465934 A 4.82E-05 0.51 PTPRB KCNMB4 PTPRR
12 rs2165627 C 4.82E-05 0.51 PTPRB KCNMB4 PTPRR
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For the replication we followed two approaches: 
1)  We set out to replicate the nine SNPs showing moderate associations with 
both airway obstruction and emphysema among Caucasians in the MESA study. Two 
out of the nine SNPs, i.e. rs 17641611 and rs1469807 were replicated with nominal p 
values in the emphysema association analysis (Table 3). rs17641611 (p=0.017) is located 
on chromosome 1 in a gene desert with pseudogenes and RNA coding genes. The 
second SNP, rs1469807 (p=0.023) on chromosome 4 annotates to KIAA1239. However, 
none of the overlapping nine SNPs showed an association with airway obstruction 
(Table 3). 
Table 3. 9 overlapping SNPs – replication in MESA cohort.
CHR SNP A1 N.p15 Eff.p15 SE.p15 P.p15 N.AO OR.AO CI.AO P.AO
1 rs300269 G 2421 0.43 0.58 0.46 884 0.91 0.73 - 1.13 0.37
1 rs6700061 A 2423 -0.05 1.10 0.96 886 0.80 0.54 - 1.19 0.26
1 rs17641611 A 2419 -1.84 0.77 0.02 884 1.19 0.90 - 1.58 0.21
4 rs1469807 A 2423 -1.49 0.66 0.02 886 0.85 0.67 - 1.08 0.18
7 rs17064 T 2423 0.23 1.17 0.85 886 0.90 0.58 - 1.40 0.64
13 rs1409255 C 2423 0.85 0.59 0.15 886 0.91 0.74 - 1.12 0.36
18 rs9789183 G 2423 -0.41 0.67 0.54 886 1.16 0.91 - 1.48 0.23
18 rs4271673 A 2423 0.59 0.64 0.35 886 0.93 0.73 - 1.17 0.52
20 rs6082843 A 2423 0.21 0.58 0.71 886 1.02 0.82 - 1.26 0.85
OR.AO has been converted from BETA estimate derived from logistic regression to aid comparisons 
of the results from Table 1.
2) We set out to replicate the 25 SNPs identified by comparing airway obstruction 
cases with and without emphysema, also among Caucasiansin the MESA study. Two SNPs 
showed nominal replication: rs10865212 on chromosome 2 (p=0.035) annotating to PRKCE and 
rs12403920 on chromosome 1 (p=0.039) located in the region between RIMKLA and ZMYND12. 
The third SNP rs6448032 on chromosome 4 annotating to KCNIP4 showed suggestive 
association (p=0.066)(Table 4).
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Table 4. Replication results from MESA cohort of the 25 SNPs identified in case-control analysis
CHR SNP A1 N.AOemph OR.AOemph 95% CI P.AOemph
2 rs10865212 C 243 0.41 0.18 - 0.94 0.04
1 rs12403920 G 243 4.10 1.08 - 15.61 0.04
4 rs6448032 G 243 0.45 0.19 - 1.06 0.07
19 rs1290616 A 243 1.88 0.86 - 4.08 0.11
19 rs1290617 C 243 1.85 0.84 - 4.08 0.12
16 rs7197966 A 243 0.56 0.26 - 1.18 0.13
3 rs12494491 A 243 2.03 0.76 - 5.41 0.15
4 rs286451 A 243 1.79 0.70 - 4.58 0.23
11 rs11022378 C 243 0.60 0.26 - 1.38 0.23
11 rs7110901 A 243 2.32 0.57 - 9.46 0.24
4 rs6448033 A 243 0.64 0.29 - 1.38 0.25
11 rs4755440 G 243 1.60 0.61 - 4.19 0.34
19 rs1613070 G 243 1.44 0.56 - 3.66 0.45
5 rs17165388 A 242 1.37 0.46 - 4.11 0.58
11 rs7107848 G 243 1.48 0.32 -6.92 0.62
2 rs16863440 G 243 0.81 0.22 - 3.00 0.75
22 rs5996566 C 243 0.89 0.35 - 2.23 0.80
22 rs738781 G 243 0.89 0.36 -2.22 0.80
22 rs915583 A 243 0.89 0.36 - 2.22 0.80
16 rs12445310 A 243 0.91 0.38 -2.19 0.84
4 rs4975160 G 243 1.09 0.47 - 2.51 0.84
12 rs1465934 A 243 0.94 0.35 - 2.57 0.91
12 rs2165627 C 243 0.94 0.35 - 2.57 0.91
OR.AOemph has been converted from BETA estimate derived from logistic regression to aid 
comparisons of the results from Table 2.
Discussion
 In the current study we performed an analysis on genetic overlap between the 
objective presence of airway obstruction and emphysema. We focused on the genes that 
most significantly pointed towards a network of genes involved in the focal adhesion pathway 
that is an important component of the epithelial repair. Specifically ABCB1 as a gene involved 
in both airway obstruction and emphysema is an interesting candidate. ABCB1 (MDR-1) belongs 
to the family of ABC-transporters, just as ABCC1 (MRP-1) that we previously identified as a 
candidate gene for COPD21 with functional relevance. It has been shown that Mrp1/Mdr1a/1b 
triple knock-out mice have a reduced inflammatory response upon cigarette smoke exposure, 
but the role of MDR-1 in COPD development has to be further explored.22 
 Other genes resulting from the airway obstruction-emphysema overlap analysis seem 
to be good candidates as well. ACOT11, coding for acyl-CoA thioesterase 11 has been shown 
to increase metabolic activity of brown fat tissue in mice exposed to cold.23 A specific SNP 
in this gene, rs300269, could be linked to weight loss which is an important co-morbidity in 
about half of the COPD patients.24 Since little is known about the functionality of the other 
genes, i.e. ALPK2, SLC30A10 and KIAA1239, interpretation of those results in relation to COPD 
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is difficult.
 We suggest some plausible candidates that should be investigated further in future 
studies. Some interesting pathways may emerge from our study, pathways which were 
not investigated yet in detail in relation to COPD. It is known already for quite some years, 
that COPD is not only a lung disease, comprising airway obstruction, chronic bronchitis and 
emphysema, but there are also so-called “systemic effects” accompanying the disease.25 These 
effects include among others muscle weakening and weight loss which usually correspond to 
poor prognosis in COPD patients, and often in significant drops in quality of life. Most literature 
presents these effects as a consequence or naturally occurring events during the disease 
progression, although origins and mechanisms underlying these events are poorly understood. 
We think our study broadens the spectrum of candidate genes and pathways that could be 
related to COPD, and stresses their potentially important role in COPD development. However, 
we cannot rule out the possibility that muscle weakening and higher energy expenditure 
resulting in weight loss can significantly contribute to the systemic inflammation either, since 
we do not know the sequence of events. 
 However, our results should be interpreted with caution, as none of the SNPs reached 
genome-wide significance. This might be due to a number of reasons. First, we used a single 
discovery cohort to investigate two phenotypes, hence we could not perform a meta-analysis 
to combine the results, but used a two-staged approach to strengthen our findings. However, 
the GWA studies on each of the phenotypes did not result in genome-wide significant findings. 
The power of each study (1,030 cases and 1,799 controls in airway obstruction and 3,047 
individuals in emphysema analyses) might be limited, and be an underlying factor explaining 
the lack of genome-wide significance. Although the results of the airway obstruction and 
emphysema overlap analysis were validated in an additional replication step in an independent 
cohort, further replication was not possible due to lack of cohorts with both spirometry 
and CT data available. For individual GWAS on airway obstruction (supplementary material) 
the replication was unsuccessful, most likely due to large heterogeneity between cohorts. 
Our attempt to account for it decreased the replication sample size and hence the power. 
Replication cohorts for airway obstruction were mostly general-population cohorts, which are 
certainly a lot different than the NELSON cohort being a highly selected population of heavy 
smokers. For replication of individual GWAS on emphysema two cohorts were available with 
less than 2,500 individuals in total raising again the power problem.
 We should also highlight the fact that many of the NELSON participants actually 
suffer from both airway obstruction and emphysema. Therefore, it cannot be ruled out that 
associations with airway obstruction already represent SNPs associated with emphysema as 
well. On the other hand, there is no direct overlap between results from airway obstruction 
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GWAS and emphysema GWAS (Supplementary data), which implies that the phenotypes 
are different. Further, it is known that presence of emphysema leads to airway obstruction, 
therefore “pure emphysema” cases can soon become patients with both phenotypes. It can 
not be excluded that these patients carry additional genetic load predisposing them to both 
phenotypes or the genes associated with emphysema lead also to the development of airway 
obstruction. This question could not be answered by the current study due to very small 
numbers of individuals with “pure phenotypes”. Taking this into account and results of the 
current study, we think that further research should include all (or as many as possible) aspects 
of COPD and include patients with both spirometry and CT measurements. 
 In summary, our current results suggest a possible overlap in genetic components of 
airway obstruction and emphysema. The SNPs we describe are located within genes pointing 
to focal adhesion pathway and so-called “systemic effects” of COPD. 
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COPACETIC Discovery cohort and phenotype definition
 The work described in the current manuscript was performed within the COPACETIC 
consortium framework (See Figure S1 for set up of the study).
The GWA on airway obstruction was performed 1,030 cases and 1,799 controls 
(including 846 controls from the blood bank). Airway obstruction cases were defined as having 
a (pre-bronchodilator) FEV
1
/FVC < 0.7. Controls were defined as having FEV
1
/FVC > 0.7 and 
FEV1 > 90% predicted. 
GWA study on quantitative emphysema was performed on 3,008 individuals from 
the NELSON cohort. Emphysema was investigated as a quantitative trait based on CT scan 
measurements. We used the 15th percentile of density distribution (p15) adjusted for peak 
in the trachea to account for possible center differences. We checked the normality of the 
distribution.
Statistical analysis
 The GWA on airway obstruction was performed in the identification cohort, NELSON, 
with the Chi-squared test with no additional adjustments. Likewise, each of the nine replication 
cohorts was analyzed separately, with additional adjustment for gender. Results were combined 
in a directional fixed effects (Mantel-Haenszel) meta-analysis.
 The GWA on emphysema was performed using a linear regression additive model 
with adjustment for age and pack-years smoked. The two cohorts available for replication 
(LUSI and DLCST) were analyzed likewise. Final results were obtained in a directional meta-
analysis.
COPACETIC Replication cohorts
COPACETIC Replication of airway obstruction GWAS results
 Nine independent cohorts were used as a replication sample for airway obstruction. 
The Vlagtwedde/Vlaardingen study (n=1,293) and the Doetinchem study (n= 898) are 
longitudinal, population-based cohorts of Caucasians of Dutch decent with a follow-up of 
25 and 15 years, respectively.1, 2 The Rucphen study (n= 158) and GLUCOLD study (n= 315) are 
patient populations with mild to moderate COPD (GOLD stage I and II, respectively) and their 
controls, also of Dutch descent.3, 4 Burden of Obstructive Lung Disease (BOLD) is a Polish 
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cohort of 147 COPD patients and 355 matched healthy controls5. The Copenhagen City Heart 
Study (CCHS,n= 8,627) is a population-based cohort of Danish descent with over 1,000 COPD 
cases.6 The Danish Lung Cancer Screening Trial (DLCST, n= 1,202) is a population-based cohort, 
recruited in Denmark for a lung cancer screening trial.7 NELSON Extra is an additional sample 
of the NELSON cohort (n=488). The LifeLines study consists of a population based sample of 
Northern part of the Netherlands including Caucasians of Dutch decent (n=3,724).8
COPACETIC Replication of emphysema GWAS results
Two cohorts had CT measurements and were available for emphysema associations 
replication: DCLST (n= 1,465) and German Lung Cancer Screening Intervention Trial (LUSI; 
n=1,013) which comprises individuals screened for lung cancer and COPD 
MESA Replication
 Among Caucasians enrolled into MESA with genotypic data, 886 had valid measures 
of pulmonary function and emphysema measures were available for 2,323.  Airway obstruction 
cases were defined as in COPACETIC, and there were 243 such cases among Caucasians in MESA. 
 The statistical analysis was performed as in COPACETIC, except that the following 
additional variables were included in the regression models to account for scanner effects: 
scanner, site, and milliamperes.
Replication Genotyping
Replication genotyping was done with a custom made Illumina GoldenGate array 
(airway obstruction) and Veracode assay (emphysema) containing 312 and 71 SNPs with p<5*10-
5, respectively. SNPs were clustered in GenomeStudio software with a standard algorithm and 
adjusted manually separately for each replication cohort. Quality control was performed as 
described before (main manuscript).
Accounting for heterogeneity in airway obstruction association replication
 To reduce heterogeneity to a minimum we followed the approach shown in Supplementary 
Figure 2. We performed a sensitivity analysis for every SNP separately, by excluding one cohort 
at a time. If homogeneity was achieved cohorts were included in a final meta-analysis. If no 
homogeneity was observed we performed sensitivity analysis excluding two cohorts at a time, 
using all possible pair -wise comparisons. These steps were repeated with three, four, five and 
six cohorts excluded at a time. Prior to the sensitivity analysis the minimum number of replication 
cohorts was set to be three, to ensure robustness of our results.
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 In a final association analysis, 492,339 SNPs were tested in 1,030 cases and 1,799 
controls. The genomic inflation factor (λ) equaled 1.02, indicating an appropriate quality control 
and no population stratification. Genome-wide significance was not reached by any of the 
SNPs (Supplementary Figure 3). We selected 312 SNPs with the lowest p values (p<0.0005) 
for replication in nine independent cohorts giving a total of 3,236 cases and 13,956 controls. 
None of the SNPs exceeded the Bonferroni-corrected p value in a replication phase (1.60·10-4, 
0.05/312; Supplementary Table 1) or reached genome-wide significance level after combining 
the results of the identification cohort and the replication cohorts (1.02·10-7, 0.05/492,339).
Emphysema
 We included 3,047 individuals and 522,104 SNPs in a linear regression on emphysema. 
We did not observe an abnormal deviation of association signals, as λ equaled 1.03. There were 
no genome-wide significant signals at this stage (Supplementary Figure 4). 71 SNPs with p 
<5·10-5 were selected for replication in two population-based cohorts. 2,476 individuals and 66 
SNPs passed quality checks in a replication phase. None of the SNPs reached the Bonferroni-
corrected p value (7.58·10-4, 0.05/66; Supplementary Table 2) or genome-wide significance 
level after combining all the results (9.58·10-8, 0.05/522,104).
Concluding remark
We found no genome-wise significant signals in the discovery population when 
performing the genome-wide association study, trying to identify genes involved in airway 
obstruction and emphysema, two major phenotypes of COPD. We found some SNPs with 
a trend of association in the replication cohorts, but no significance after multiple testing 
corrections, neither for airway obstruction nor for emphysema. In both cases, this can be 
explained by the fact, that these phenotypes of COPD are complex and vary much between all 
the cohorts used in this study, introducing a lot of heterogeneity.  Especially in the emphysema 
phenotype, where computer tomography is used to assess its presence, differences in type 
of CT-scanner and software used can introduce noise and make replication more difficult. 
Moreover, the size of our replication sample for the emphysema phenotype was small and 
thus had limited power. In addition, the differences between populations studied as well as 
confounding factors that were not accounted for could be the reason that major signals found 
in the discovery set were not replicated. In the GWA on airway obstruction we included blood 
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bank controls to increase the power. However, except for gender, there is no information 
available for these individuals, hence we could not account for smoking habits in this analysis. 
Also, taking into account the relatively small size of the discovery sets (1,030 cases and 1,799 
controls in the airway obstruction and 3,047 individuals in the emphysema analyses) the initial 
signals from the identification cohort could simply have been false positives. 
However in light of findings made in Soler Artigas et al9 in lung function parameters 
we think our results are valid, even despite lack of genome-wide significance. Soler Artigas 
in their meta-analysis of 23 cohorts summing up to over 48,000 individuals and replication 
sample of over 46,000 individuals identified 16 novel loci associated with lung function, among 
them transforming growth factor β (TGFB2). In the current study, GWAS in airway obstruction 
identified rs1317681 (combined p=2.17*10-06) located also in TGFB2 gene. 
In conclusion, the current study showed no genome-wide significant findings however, 
our results are suggestive and strengthened by findings from previous studies by other groups. 
Future studies should include higher numbers of cases and controls, which can be only done 
within consortia with detailed phenotyping data enabling sub-phenotype studies.Supplementary 
Figure 1. The COPACETIC study set up.
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Supplementary Figure 2. Accounting for heterogeneity – a workflow.
Supplementary Figure 3. QQ and Manhattan plots – airway obstruction association results
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Supplementary Figure 4. QQ and Manhattan plots – emphysema association results
Supplementary Table 1. Six SNPs with the lowest p value in airway obstruction analysis. 
GWAS Replication Combined
CHR SNP Gene A1 P OR P OR P OR
13 rs7337088 NA G 7.04E-05 1.45 7.01E-04 1.47 1.87E-07 1.46
8 rs189509 PNOC G 1.13E-04 1.55 7.39E-04 1.52 3.25E-07 1.54
1 rs1317681 TGFB2 A 4.47E-04 0.75 1.13E-03 0.68 2.17E-06 0.73
12 rs7956804 CD4 G 2.25E-04 0.77 1.27E-03 0.86 2.38E-06 0.83
14 rs17091195 SERPINA13 A 3.07E-05 1.37 1.39E-02 1.18 4.04E-06 1.26
18 rs930027 NA A 3.09E-04 0.73 6.40E-03 0.81 9.40E-06 0.78
Supplementary Table 2. Five SNPs with lowest p values in p15 (emphysema) analysis.
GWAS Replication Combined
CHR SNP Gene A1 P BETA P BETA P BETA
5 rs11948188 GFM2 A 1.26E-05 2.65 4.51E-03 4.19 2.91E-07 2.87
7 rs10486076 NA A 3.53E-05 -2.39 9.60E-03 -3.53 1.38E-06 -2.57
4 rs4697618 SEL1L3 A 1.04E-05 -2.48 5.50E-02 -1.41 2.96E-06 -2.09
6 rs1224526 NA A 4.72E-05 -3.12 3.04E-02 -2.09 5.71E-06 -2.72
12 rs3764875 SCNN1A G 9.66E-06 2.25 0.2824 1.35 6.41E-06 2.12
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Asthma and chronic obstructive pulmonary disease (COPD) are thought to share a genetic 
background (the “Dutch hypothesis”). 
METHODS 
We investigated whether asthma and COPD have common underlying genetic factors, 
performing genome-wide association studies for both asthma and COPD and by combining 
results in meta-analyses.
RESULTS
Three loci showed potential involvement in both diseases: chr2p24.3, chr5q23.1and chr13q14.2, 
containing DDX1, COMMD10 (both participating in the NFκβ pathway) and GNG5P5, 
respectively, as most likely candidate genes to harbor the causal variants. SNP rs9534578 
in GNG5P5 reached genome-wide significance after first stage replication (p=9.96·10-9). The 
second stage replication in two independent cohorts provided similar direction of associations, 
without significant replication. eQTL analysis performed on the top seventeen associated SNPs 
identified 3 SNPs in COMMD10 influencing gene expression levels. 
CONCLUSIONS
Although inflammatory processes differ in asthma and COPD, they are unequivocally mediated 
by NFκβ, and as suggested by our results, they could be driven by the same underlying genes, 
COMMD10 and DDX1, implying that the Dutch hypothesis may have some validity. Since none 
of the SNPs reached genome-wide significance further investigation of the loci should be 
performed to assess their role in both asthma and COPD. 
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Introduction
 Asthma and Chronic Obstructive Pulmonary Disease (COPD) are two common 
respiratory diseases, their estimated prevalences ranging from approximately 1% to 18% in 
different countries1-3. Both diseases may lead to airways obstruction, which is reversible in 
asthma in contrast to COPD. However, the diagnosis cannot rely on reversibility, as it can 
disappear with asthma progression, making asthma and COPD harder to distinguish. The 
immune mechanisms underlying the two diseases are thought to be very different, but 
similarities in inflammatory processes have been reported in both disease entities recently4. 
Classically inflammation in asthma is represented by elevated numbers of CD4+ lymphocytes 
and eosinophils, and by elevated CD8+ lymphocytes, macrophages and neutrophils in COPD5. 
However, severe asthma can be accompanied by neutrophilia6 and COPD exacerbation by 
eosinophilia7.
 Over fifty years ago, the so called ‘Dutch hypothesis’ was formulated by Orie and 
colleagues8 stating that asthma and COPD are two features of one disease entity, referred to 
as chronic non-specific lung disease (CNSLD). CNSLD was defined to result from the interplay 
of endogenous factors like genetic predisposition, and exogenous factors like viral infections, 
air pollution, tobacco smoking and allergen exposures. The timing of this interplay would then 
determine which clinical syndrome one developed during a lifetime, i.e. asthma, or COPD, or 
features of both asthma and COPD. 
 So far this hypothesis has neither been confirmed nor refuted completely9, but 
several common environmental exposures have been unequivocally identified as shared risk 
factors for both asthma and COPD, e.g. maternal smoking during pregnancy, air pollution and 
active smoking10. Genetic factors have been associated with either asthma or COPD using 
linkage11-15, candidate gene16-19 and genome-wide association studies (GWAS)20, 21. These studies 
elucidated genetic factors unique either to asthma or COPD, but additionally potentially shared 
genetic risk factors including TGFB1, TNFA, GSTP1, IL1322 and SERPINE223. ADAM33 has been 
linked to the presence of asthma24, COPD and accelerated lung function decline in the general 
population and in asthma25, 25, suggesting common underlying genetic factors of both onset 
and course of asthma and COPD26. So far, hypothesis free GWAS studies aiming to identify 
novel genes underlying both asthma and COPD in the same source population are lacking. The 
aim of our study was to identify shared genetic risk factors for asthma and COPD using an 
unbiased GWAS approach. We first performed a GWAS on asthma and COPD separately using 
individuals of Dutch descent and subsequently combined these in a meta-analysis, followed by 
3 replication studies.
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 For the identification phase (meta-analysis1), subjects were recruited as participants 
of the following cohorts: 
1. The Dutch Asthma GWAS (DAG) Study: a cohort screened for genetic studies, 
characterized by the presence of a doctor diagnosis of asthma and hyperresponsiveness.
2. The NELSON cohort study27: a population-based cohort screening for lung cancer, 
including current or ex-smokers with at least 20 pack-years. To increase power of 
the COPD set, blood bank controls from Amsterdam and Utrecht without clinical data 
except for age (range 18-65), were added. 
For the 1st replication phase (meta-analysis2) subjects were participants of the 
LifeLines cohort study (LifeLines1). 
The 2nd replication phase (meta-analyses3+4) evaluated the top 17 SNPs; subjects were 
participants of LifeLines (LifeLines2), an independent sample of LifeLines, and the SAPALDIA 
cohort.
There were no overlapping subjects in all cohorts used. All participants signed informed 
consent; studies were approved by institutional ethics committees. Detailed information and 
characteristics of the study populations are shown in Supplementary Appendix (Supplementary 
table 3 and methods).
Asthma and COPD phenotype definition 
In all cohorts, asthma was defined as having a doctor diagnosis of asthma ever, or use 
of asthma medication (beta-agonists, steroids, anticholinergics, cromoglycate, montelukast, 
theophyllines) while having 2 or more of the following symptoms: wheeze without a cold, 
an attack of breathlessness while resting, waking up with an attack of breathlessness, ever. 
Controls were defined as not having asthma. 
In all cohorts, COPD was defined as a pre-bronchodilator FEV
1
/FVC<0.7 (asthma cases 






Genotyping, quality control and imputation
All cohorts were genotyped with Illumina arrays with different SNP content. Genotypes 
were called and quality control was performed for each dataset to ensure the best quality 
(Supplementary methods). 
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Study design and statistical analyses
The analytic work flow is shown in Figure 1. Genome-wide associations on asthma 
(2,004,043 SNPs) and COPD (1,872,289 SNPs) were performed using χ2- test on a genetic 
additive model (0, 1, and 2). The results presented are crude odds ratios. The reasons for not 
adjusting are several:
1. NELSON study consisted of males only that were heavy-smokers with 20 pack-years 
at least. This forces already a specific age group, which is in this case age range of 
51-79 years of age. In addition, a use of blood bank controls does not allow making 
any adjustments, except for gender, which was not included as females were just a 
subset of controls.
2. DAG study and LifeLines asthma cohorts were not adjusted for any covariates to 
ensure the similarity of the analysis, following the NELSON cohort. LifeLines COPD 
cohorts included smoking patients, in line with the NELSON cohort characteristics.
3. SAPALDIA cohort is a multi-center study, which forces use of specific covariates, 
like area. Smoking adjustment was necessary, as analysis in COPD included also non-
smokers (in contrast with other cohorts, as shown in Table S3), as they constituted 
the 50% of an already small group of COPD patients.
Next, results were combined in a directional meta-analysis on 1,811,026 SNPs shared 
between the asthma and COPD datasets (meta-analysis1). 2,048 SNPs showing p<0.001 were 
selected for in silico replication in a second set of asthma and COPD case-control groups 
derived from the LifeLines cohort (LifeLines1). These markers were analyzed with χ2- tests and 
then combined in a second directional meta-analysis (meta-analysis2). The top 17 SNPs with 
p≤0.001 from meta-analysis2 were investigated in the second stage replication consisting of 
meta-analysis3 and meta-analysis4 in LifeLines2 and SAPALDIA, respectively.
In SAPALDIA genetic associations with asthma and COPD were tested using 
logistic regression. Models were controlled for pack-years smoking, study area and principal 
components capturing inter-European population structure. Results were combined in meta-
analysis4. 
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Figure 1. Analytic work flow 
Cis-eQTL mapping
Cis-eQTL (expression quantitative trait locus) mapping was performed as described 
previously by Fehrmann et al.28 Briefly, each probe on the expression chip was mapped and 
correlated with SNPs in the vicinity of 250kb. Principal component analysis was applied to 
the data prior to the analysis to ensure that signals detected as eQTLs are not due to e.g. 
batch effects. Analysis involved non-parametric Spearman’s rank correlation test. Because two 
different expression chips were used, when probes were present on both, the final result came 
from meta-analysis. False discovery rate was applied to account for multiple testing.
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Network analysis
Gene network was constructed using GeneMANIA. The gene set resulting from this 
approach was investigated with GATHER to identify enriched pathways.
More details are presented in Supplementary methods.
Results
Genome-wide association and meta-analyses
GWAS were performed on both asthma (921 cases, 3,246 controls) and COPD (1,030 
cases, 1,808 controls). Genomic inflation factors (λ) equaled 1.01 for both asthma and COPD, 
indicating no population stratification and presence of true association signals (Figure S1). 
Individual p-values and odds ratios (ORs) were combined in a directional meta-analysis using 
a fixed-effects model (meta-analysis1, Figure 1; this data is publicly available at The European 
Genome-phenome Archive (EGA), accession number EGAS00000000130). All 2,048 single 
nucleotide polymorphisms (SNPs) with p≤0.001 were selected for a first replication analysis 
in asthma and COPD cohorts separately, respectively 534 and 711 cases and 2,568 and 1,854 
controls. Subsequently results were combined in a meta-analysis (meta-analysis2, Figure 1). 
Seventeen SNPs replicated at p<0.001 (Table 1) in the combined meta-analysis1 and 
meta-analysis2, one SNP reaching genome wide significance. Sixteen of these 17 SNPs map to 
three genomic locations: 2p24.3, 5q23.1, and 13q14.2 (Table S1).
The chromosome 2p24.3 locus spans ~380 kb and contains genes encoding functional 
units, like processed transcripts, pseudogenes and RNA genes (Figure 2). The nearest gene with 
a known function, DEAD-box polypeptide 1 (DDX1), is ~139kb away from the top associated 
2p24.3 SNP rs1477253. The locus on chromosome 5 is ~328 kb and contains a single gene: 
COMM domain containing 10 (COMMD10) (Figure 2). The locus on chromosome 13 spans ~320 
kb and only contains a pseudogene: guanine nucleotide binding protein (G protein), gamma 
5 pseudogene 5 (GNG5P5) (Figure 2). SNP rs9534578 in GNG5P5 reached genome-wide 
significance (p = 9.96*10-9). 
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Figure 2. Regional association plots for DDX1, COMMD10 and GNG5P5 loci.








0.8 < r2 ≥ 0.5
0.5 < r2 ≥ 0.2
r2 < 0.2
copd.indd   80 9/2/2013   10:33:59 AM































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































copd.indd   81 9/2/2013   10:34:00 AM
chapter FOUR gwas ON DUTCH HYPOTHESIS
82
Replication phase 2 of top 17 SNPs 
The top 17 markers from the combined analysis were further evaluated in an independent 
sample of the LifeLines cohort (LifeLines2; 317 asthma and 2,363 controls; 601 COPD and 1,868 
controls, 14 SNPs present) and the SAPALDIA cohort (461 asthma, 118 COPD, 656 controls). 
None of the SNPs replicated at a nominal p-value <0.05 in LifeLines2 or SAPALDIA although 
nine and eight SNPs, respectively, showed similar effect estimates. Meta-analysis of all cohorts 
together did not result in genome-wide significant associations (Table 1).
eQTL analysis of top 17 SNPs
Three of the top 17 SNPs from the combined analysis showed a cis-eQTL effect, when 
correlating the genotypes with gene expression levels in 1,469 peripheral blood mononuclear 
cell samples with both GWAS and genome-wide gene expression data available28. The three 
SNPs were located in COMMD10. The risk allele (G) of rs254149 decreased COMMD10 expression 
levels; risk alleles of rs10043228 (T) and rs10036292 (G), which are in perfect LD (r2=1), increased 
COMMD10 expression levels (Figure 3). Out of these SNPs, rs254149 showed the strongest 
association and was in rather weak LD with two remaining SNPs (r2=0.292 for both, Table S1).
Network analysis
The genes found were investigated with GeneMANIA which does not support 
pseudogenes. Hence we queried only COMMD10 and DDX1. This gene enrichment approach 
resulted in a set of genes, two genes (RAD50 and MRE11A) being involved in regulation of 
mitotic recombination (Bayes factor 11, p<0.0001) and telomere maintenance (Bayes factor 
6, p<0.0001), possibly implicating COPD as a disease of rapidly aging lungs29. Another gene 
(BICD1) involved in telomere maintenance was previously reported in emphysema30.
Moreover, products of DDX1 and COMMD10 interact with NFκβ2. COMMD10 has a 
direct interaction, while DDX1 interacts with RELA and RELB, known to interact directly with 
NFκβ2 and to function in the same pathway (Figure 4).
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Figure 3. eQTLs identified for COMMD10 SNPs. Order on x-axis is from non-risk homozygote, 
heterozygote and risk homozygote for all three eQTLs
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Discussion
This is the first investigation of shared genetics of asthma and COPD in a hypothesis-
free manner using a genome-wide screening in well-defined asthma and COPD cohorts and a 
large population-based sample. We report three novel loci as potentially shared genetic factors 
between asthma and COPD, none reaching genome-wide significance in the discovery set or 
two replication cohorts. None of these three loci were previously reported to be associated 
with either asthma or COPD. However, DDX1 locus was reported in a recently published meta-
analysis of lung function31, with a p-value of 9*10-6. The T allele of rs2544527 in DDX was 
associated with lower lung function and in our study with a higher risk of both asthma and 
COPD.
The shared 5q23.1 risk locus contains the COMMD10 gene. COMMD10 is a member of 
COMM domain containing proteins32 with a largely unknown function. COMMD10 has shown 
to form a complex with COMMD1, another member of this family of proteins, which regulates 
copper metabolism and sodium uptake and inhibits NFκβ activation33. Copper and sodium 
levels are inversely regulated, i.e. when copper levels increase, sodium import in cells is inhibited 
and vice versa. Both ion levels can be regulated by COMMD1, with sodium control mediated 
through epithelial sodium channels (ENaCs) that are abundantly present in lung epithelial cells34. 
Sodium is crucial for maintaining a fluidic layer in the alveolar part of the lungs and ENaCs play 
a crucial role in this process35. It is tempting to speculate that COMMD10 is involved in this 
maintenance either through interaction with COMMD1, or independently by displaying similar 
functions as COMMD1. Also, its function in inhibition of NFκβ activation could play a role in 
regulating inflammatory processes in airways diseases.
The 13q14.2 locus contains the guanine nucleotide binding protein (G protein), gamma 
5 pseudogene 5 (GNG5P5). Poliseno et al recently showed that pseudogenes can have a 
pronounced role in regulation of their putative transcripts by competing in non-coding RNA 
binding36. It needs to be tested whether GNG5P5 can affect GNG5 levels, but it is interesting 
to note that the pseudogene is processed and has a transcript (ENST00000420444). The 
biological consequence of a change in GNG5 levels in relation to asthma and COPD pathology 
is unclear but it is well established that G proteins play a crucial role in signal transduction 
from cell surface to its interior. It is also known that G-protein coupled receptors (GPCRs) 
are involved in asthma and more generally are a target of many of the currently used asthma 
drugs37.
A third locus on 2p24.3 is bordered by the DDX1 gene, encoding DEAD-box protein 
1, RNA helicase I, and the MYCN genes whereas the locus itself contains non-protein coding 
genes including lincRNAs, ncRNAs, pseudogenes, processed transcripts and one newly 
discovered, protein-coding gene. Theoretically, any of these could be involved in asthma and 
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COPD, hindering interpretation of our findings. However, the regional association plot (Figure 
2) shows that the signal is mostly confined to AC008278.3 and AC008271.1. Further refinement 
of the region and functional assessment of the associated variants could help to potentially 
pin-point the actual causal gene. DDX1 is a plausible candidate for both asthma and COPD since 
it interacts with RELA, one of NFκβ subunits, upon which it acts as a co-activator of NFκβ-
mediated transcription38. Since this is a central and common pathway of inflammation present 
in the airways of both asthma and COPD, this may signify a unifying underlying mechanism of 
both disease entities. Further studies are needed to confirm this hypothesis.
The strengths of our study are clearly the data quality of the cohorts involved, the 
design of the study and the analysis strategy of the discovery and replication phases. There 
are some limitations to our study as well. First, we investigated Caucasians of Dutch descent 
only for discovery and used Caucasians of Swiss and Dutch descent for replication, thus our 
results are only representative of part of the Caucasian population. However, the markers 
identified were reasonably common (MAF >5%), with a likely generality to a population of 
broader ancestry. Secondly, we found no replication in an independent sample of LifeLines 
(LifeLines2), which might raise the question whether our findings are robust. One explanation 
for the lack of replication might be the somewhat lower prevalence of asthma in LifeLines2 
(7.5% versus 8.5% in LifeLines1) due to the average older age of the subjects included in 
LifeLines2. This could reflect a cohort effect or some asthma remission at elderly ages39. Since 
we did observe nominal associations with COPD in LifeLines2, but not with asthma (Table S2) 
the joint analysis did not yield nominal associations. This could be due to use of patients with 
self-reported doctor diagnosis of asthma ever. It cannot be excluded that this group consists 
in part of individuals diagnosed with asthma in childhood, who now are in complete remission. 
Replication of the top 17 SNPs in SAPALDIA was also unsuccessful, possibly due to limited 
statistical power. Important limitations common to most GWAS remain the heterogeneity 
of the phenotypes assessed, and heterogeneity between discovery and replication samples. 
Table S5 shows heterogeneity per meta-analysis performed, i.e. for each asthma-COPD meta-
analysis. It differs substantially and due to specificity of the study we could not account for 
the heterogeneity between meta-analyses. We did not want to perform meta-analysis of 
meta-analyses, hence we chose Fisher’s exact method to combine p values.  As highlighted by 
the Dutch hypothesis the importance of both type and temporal sequences of environmental 
exposures contribute to the occurrence of either phenotype. This may have affected the 
phenotypic outcome considerably and hence a crude covariate adjustment may represent 
an underestimated challenge to identify common genetic determinants of asthma and COPD. 
Recent efforts to characterize substantial number of patients diagnosed with both 
asthma and COPD40 show the increasing scientific interest in the phenotypic overlap between 
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asthma and COPD. Future studies on the underlying genetics in this group of overlap patients 
would be of interest, specifically comparing outcomes with our results. 
Overall, our results are suggestive of a role of the NFκβ pathway, a key transcription 
factor in the inflammatory response, in both asthma and COPD, suggesting that the Dutch 
hypothesis may have some validity. Since none of the SNPs reached genome-wide significance 
further investigation of the loci should be performed to assess their role in both asthma and 
COPD. Although inflammatory processes differ in asthma and COPD, they are unequivocally 
mediated by NFκβ, and as suggested by our current results, they could be driven by the same 
underlying genes, COMMD10 and DDX1. Our eQTL study supported the role of COMMD10, since 
we established that three SNPs in COMMD10 region influence expression of this gene. There 
were opposite effects of these SNPs, therefore the natural next step is to perform genome-
wide epistatic analysis in large cohorts of asthma and COPD patients to reveal the complex 
nature of interactions between SNPs and loci and their impact on the ultimate phenotype.
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For the identification phase (meta-analysis1), subjects were recruited as participants 
of the following cohorts: 
1. The Dutch Asthma GWAS (DAG) Study: a cohort screened for genetic studies, 
characterized by the presence of a doctor diagnosis of asthma and hyperresponsiveness 
and extensive phenotyping.
2. The NELSON cohort study1: a population-based cohort screening for lung cancer, 
including current or ex-smokers with at least 20 pack-years. Blood bank controls, 
collected in Amsterdam and Utrecht, were added to increase power of the COPD set, 
and except for the age (range 18-65) no clinical data were available. 
For the 1st replication phase (meta-analysis2, 2,048 SNPs) subjects were recruited as participants 
of the LifeLines cohort study.
 LifeLines2 is a biobanking initiative collecting random individuals from the general 
population and their relatives in order to perform intense phenotyping which will be used to 
better define disease type and/or subtype and relate it to genetic and environmental factors. 
Amongst others spirometry is performed (following ATS guidelines) and data on respiratory 
symptoms are collected (using standardized questionnaires) enabling a diagnosis of asthma 
and/or COPD. For purpose of current study all relatives were excluded.
 The 2nd replication phase (meta-analyses3+4) evaluated the top 17 SNPs; subjects were 
recruited as participants of the LifeLines cohort study (LifeLines2), an independent sample of 
Lifelines and the SAPALDIA cohort.
 The SAPALDIA cohort: a multi-center study in eight geographic areas representing 
the range of environmental, meteorological and socio-demographic conditions in Switzerland. 
It was initiated in 1991 (SAPALDIA1) with a follow-up assessment in 2002 (SAPALDIA2) and 
2011 (SAPALDIA3). This study has specifically been designed to investigate longitudinally lung 
function, respiratory and cardiovascular health, and to study and identify the associations of 
these health indicators with individual long term exposure to air pollution, other toxic inhalants, 
life style and molecular factors. SAPALDIA2 was used in current study.
Genotyping, quality control and imputation
The Dutch Asthma GWAS cohort was genotyped on Illumina Hap300 and Hap370 
platforms. The NELSON COPD cohort was genotyped using Illumina 610 Quad BeadChip 
containing 620,901 probes. The blood bank controls for the NELSON COPD cohort were 
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genotyped with Illumina 670 Quad BeadChip containing custom and tagging SNPs selected 
by WTCCC2. 
The LifeLines cohort was genotyped on CytoChip containing a selection of 299,140 
SNPs to tag the whole genome and capture regions most frequently used in cytogenetic 
screening. Genotypes were called with an algorithm provided by Illumina and implemented in 
Genome Studio. Quality control was performed for each dataset to ensure the best quality.
SNPs were removed if call rates were <95%, the minor allele frequency was below 5% and/
or Hardy-Weinberg equilibrium was not met (HWE; p<0.0001). Samples were removed when 
more than 5% of genotypes were missing, samples were duplicated (PI_HAT value ~ 1) or 
from individuals related to another individual in the dataset (PI_HAT>0.5) or ethnic outliers 
(based on components from multidimensional scaling C1 and C2). To enable uniform analyses 
across all datasets imputation was performed using BEAGLE 3.03 and HapMap CEU as reference 
panel (HapMap 2, release 24, genome build 36). Genotype dosages were converted to regular 
genotypes with a best-guess method. SNPs imputed with less confidence were removed 
(correlation r2<0.5). 
In the framework of the European GABRIEL study on asthma genetics, genotyping in 
the SAPALDIA cohort was done on the Illumina Human610 Quad platform at the Centre National 
de Génotypage in Evry, France on 663 asthmatics and a random sample of 997 non-asthmatic 
participants. 567589 successfully genotyped autosomal SNPs were imputed to 2.5 Mio by 
MACH v 1.0 software4 using the HapMap v22 CEPH panel of Utah residents with ancestry from 
northern and Western Europe as reference. Samples with <97% genotyping success rate, non-
European origin, cryptic relatedness or sex inconsistencies were excluded from analysis. After 
quality control procedures, genetic and covariate data from 461 cases of doctor diagnosed 
asthma, 118 cases of COPD and 656 controls was available.
Statistical analysis
 Case-control analysis was performed using Χ2 test for both asthma and COPD. 
Association results were combined in a directional meta-analysis. Same approach was used 
for later replication stages. All above mentioned analyses were performed using PLINK5 in case 
of NELSON, DAG and LifeLines cohorts. SAPALDIA performed the analysis using ProbABEL 
software version 0.1.36.
 Directions of the signals were compared between the meta-analyses and if they were 
the same results were combined with Fishers’ method using R7. We used Fishers’ method to 
combine p values resulting from meta-analyses, as meta-analysis of meta-analysis is statically 
inappropriate. 
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Network analysis
 To perform gene enrichment base on networks we used publically available tool: 
GeneMANIA8 (http://www.genemania.org/). Because GeneMANIA does not support pseudogenes, 
we queried two genes resulting from our analysis: DDX1 and COMMD10. The settings were the 
following: we chose to show up to 20 genes in the network, we used automatic weighting for 
the network. For the network creation we used only physical interactions, predicted interaction, 
pathways and coexpression. GeneMANIA was accessed on 28th September 2011.
 In order to identify the overrepresented pathways in the above mentioned network we 
used GATHER9. GATHER is web-based tool (http://gather.genome.duke.edu/), which performs 
annotations, among others, to pathways, based on the query genes. The resulting annotations 
are given Bayes factor and p value to indicate the strength of the annotation with the gene list 
provided. We queried 22 genes in total: DDX1, COMMD10 and 20 genes resulting from gene 
enrichment in GeneMANIA: SBDS, NAGLU, ROGDI, SAP30L, SAP30, ATP2A2, MTHFSD, COMMD1, 
DAB2IP, RELB, CSTF2, SETD3, CEP250, NBN, RAD50, CDK5, MRE11A, NFKB2, RELA and HNRNPK. 
GATHER was last accessed on August 3rd 2012.
Figure S1. Quantile-quantile plots for asthma and COPD GWAS
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Table S1. Linkage disequilibrium between top 17 SNPs in asthma-COPD meta-analysis with highest 
significance level 
SNP Proxy Distance RSquared DPrime Chromosome Coordinate_HG18
rs2112101 rs6728750 2055 0.867 1 chr2 15822185
rs2112101 rs2544534 3787 0.863 0.963 chr2 15823917
rs2112101 rs1477253 7778 0.863 0.963 chr2 15827908
rs2112101 rs6728667 2026 0.838 1 chr2 15822156
rs2112101 rs2693008 10340 0.828 0.927 chr2 15830470
rs2112101 rs2544523 17644 0.609 0.84 chr2 15837774
rs2112101 rs2693019 19609 0.609 0.84 chr2 15839739
rs6728667 rs6728750 29 0.966 1 chr2 15822185
rs6728667 rs2544534 1761 0.9 1 chr2 15823917
rs6728667 rs1477253 5752 0.9 1 chr2 15827908
rs6728667 rs2112101 2026 0.838 1 chr2 15820130
rs6728667 rs2693008 8314 0.804 0.962 chr2 15830470
rs6728667 rs2544523 15618 0.604 0.915 chr2 15837774
rs6728667 rs2693019 17583 0.604 0.915 chr2 15839739
rs6728750 rs6728667 29 0.966 1 chr2 15822156
rs6728750 rs2544534 1732 0.932 1 chr2 15823917
rs6728750 rs1477253 5723 0.932 1 chr2 15827908
rs6728750 rs2112101 2055 0.867 1 chr2 15820130
rs6728750 rs2693008 8285 0.833 0.963 chr2 15830470
rs6728750 rs2544523 15589 0.627 0.916 chr2 15837774
rs6728750 rs2693019 17554 0.627 0.916 chr2 15839739
rs2544534 rs1477253 3991 1 1 chr2 15827908
rs2544534 rs6728750 1732 0.932 1 chr2 15822185
rs2544534 rs6728667 1761 0.9 1 chr2 15822156
rs2544534 rs2112101 3787 0.863 0.963 chr2 15820130
rs2544534 rs2693008 6553 0.83 0.927 chr2 15830470
rs2544534 rs2544523 13857 0.676 0.918 chr2 15837774
rs2544534 rs2693019 15822 0.676 0.918 chr2 15839739
rs1477253 rs2544534 3991 1 1 chr2 15823917
rs1477253 rs6728750 5723 0.932 1 chr2 15822185
rs1477253 rs6728667 5752 0.9 1 chr2 15822156
rs1477253 rs2112101 7778 0.863 0.963 chr2 15820130
rs1477253 rs2693008 2562 0.83 0.927 chr2 15830470
rs1477253 rs2544523 9866 0.676 0.918 chr2 15837774
rs1477253 rs2693019 11831 0.676 0.918 chr2 15839739
rs2693008 rs6728750 8285 0.833 0.963 chr2 15822185
rs2693008 rs1477253 2562 0.83 0.927 chr2 15827908
rs2693008 rs2544534 6553 0.83 0.927 chr2 15823917
rs2693008 rs2112101 10340 0.828 0.927 chr2 15820130
rs2693008 rs6728667 8314 0.804 0.962 chr2 15822156
rs2693008 rs2544523 7304 0.766 0.96 chr2 15837774
rs2693008 rs2693019 9269 0.766 0.96 chr2 15839739
rs2544523 rs2693019 1965 1 1 chr2 15839739
rs2544523 rs2693008 7304 0.766 0.96 chr2 15830470
rs2544523 rs1477253 9866 0.676 0.918 chr2 15827908
rs2544523 rs2544534 13857 0.676 0.918 chr2 15823917
rs2544523 rs6728750 15589 0.627 0.916 chr2 15822185
rs2544523 rs2112101 17644 0.609 0.84 chr2 15820130
rs2544523 rs6728667 15618 0.604 0.915 chr2 15822156
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rs2693019 rs2544523 1965 1 1 chr2 15837774
rs2693019 rs2693008 9269 0.766 0.96 chr2 15830470
rs2693019 rs1477253 11831 0.676 0.918 chr2 15827908
rs2693019 rs2544534 15822 0.676 0.918 chr2 15823917
rs2693019 rs6728750 17554 0.627 0.916 chr2 15822185
rs2693019 rs2112101 19609 0.609 0.84 chr2 15820130
rs2693019 rs6728667 17583 0.604 0.915 chr2 15822156
rs10036292 rs10043228 1177 1 1 chr5 115624947
rs10036292 rs7727882 18636 1 1 chr5 115642406
rs10036292 rs254149 10049 0.292 1 chr5 115633819
rs10043228 rs10036292 1177 1 1 chr5 115623770
rs10043228 rs7727882 17459 1 1 chr5 115642406
rs10043228 rs254149 8872 0.292 1 chr5 115633819
rs254149 rs7727882 8587 0.292 1 chr5 115642406
rs254149 rs10043228 8872 0.292 1 chr5 115624947
rs254149 rs10036292 10049 0.292 1 chr5 115623770
rs7727882 rs10043228 17459 1 1 chr5 115624947
rs7727882 rs10036292 18636 1 1 chr5 115623770
rs7727882 rs254149 8587 0.292 1 chr5 115633819
rs17069787 rs9534578 3353 0.901 1 chr13 46741378
rs17069787 rs7989394 139445 0.49 0.7 chr13 46877470
rs17069787 rs7994542 976 0.489 0.894 chr13 46739001
rs7994542 rs7989394 138469 0.611 1 chr13 46877470
rs7994542 rs9534578 2377 0.551 1 chr13 46741378
rs7994542 rs17069787 976 0.489 0.894 chr13 46738025
rs9534578 rs17069787 3353 0.901 1 chr13 46738025
rs9534578 rs7994542 2377 0.551 1 chr13 46739001
rs9534578 rs7989394 136092 0.548 0.78 chr13 46877470
rs7989394 rs7994542 138469 0.611 1 chr13 46739001
rs7989394 rs9534578 136092 0.548 0.78 chr13 46741378
rs7989394 rs17069787 139445 0.49 0.7 chr13 46738025
Table S2.  Top 17 SNPs replication in LifeLines2 sample*
LifeLines 2 association signals asthma COPD
CHR SNP BP A1† A2‡ P OR P OR
2 rs2112101 15820130 T C 3.46E-01 0.9197 9.07E-02 1.123
2 rs6728667 15822156 G A 3.85E-01 0.9261 5.01E-02 1.143
2 rs6728750 15822185 G A 3.24E-01 0.9163 5.64E-02 1.139
2 rs2544534 15823917 T C 2.31E-01 0.9013 5.28E-02 1.139
2 rs1477253 15827908 T C 2.86E-01 0.9113 6.78E-02 1.131
2 rs2693008 15830470 G C 2.08E-01 0.8948 4.21E-02 1.148
2 rs2544523 15837774 T C 4.14E-01 0.9301 2.79E-02 1.161
2 rs2693019 15839739 T C 3.82E-01 0.9253 2.56E-02 1.164
5 rs10036292 115623770 G A 4.23E-01 0.8735 5.07E-02 1.266
5 rs10043228 115624947 T C 4.13E-01 0.8709 5.91E-02 1.256
5 rs254149 115633819 G C 6.48E-01 0.9482 7.11E-02 1.172
13 rs17069787 46738025 A G 9.37E-01 1.013 9.24E-01 0.9869
13 rs7994542 46739001 T C 5.92E-01 0.9349 6.26E-01 1.049
13 rs9534578 46741378 A C 6.60E-01 0.9336 7.96E-01 0.9688
* only 14 SNPs were genotyped/imputed in LifeLines2
† A1 is a minor allele and the risk allele
‡ A2 is a major allele
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Table S4. Heterogeneity between asthma and COPD cohorts.








CHR BP SNP Q I Q I Q I Q I
2 15822156 rs6728667 0.60 0.00 0.56 0.00 0.06 71.84 0.86 0.00
2 15822185 rs6728750 0.61 0.00 0.57 0.00 0.05 73.63 0.95 0.00
2 15823917 rs2544534 0.58 0.00 0.24 28.27 0.03 78.03 0.97 0.00
2 15827908 rs1477253 0.58 0.00 0.28 15.12 0.05 74.04 0.97 0.00
2 15830470 rs2693008 0.57 0.00 0.72 0.00 0.03 79.96 1.00 0.00
2 15837774 rs2544523 0.50 0.00 0.90 0.00 0.05 74.58 0.81 0.00
2 15839739 rs2693019 0.44 0.00 0.94 0.00 0.04 76.24 0.78 0.00
2 215298827 rs280621 0.63 0.00 0.14 55.22 NA NA 0.08 66.46
5 115623770 rs10036292 0.52 0.00 0.72 0.00 0.07 68.61 0.06 72.49
5 115624947 rs10043228 0.49 0.00 0.79 0.00 0.08 67.80 0.06 72.04
5 115633819 rs254149 0.73 0.00 0.40 0.00 0.15 52.30 0.03 77.59
5 115642406 rs7727882 0.57 0.00 0.81 0.00 NA NA 0.07 69.11
13 46738025 rs17069787 0.92 0.00 0.59 0.00 0.90 0.00 0.52 0.00
13 46739001 rs7994542 0.45 0.00 0.14 54.75 0.47 0.00 0.65 0.00
13 46741378 rs9534578 0.61 0.00 0.57 0.00 0.85 0.00 0.60 0.00
13 46877470 rs7989394 0.04 76.36 0.04 76.51 NA NA 0.25 23.28
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AT A GLANCE COMMENTARY
Scientific Knowledge on the Subject
Genetics of lung function decline have scarcely been studied and outcomes were 
inconsistent probably due to differences in study populations and environmental factors.
What This Study Adds to the Field
The current study identified multiple genes for lung function decline, interacting with 
smoking habits and COPD status, which indicates differential effects of the same loci in 
several subgroups. Future studies on lung function decline should include analyses stratified 
by risk factors and health status in order to detect signals that might otherwise be missed.
This article has an online data supplement, which is accessible from this issue’s table of 
content online at www.atsjournals.org
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Lung function decreases gradually with time due to ageing however, some subjects experience 
an accelerated FEV
1
 decline leading to COPD. 
OBJECTIVES 
The aim of this study was to identify genetic factors and gene-environment interactions 




We performed a genome-wide association study on accelerated FEV
1
 decline in the NELSON 
cohort, a population of heavy smoking males, with replication of the 50 most significantly 
associated SNPs in four independent replication cohorts. These SNPs were also investigated 
for interactions with COPD status and smoking history.
RESULTS 
Two SNPs were replicated at nominal level (rs7182547 and rs2458416 annotating to TM7SF4 
and TRPM1), but genome-wide significance for lung function decline was not reached. We 
identified SNPs interacting with COPD status (rs10928087) and smoking (rs2492321 annotating 
to JUN, rs12671330 and rs12705973 annotating to FOXP2 and rs4723295 annotating to BBS9). 
CONCLUSIONS 
The current study identified multiple genes interacting with smoking habits and COPD status, 
which suggests a differential effect of the same loci in several subgroups. Future studies on 
lung function decline should include stratified analyses in order to detect signals that might 
otherwise be missed. 
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Introduction
Human lung growth and development starts prenatally and continues until reaching 
a plateau. After the plateau phase which ends between 18-25 years of age1, lung function 
decreases gradually with time due to ageing. Rapid decline is observed in some smokers 
and COPD patients, which can result in early lung function impairment1;2 (Figure 1). Notably, 
the decline in FEV
1
 does not always start from an optimal FEV
1
, since not all subjects reach 
their maximal attainable level at young adulthood. Lung function impairment at elderly age can 
therefore be due to a] sub-maximally attained level of lung function, b] an abnormally early onset 
of decline, c] an abnormally high rate of decline, or d] a combination of any of these (see Figure 
1). Therefore, the genetics of these different patterns are best studied using a longitudinal 
population-based study design, covering the time span during which these different patterns 
and their underlying causes can evolve3. 
Figure 1. Lung function decline in relation to age. From Kerstjens et al (with permission)1.
a – healthy normal subjects; b – submaximal growth but normal decline; c – premature or early decline; 
d – an accelerated decline
Apart from genetics, the rate of the decline is dependent on many other factors, 
specifically cigarette smoking. Cigarette smoking may have different effects at different 
periods of life. Moreover, smoking might interact with distinct genes throughout different 
phases in life. Therefore, taking such potential gene-by-smoking interactions into account 
may lead to identification of specific genetic variants playing a role in lung function decline, 
other than those identified in genome wide association studies (GWAS)3 focusing on main 
gene effects only. Studying genetics of FEV
1
 decline in both smokers and non-smokers thus 
seems to be a crucial issue.
Most GWAS so far have focused on the level and not on decline of lung function 
4-8. Only two GWAS addressing FEV
1
 decline were published so far. The first study focused 
on decline in asthmatic and non-asthmatic subjects9. Although the top hits in this study did 
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not reach genome-wide significance, the study clearly showed that the main genetic signals 
identified differed between asthmatic and non-asthmatic subjects. The second GWAS 
identified two loci associated with decline in smokers with mild COPD10, which were distinct 
from those identified in the GWAS in asthmatics and non-asthmatics. Together, these findings 
are in line with the hypothesis that different genetic factors may affect biologically different 
pathways leading to lung function decline in different subgroups like asthmatics, subjects with 
COPD and individuals without COPD.
In the current study we aimed to identify novel genes associated with lung function 
decline in smokers and non-smokers, and studied interactions with smoking and COPD status. 
Methods
Study populations
The discovery cohort was derived from the NELSON study11 which consisted of heavy-
smoking Caucasian males of Dutch descent. Longitudinal data, with a follow-up FEV
1
 
measurement three to four years after the baseline FEV
1
 measurement were available for 1,942 
males with age ranging from 47.0 to 76.9 years. We performed replication in four population-
based cohorts, being:
1. The Vlagtwedde/Vlaardingen cohort, a Dutch population-based cohort including individuals 
from Vlagtwedde, a rural area, and Vlaardingen, an urban area in the Netherlands. Participants 
were followed for over 25 years with lung function measurements every 3 years. The age of 
participants ranged from 35.0 to 79.0 years. Details have been described previously12.
2. The Doetinchem cohort, a Dutch population-based cohort followed up for 10-15 years 
with lung function measurements every 5 years. Participants were aged from 31.2 to 70.9 
years. Details have been described previously13.
3. The SAPALDIA cohort, a multi-center study in eight geographic areas representing the 
range of environmental, meteorological and socio-demographic conditions in Switzerland. 
It was initiated in 1991 (SAPALDIA 1) with a follow-up assessment in 2002 (SAPALDIA 2) 
and 2011 (SAPALDIA3). Only non-asthmatic participants of SAPALDIA cohort were used for 
current study with age ranging from 18.30 to 61.40 years.
4. The British 1958 birth cohort (B58C) is an ongoing follow-up of all persons born in Britain 
during one week in 1958. Lung function was measured at ages 35 and 45 years on a 
subsample of the cohort with a history of chest illness in childhood, and a control sample 
with no such history, as described in detail elsewhere14. The main characteristics of the 
cohorts used in the current study are shown in Table 1.
SAPALDIA and B58C were part of previous GWA study on lung function decline 9.
More details can be found in the supplementary methods.
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Genotyping
Samples from the discovery cohort NELSON were genotyped using the Illumina 
Quad610 BeadChip. The replication cohorts Vlagtwedde/Vlaardingen and Doetinchem were 
genotyped using custom-made VeraCode assay from Illumina. The SAPALDIA cohort and 
the B58C performed in silico replication using their genome-wide genotyping data (See 
supplementary methods).
Quality control
Quality control was performed for both the genome-wide and replication genotyping 
data. Genome-wide data were passed through standard filtering to remove single nucleotide 
polymprphisms (SNPs) and individual samples of lower quality. SNPs with call rate below 95%, 
minor allele frequency below 5% and deviating from Hardy-Weinberg equilibrium (HWE; 
p<0.0001) were removed. Samples with more than 5% of genotypes missing were removed, 
as well as duplicates, related individuals or ethnic outliers (based on components from 
multidimensional scaling C1 and C2). In the replication cohorts the same filters were applied, 





 was measured following ATS/ERS guidelines in all cohorts (see online supplement 
for detailed information regarding the specificities). Lung function decline was defined as the 
baseline FEV
1 
minus the last FEV
1
 measurement during the follow-up, divided by the time 
between measurements. The decline in FEV
1
 is expressed in milliliters per year.
Statistical analysis
The association between genotypes and the annual decline in FEV
1
 in the NELSON 
cohort was assessed using linear regression models. Covariates included in the model were: 
baseline FEV
1
, packyears smoked and current/ex- smoking status. We did not adjust for 
gender, since NELSON consisted of males only, or age, given the cohort’s restricted age range 
resulting in a high correlation with packyears. Baseline FEV
1
 was included in order to assure that 
genetic effects detected will refer to lung FEV
1
 decline solely, irrespective of the initial level. 
The analyses in the different replication cohorts were performed as in the discovery 
cohort (i.e. with adjustment for baseline FEV
1
, packyears smoked and current/ex- vs. never-
smoking status) and additional adjustment for gender. The analysis in SAPALDIA was additionally 
adjusted for area.
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 Within the Doetinchem and the Vlagtwedde/Vlaardingen cohort we performed 
stratified analyses according to:
1. presence or absence of COPD (FEV
1
/FVC<0.7 according to GOLD criteria) 
2. smoking habits, dichotomized at 20 packyears
For each stratum linear regression was performed and regression coefficients of the groups 
were compared (Z-score comparison) to test for interaction between gene and ‘environment’ 
(GxE), i.e. gene-by-COPD interaction and gene-by-smoking interaction.
Additionally, GxE analyses were performed according to COPD status separately in the 
Doetinchem cohort, i.e. gene-by-smoking interaction within COPD controls and COPD cases. 
Due to an insufficient number of COPD cases these analysis could not be performed in the 
Vlagtwedde/Vlaardingen cohort study. 
Results
All estimates of genetic effects presented in the current manuscript represent decline of 
lung function expressed in milliliters per year. The values above zero reflect accelerated FEV
1 
decline, while values below zero indicate attenuated FEV
1
 decline due to a particular allele.
SNPs associated with annual FEV
1
 decline in NELSON
Quality control indicated there was no population stratification (see Q-Q plot, Figure 
2). After quality control 522,004 SNPs and 1,942 individuals remained. The genomic inflation 
factor (λ) equaled to 1. The genome-wide screen for variants associated with FEV
1
 decline did 
not identify any SNPs at a genome-wide significance threshold (being 5·10-8, Figure 3). Fifty 
SNPs with p<5·10-5 were selected for further replication in the replication cohorts. 
Figure 2. Q-Q plot. Observed p values are derived from linear regression analysis of lung function decline.
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association signals across the genome.
Replication of SNPs associated with annual FEV
1
 decline in Vlagtwedde/Vlaardingen, Doetinchem, 
SAPALDIA and B58C
After quality control in the Vlagtwedde/Vlaardingen cohort 1,056 individuals and 43 
SNPs and in the Doetinchem cohort 1,093 individuals and 41 SNPs were included. SAPALDIA 
and B58C had genotypes available for all top 50 SNPs in 788 individuals and 834 individuals 
respectively. Characteristics of the cohorts used are shown in Table 1.
 Table 1. Cohorts characteristics.
Cohort NELSON Vlagtwedde/Vlaardingen Doetinchem SAPALDIA B58C
N 1942 1056 1093 788 834
Age at baseline (Y, SD) 59.8 (5.4) 50.7 (10.4) 46.2 (9.9) 41.63  (11.10) 35.0 (0.2)
Height (cm, SD) 178.7 (6.3) 170.3 (9.3) 173.2 (9.0) 169.1 (9.32) 169.7 (9.3)
Follow-up time (Y, SD) 2.99 (0.44) 19.83 (4.45) 8.36 (2.33) 10.96 (0.23) 10.2 (0.5)
FEV1 (l, SD) 3.44 (0.73) 3.05 (0.76) 3.51 (0.81) 3.63 (0.81) 3.62 (0.75)
FVC (l, SD) 4.22 (1.29) 3.92 (0.96) 4.65 (1.04) 4.57 (1.01) 4.53 (0.92)
FEV1/FVC (%, SD) 72 (9.5) 77.84 (5.22) 75.77 (7.95) 79.68 (7.10) 80.1 (6.5)
FEV1 decline (ml, SD) 199.44 (242.32) 12.97 (21.52) 31.13 (38.67) 33.87 (28.22) 33.8 (32.1)
FEV1%pred (%, SD) 98.9 (18.5) 98.13 (13.02) N/A 101.64 (12.43) N/A
% male 100 48.6 50.4 49.24 48.4
N (%) never smoker 0 (0) 366 (34.6) 337 (30.8) 339 (43.02) 423 (50.7)
N (%) current smoker 867 (44.6) 298(28.2) 339 (38.1) 243 (30.84) 159 (19.1)
N (%) former smoker 1075 (55.4) 392? 416 (311.0) 206 (26.14) 252 (30.2)
Pack-years smoking* 37.95 (21.5-133.2) 5.62 (0 – 128.0) 6 (0 – 118) 19.06 (20.87) 14.5 (0.1 – 58.0)
 All values expressed as mean (SD), unless specified otherwise. *median (range)
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Table 2. Main results of genome-wide association study on lung function decline and replication in the 
    Nelson Vlagtwedde/Vlaardingen Doetinchem
CHR SNP GENE A1 BETA SE P BETA SE P BETA SE P
15 rs7182547 TRPM1 A 15.78 3.82 3.69E-05 0.99 0.86 0.25    
8 rs2458416 TM7SF4 G 23.39 5.92 8.17E-05 1.53 1.32 0.25 0.39 2.69 0.89
6 rs4947133 NA A 20.72 5.20 6.91E-05       
7 rs12667992 NA A 25.63 6.29 4.73E-05 2.03 1.43 0.16 2.44 2.64 0.36
2 rs4664511 CACNB4 G 20.23 5.44 0.000203 1.22 1.36 0.37 5.42 2.83 0.06
7 rs1916602 NA G 24.31 5.90 3.89E-05 1.28 1.31 0.33 1.96 2.53 0.44
7 rs12705973 FOXP2 G -12.96 3.25 7.00E-05 -1.04 0.80 0.19 -0.08 1.62 0.96
5 rs11949657 PHF15 C 22.70 5.46 3.37E-05 2.49 1.18 0.04 -1.80 2.56 0.48
7 rs12671330 NA G -13.10 3.26 5.91E-05 -0.83 0.79 0.29 -0.10 1.61 0.95
17 rs17581728 UNC13D A 15.28 3.87 8.33E-05       
21 rs13049780 NA G 25.99 5.70 5.32E-06 0.05 1.35 0.97 0.41 2.68 0.88
1 rs2492321 LOC645757 A -18.15 3.98 5.41E-06 -1.10 0.98 0.26 2.66 1.91 0.16
17 rs2258367 SLC5A10 C 23.68 5.46 1.49E-05 0.60 1.28 0.64 -2.51 2.52 0.32
5 rs1366331 NA A 22.87 5.79 8.10E-05 0.18 1.46 0.90 3.44 2.94 0.24
2 rs892867 NA G -13.09 3.57 0.000251 -0.56 0.84 0.51 -3.13 1.72 0.07
1 rs6604558 SPATA17 A 18.62 4.04 4.37E-06 -0.03 0.95 0.98 2.40 1.90 0.21
4 rs1394339 NA A -12.57 3.34 0.000171 -0.42 0.79 0.59 -0.54 1.59 0.73
1 rs6694862 SPATA17 G 18.46 4.05 5.53E-06 0.09 0.95 0.92 2.24 1.90 0.24
6 rs221749 PDE10A G -15.62 3.81 4.22E-05 -0.75 0.91 0.41 0.56 1.80 0.75
22 rs139156 PARVG A 25.34 5.98 2.35E-05       
21 rs2827251 NA A 26.56 6.27 2.39E-05 0.85 1.54 0.58 1.20 3.04 0.69
2 rs11679243 NA A 16.72 3.88 1.75E-05       
6 rs1498426 CDKAL1 G -13.45 3.37 6.67E-05 1.22 0.80 0.13 -1.74 1.59 0.28
7 rs9791835 NA A 22.70 5.66 6.38E-05 1.60 1.28 0.21 -1.96 2.59 0.45
12 rs11058897 NA A 29.88 7.37 5.22E-05       
12 rs10847254 NA G 30.14 7.37 4.47E-05       
12 rs11058900 NA G 29.58 7.44 7.22E-05       
5 rs1862404 NA G -15.66 3.52 9.11E-06 2.63 0.84 0.00 0.96 1.68 0.57
5 rs4836058 NA G -14.17 3.35 2.51E-05 2.13 0.80 0.01 0.18 1.62 0.91
6 rs12528430 NA A 13.80 3.34 3.79E-05 -1.32 0.80 0.10 0.10 1.65 0.95
6 rs17182135 NA G 13.84 3.36 3.88E-05 -1.23 0.80 0.13 0.16 1.65 0.92
9 rs10962687 NA G 26.59 6.75 8.42E-05 -1.26 1.59 0.43 0.36 3.52 0.92
9 rs10962689 NA G 26.55 6.75 8.69E-05 -1.16 1.55 0.45 0.64 3.51 0.85
3 rs1554328 NA A 25.60 5.28 1.35E-06 -0.05 1.23 0.96 -4.34 2.46 0.08
20 rs1013562 NA G 18.08 4.41 4.29E-05 -1.28 0.99 0.20 2.72 2.14 0.21
3 rs938111 NA C 21.08 5.08 3.47E-05 -0.09 1.18 0.94 -1.20 2.36 0.61
2 rs10928087 LRP1B G 24.24 5.96 4.97E-05 0.20 1.51 0.90 0.65 2.84 0.82
1 rs927743 NA A -13.54 3.42 7.96E-05 -0.97 0.82 0.23 3.02 1.62 0.06
20 rs6073768 NA G 18.90 4.45 2.25E-05 -0.65 1.00 0.52 2.43 2.14 0.26
2 rs2690751 MGC13057 A 17.01 3.98 1.97E-05 -0.56 0.96 0.56 -2.60 1.89 0.17
12 rs4639992 NELL2 G 19.08 4.87 9.35E-05 1.31 1.13 0.24 -3.32 2.30 0.15
1 rs11589174 NA C 18.78 4.81 9.72E-05 -1.03 1.15 0.37 2.21 2.46 0.37
12 rs16946677 NA C 20.51 5.27 0.000102 -1.10 1.18 0.35 0.92 2.48 0.71
20 rs6073862 WFDC10B G 18.10 4.41 4.21E-05 -1.09 0.97 0.26 3.12 2.14 0.15
1 rs6677308 NA A 20.33 4.76 2.03E-05 -1.54 1.16 0.19 2.32 2.40 0.34
7 rs4723295 BBS9 G 20.84 5.08 4.32E-05 -0.42 1.18 0.72 -3.88 2.40 0.11
1 rs12093170 NA C 17.27 4.50 0.000128 -0.50 1.08 0.64 0.26 2.29 0.91
2 rs12467492 NA A 14.14 3.35 2.57E-05 -1.43 0.77 0.06 -0.11 1.60 0.95
1 rs920307 NA A -20.74 5.01 3.63E-05 0.20 1.05 0.85    
2 rs3770111 ITGA4 A 21.74 5.45 6.98E-05 -1.15 1.28 0.37 0.07 2.53 0.98
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total population. 
SAPALDIA B58C Replication Overall
BETA SE P BETA SE P BETA P BETA P
2.98 1.34 0.03 1.24 1.67 0.46 1.52 0.02 1.93 5.68E-06
4.89 2.10 0.02 1.23 2.68 0.65 2.05 0.03 2.60 1.76E-05
6.28 3.12 0.04 2.28 3.25 0.48 4.36 0.05 6.95 2.86E-05
2.71 2.08 0.19 -2.88 2.90 0.32 1.65 0.10 2.26 5.45E-05
2.92 2.11 0.17 0.05 2.73 0.98 1.95 0.05 2.53 5.73E-05
2.71 1.87 0.15 -2.48 2.63 0.35 1.25 0.17 1.81 1.09E-04
-0.92 1.25 0.46 -0.47 1.51 0.76 -0.81 0.16 -1.18 1.42E-04
2.34 2.54 0.36 -4.12 2.43 0.09 0.98 0.28 1.58 2.24E-04
-0.74 1.25 0.55 -0.55 1.51 0.72 -0.68 0.23 -1.05 2.33E-04
-0.42 1.49 0.78 3.88 1.76 0.03 1.36 0.23 2.47 2.82E-04
1.34 2.54 0.60 0.66 2.72 0.81 0.39 0.70 1.18 4.78E-04
-2.64 1.92 0.17 1.87 1.78 0.29 -0.28 0.70 -0.86 4.82E-04
3.23 2.23 0.15 -2.70 5.99 0.65 0.54 0.59 1.30 5.71E-04
2.61 2.27 0.25 -1.76 3.25 0.59 0.94 0.38 1.66 6.56E-04
-1.14 1.42 0.42 1.53 1.64 0.35 -0.71 0.25 -1.06 6.81E-04
-1.37 1.58 0.38 -0.22 1.86 0.91 0.01 0.99 0.54 1.14E-03
0.70 1.35 0.60 -2.15 1.52 0.16 -0.48 0.41 -0.83 1.17E-03
-1.45 1.58 0.36 -0.47 1.86 0.80 0.00 0.99 0.53 1.29E-03
0.97 1.45 0.50 -1.15 1.71 0.50 -0.29 0.66 -0.73 1.36E-03
2.56 2.65 0.33 -1.80 2.88 0.53 0.56 0.77 2.94 1.41E-03
2.35 3.05 0.44 -4.00 2.67 0.13 0.23 0.84 1.07 1.73E-03
0.27 1.63 0.87 0.04 1.75 0.98 0.16 0.89 1.59 1.74E-03
-1.83 1.28 0.15 -1.31 1.51 0.39 -0.15 0.80 -0.53 2.67E-03
-1.15 2.22 0.61 -1.61 2.72 0.55 0.22 0.82 0.84 2.80E-03
-0.72 2.27 0.75 2.45 3.37 0.47 0.27 0.89 2.08 3.07E-03
-0.90 2.31 0.69 2.42 3.42 0.48 0.13 0.94 2.03 3.33E-03
-0.71 2.27 0.75 2.45 3.37 0.47 0.27 0.88 2.04 3.62E-03
0.41 1.50 0.79 0.81 1.61 0.62 1.76 0.00 1.23 0.04
0.22 1.39 0.87 1.14 1.55 0.46 1.39 0.02 0.92 0.11
-0.99 1.27 0.43 -1.40 1.54 0.36 -1.09 0.06 -0.65 0.25
-0.89 1.27 0.48 -1.40 1.54 0.36 -1.01 0.08 -0.58 0.31
-4.21 3.15 0.18 -5.23 3.23 0.11 -2.07 0.09 -1.17 0.33
-4.21 3.15 0.18 -5.23 3.23 0.11 -1.96 0.10 -1.08 0.36
1.64 2.04 0.42 4.66 2.36 0.05 -0.92 0.41 -0.92 0.41
0.38 1.91 0.84 -3.46 2.05 0.09 -0.82 0.28 -0.28 0.70
-0.20 1.98 0.92 -4.34 2.21 0.05 -0.90 0.30 -0.29 0.73
-2.21 2.45 0.37 -1.30 2.65 0.63 -0.45 0.68 0.33 0.76
0.45 1.26 0.72 1.54 1.53 0.31 0.21 0.72 -0.17 0.76
0.45 1.98 0.82 -2.48 2.11 0.24 -0.33 0.67 0.22 0.77
0.24 1.46 0.87 -0.70 1.65 0.67 -0.67 0.32 -0.18 0.79
-1.15 1.77 0.52 -5.98 2.25 0.01 -0.76 0.35 -0.22 0.79
-0.20 1.87 0.92 -0.73 2.30 0.75 -0.44 0.61 0.14 0.87
-1.19 1.95 0.54 0.20 2.23 0.93 -0.68 0.43 -0.13 0.88
0.54 1.92 0.78 -3.35 2.04 0.10 -0.63 0.40 -0.11 0.88
0.24 1.89 0.90 -0.28 2.24 0.90 -0.52 0.54 0.12 0.89
-0.34 2.02 0.87 0.57 2.28 0.80 -0.71 0.41 -0.11 0.90
-1.58 1.68 0.35 0.04 2.05 0.99 -0.57 0.47 -0.05 0.95
2.40 1.24 0.05 -1.06 1.48 0.48 -0.43 0.45 -0.03 0.96
2.36 1.98 0.23    0.67 0.47 -0.04 0.97
-0.17 2.29 0.94 0.14 2.42 0.95 -0.61 0.51 0.03 0.97
Table 2 shows the results for each replication cohort, for the replication cohorts 
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combined, and for the replication cohorts combined with the discovery cohort NELSON. 
Overall, two of the top SNPs were replicated with nominal p values after combining all 
replication cohorts (rs7182547 p=0.02 and rs2458416 p=0.03). Genome-wide significance was 
not achieved after combining the discovery and replication cohorts. 
Gene annotations for all SNPs selected for replication are also shown in Table 2. The two 
replicated SNPs annotated to TM7SF4 (rs2458416) and TRPM1 (rs7182547) genes.
Stratified analyses of SNPs associated with annual FEV
1
 decline and gene-environment 
interaction (GxE) in Vlagtwedde/Vlaardingen and Doetinchem 
We performed stratified analyses based on presence or absence of COPD and 
smoking in Vlagtwedde/Vlaardingen and Doetinchem cohorts for the 50 top hits for FEV
1
 
decline. Beta estimates differed in all sub-groups, indicating that both factors play a role in a 
genetic association with lung function decline and suggesting possible interactions (i.e. COPD 
cases vs COPD controls and smokers with ≥20 packyears vs smokers with <20 packyears). 
Stratification according to COPD status and gene-by-COPD interaction
In Doetinchem, the effect estimates for FEV
1
 decline differed in the COPD cases and 
in subjects without COPD. In subjects with COPD, some of the SNPs effect estimates were 
in line with those observed in the NELSON (identification) cohort (Supplementary table 1). 
However, the analysis in within COPD subjects reduced the sample size, and hence the power. 
In the Vlagtwedde/Vlaardingen cohort the stratified analysis according to COPD status was 
not feasible since there were only 13 COPD cases. 
The interaction in the Doetinchem cohort was significant at the nominal level for 
one SNP: rs10928087 on chromosome 2 (p=0.031) annotating to LRP1B gene (Table 3). Two 
other SNPs, rs1862404 and rs1366331 on chromosome 5 showed borderline significance for the 
interaction with p=0.051 and p=0.089, respectively. None of these SNPs showed any association 
with FEV
1
 decline in COPD controls (n=833) and only two showed borderline association in 
COPD cases (n=250; rs10928087, p=0.086 and rs1862404, p=0.068).




Doetinchem all Doetinchem COPD Doetinchem non-COPD GxE
CHR SNP N BETA SE N BETA SE N BETA SE Z_GXE P_GXE
2 rs10928087 1092 0.6451 2.836 250 12.58 6.84 833 -3.759 3.235 -2.16 0.03079
5 rs1862404 1093 0.9597 1.678 251 7.84 4.305 833 -1.307 1.868 -1.949 0.05129
5 rs1366331 1093 3.439 2.942 251 10.76 7.053 833 -2.525 3.36 -1.701 0.08891
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Stratification according to smoking habits and gene-by-smoking interactions 
There was a clear difference in genetic effects between subjects smoking less 
and subjects smoking 20 packyears or more in both cohorts. Especially Doetinchem 
heavy-smokers were the most alike the NELSON cohort despite inclusion of females 
in the Doetinchem cohort. In Doetinchem five SNPs showed significant interaction 
with smoking (p<0.05, Table 4). One of them remains significant after multiple testing 
correction (p<0.001): rs2492321 annotating to LOC100131060, an uncharacterized 
gene located next to JUN gene. In Vlagtwedde/Vlaardingen two SNPs showed nominal 
interaction with smoking, of which one was also identified in the Doetinchem cohort, 
i.e. rs4723295 on chromosome 7 (Tables 4 and 5, highlighted with bold), but with the 
opposite effect.

















































1 rs2492321 807 -0.8699 2.164 0.6877 286 15.96 4.536 0.0005037 -3.35 0.0008093
7 rs12671330* 807 -3.743 1.872 0.04597 285 8.385 3.502 0.01731 -3.054 0.00226
7 rs12705973* 806 -3.562 1.886 0.05929 286 7.87 3.552 0.0275 -2.843 0.004473
7 rs4723295 807 -8.503 2.783 0.002323 286 6.051 5.273 0.2522 -2.441 0.01466
2 rs10928087 807 -3.97 3.421 0.2462 285 10.05 5.754 0.08177 -2.094 0.03622
20 rs1013562 805 5.247 2.44 0.0318 286 -5.391 5.027 0.2845 1.904 0.05695
20 rs6073862 806 5.71 2.446 0.01983 286 -4.687 4.937 0.3432 1.887 0.05914
2 rs4664511* 807 1.78 3.32 0.592 286 13.58 6.111 0.02705 -1.697 0.08972
2 rs2690751 806 -0.4001 2.178 0.8543 286 -8.389 4.308 0.05247 1.655 0.09793
* SNPs identified also in the similar analysis, but restricted to COPD cases (Table 6)
Table 5. Gene-by-pack years interaction in the Vlagtwedde/Vlaardingen cohort (with pack 
















































7 rs4723295 806 2.063 1.68 0.2199 250 -5.252 2.385 0.0286 2.507 0.01217
8 rs2458416 806 2.939 1.816 0.1059 250 -4.179 2.986 0.1629 2.037 0.04167
2 rs3770111 806 2.542 1.849 0.1696 250 -2.983 2.515 0.2368 1.77 0.07676
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Stratification according to smoking habits within COPD strata and gene-by-smoking 
interactions in the Doetinchem cohort
We performed a gene-by-smoking interaction analysis in the groups of individuals 
with and without COPD of the Doetinchem cohort (Tables 6 and 7). Four and five SNPs 
interacted significantly with smoking in groups with and without COPD, respectively. 
These SNPs did not overlap. Three of the SNPs identified in the group with COPD were also 
identified in gene-by-smoking interaction analysis in the total Doetinchem cohort (marked 
with asterisk in Tables 4 and 7, full results in Supplementary Tables 2 and 3). 
Table 6. Gene-by-pack years interaction in the Doetinchem cohort in individuals without COPD (with 
















































1 rs2492321 659 -1.612 2.23 0.4701 180 14.39 5.282 0.0071 -2.79 0.005266
7 rs4723295 659 -8.674 2.88 0.0027 180 7.651 5.752 0.1852 -2.538 0.01116
20 rs6073768 658 3.2 2.583 0.2159 180 -10.2 5.784 0.07957 2.115 0.03442
20 rs6073862 658 4.378 2.576 0.08971 180 -8.076 5.803 0.1658 1.961 0.04982
20 rs1013562 657 3.959 2.565 0.1232 180 -8.076 5.803 0.1658 1.897 0.05785
Table 7. Gene-by-pack years interaction in the Doetinchem cohort in individuals with COPD only (with 

















































2 *rs4664511 148 -16.76 9.436 0.0776 106 22.89 8.783 0.01051 -3.076 0.0021
1 rs6677308 148 -4.606 7.012 0.5123 106 26.56 9.621 0.006819 -2.618 0.008848
7 *rs12671330 148 -5.28 5.321 0.3227 105 13.29 6.244 0.03563 -2.264 0.02357
7 *rs12705973 148 -4.751 5.514 0.3903 106 12.86 6.361 0.04574 -2.092 0.03641
1 rs12093170 148 -6.546 7.094 0.3576 106 18.71 9.929 0.06232 -2.07 0.03849
1 rs11589174 148 -2.635 7.3 0.7187 106 20.75 10.78 0.05685 -1.797 0.07235
* SNPs identified also in the similar analysis, but in the entire cohort (Table 3)
Discussion
In the current study we performed a genome-wide search for SNPs associated with 
FEV
1
 decline. Additionally, we studied gene-by-smoking interactions and gene-by-COPD 
status interactions. Our GWA study did not identify genome-wide significant SNPs with lung 
function decline. Three SNPs showed nominal level of association in the replication sample: 
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rs1862404 (p=0.009), rs12467492 (p=0.012) and rs4836058 (p=0.027), however, the direction 
of the association was opposite to the discovery cohort.
In the Doetinchem cohort four SNPs had a significant interaction with smoking habits 
with respect to FEV
1
 decline: rs2492321 annotating to LOC100131060, next to JUN, rs12671330 
and rs12705973 annotating to FOXP2 and rs4723295 located in BBS9 gene. While nothing is 
known about LOC100131060, Jun is a proto oncogene, known to interact with many proteins 
and involved in many pathways. One of them is the JNK (c-Jun N terminal kinase) pathway which 
has been shown to be activated in human endothelial cells upon cigarette smoke exposure17. 
FOXP2 (forkhead box P2) encodes forkhead/winged-helix (FOX) transcription factor that is 
mainly expressed in fetal brain and interestingly in fetal lungs as well. FOXP2 was previously 
shown to repress gene expression in epithelium of the lungs, together with FOXP118. Further, 
studies in mice identified Foxp2 and Foxp1 as crucial regulators of lung development and 
specifically peripheral epithelial cells19, which signifies its putative role in FEV
1
 decline.
Lung function decline is a heterogeneous phenotype depending on many internal and 
external factors. One of the reasons for not replicating our findings might be the fact that 
the follow-up in the discovery cohort in our current study is shorter than in our replication 
cohorts, hence we might be studying not entirely the same type of decline. In case of complex 
phenotypes, like lung function decline, even when we adjust for covariates we know to 
influence the phenotype like duration of follow-up, this can simply be insufficient to account 
for heterogeneity within and especially between cohorts. We take differences in smoking 
habits and history, gender distribution and baseline FEV
1
 levels into account in our analyses. 
However, there may have been other components that might result in heterogeneity we cannot 
measure, do not have access to or we are not aware of and thus cannot adjust for, yet they 
may contribute to cohort heterogeneity (for example physical activity, occupational exposure, 
etc.). In addition, as shown in Figure 1, the course of the decline can be different. The NELSON 
cohort consists of selected individuals, heavy-smokers that probably will display mostly the 
accelerated decline (Figure 1d). The replication cohorts are population based hence individuals 
can display any course of decline shown in Figure 1. This could be a main reason for the lack 
of replication in our study.
We performed gene-by-smoking and gene-by-COPD status interaction analyses in 
order to identify differential effects of smoking and COPD-status within strata. Alternatively, 
construction of a more complicated model like three-way interactions would have been feasible. 
However, interpretation of such results is more problematic compared to results from two-
way interactions within e.g. COPD strata. The more specific the phenotype is, the lower is the 
available number of subjects. Indeed, if the analyses are restricted to specific phenotypes such 
as the Doetinchem COPD cases with ≥ 20 packyears, the effect estimates are comparable to 
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those in the discovery cohort (Table 7). However, even for two-way interactions the power of 
the current study might not be sufficient, as only one of the interactions remained significant 
after multiple testing correction.
The limited number of GWA studies on lung function decline performed previously, 
like ours, showed ambiguous results. A recent meta-analysis published by Imboden et al.9 did 
not yield genome-wide significant SNPs despite a large number of individuals included in their 
study (the discovery set comprising 1,441 asthmatic and 2,677 non-asthmatic participants and 
the replication set comprising 1,160 asthmatic and 10,858 non-asthmatic participants). Lack of 
replication of results from a GWA study on lung function decline was also shown recently in 
the study by Hansel et al10. This study reported two genome-wide loci, but none of them was 
even nominally associated in the replication cohorts. This stresses the importance of optimal 
use of the limited resources for such genetic studies, i.e. there might be lack of replication 
cohorts with specific phenotypes, like lack of mild COPD patients in case of the Hansel study 
and heavy smoking COPD patients in case of our study. All the studies performed so far on 
genetics of FEV
1
 decline, including our, lack overlap in reported associations and also lack 
overlap with GWA studies on lung function level. This stresses the complexity of the FEV
1
 
decline phenotype and the difficulties related to cohort heterogeneity mentioned before.
In summary, the current study reports no genome-wide significant SNPs associated 
with lung function decline. We identified multiple genes interacting with smoking habits and 
with COPD status, which indicates differential effects of the same loci in several subgroups. 
Future studies on lung function decline should include stratified analyses in order to detect 
signals that are otherwise missed in the full data set due to adding up the opposite effects 
of relevant loci. Efforts should be directed towards deep phenotyping and collecting detailed 
data on environmental exposures data.
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Supplementary methods
Study populations and genotyping
NELSON: the NELSON cohort was established as a lung cancer screening trial, in the beginning 
only males of Dutch descent smoking more than 20 pack-years were recruited. At later stage 
females were recruited as well, but they are a minority of the cohort. Individuals filled the 
questionnaires, underwent spirometry and CT scan of the chest in 2004 Blood was drawn 
to enable DNA (and in some cases RNA) extraction. The second survey took place three to 
four years later and same measurements were taken. Samples were genotyped using Illumina 
610 Quad BeadChip, genotypes were called using a standard algorithm implemented in 
GenomeStudio software from Illumina.
Vlagtwedde/Vlaardingen cohort: is a Dutch population-based cohort including individuals 
from Vlagtwedde, a rural area, and Vlaardingen, an urban area in the Netherlands. The cohort 
was established in 1965 to study differences among others in lung function decline in relation 
to two types of environment. Participants were followed for over 25 years, with last surveys 
performed in 1989/1990, when lung function and other measurements taken every three 
years. Information on area of residence, age, sex, smoking habits and respiratory symptoms 
was collected by the Dutch version of the UK MRC standard questionnaire. Also blood and 
serum were collected for DNA extraction. Samples were genotyped using Illumina Veracode 
assay with custom content. Genotypes were called with standard algorithm implemented 
in GenomeStudio software from Illumina and genotype clusters were adjusted manually if 
necessary. 
Doetinchem cohort: is a prospective part of the MORGEN (Monitoring of Risk Factors and 
Health in The Netherlands) study. FEV
1 
was according to the European Respiratory Society 
(ERS) guidelines. Samples were genotyped using Illumina Veracode assay with custom content. 
Genotypes were called with standard algorithm implemented in GenomeStudio software from 
Illumina and genotype clusters were adjusted manually if necessary. 
SAPALDIA: The SAPALDIA cohort, a multi-center study in eight geographic areas representing 
the range of environmental, meteorological and socio-demographic conditions in Switzerland. It 
was initiated in 1991 (SAPALDIA 1) with a follow-up assessment in 2002 (SAPALDIA 2) and 2011 
(SAPALDIA3). This study has specifically been designed to investigate longitudinally lung function, 
respiratory and cardiovascular health; and to study and identify the associations of these health 
indicators with individual long term exposure to air pollution, other toxic inhalants, life style and 
molecular factors. Genome-wide genotyping was done on the Illumina Human 610quad BeadChip 
in the framework of the EU-funded GABRIEL study. More details can be found in Moffatt et alE1.
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B58C: The British 1958 birth cohort (B58C) is an ongoing follow-up of all persons born in Britain 
during one week in 1958. Lung function was measured at ages 35 and 45 years on a subsample 
of the cohort with a history of chest illness in childhood, and a control sample with no such 
history, as described in detail elsewhere E2. Genotypes were collated from data deposited by the 
Wellcome Trust Case-Control Consortium E3, the Type 1 Diabetes Genetics Consortium E4 and 
the GABRIEL asthma genetics consortium E1. Genotypes measured by the Illumina 550K v1 array 
(WTCCC), Illumina 550K v3 array (T1DGC) or Illumina 610K array (GABRIEL) were combined and 
imputed against the HapMap CEU release 21 reference haplotypes using MACH version 1.0.16.a.
Figure E1. Q-Q plot. Observed p values are derived from linear regression analysis in lung function decline.




association signals across the genome.
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Supplementary Table 1. Beta estimates in Doetinchem: whole cohort, COPD, non-COPD and GxE test.































1 rs2492321 59124034 A 1093 2.66 1.91 251 9.73 5.21 833 0.91 2.09 -1.57 0.12
1 rs927743 59141535 A 1090 3.02 1.62 251 2.26 4.41 830 2.86 1.78 0.12 0.90
1 rs6604558 216001829 A 1093 2.40 1.90 251 2.89 4.99 833 2.69 2.12 -0.04 0.97
1 rs6694862 216033717 G 1093 2.24 1.90 251 2.19 4.99 833 2.69 2.12 0.09 0.93
1 rs11589174 240756312 C 1093 2.21 2.46 251 2.67 6.17 833 1.19 2.78 -0.22 0.83
1 rs12093170 240757607 C 1093 0.26 2.29 251 -0.23 5.89 833 0.41 2.57 0.10 0.92
1 rs6677308 240763170 A 1091 2.32 2.40 251 4.69 5.85 831 0.98 2.74 -0.57 0.57
2 rs892867 79218487 G 1093 -3.13 1.72 251 0.58 4.32 833 -4.23 1.92 -1.02 0.31
2 rs10928087 141458573 G 1092 0.65 2.84 250 12.58 6.84 833 -3.76 3.24 -2.16 0.03
2 rs4664511 152522710 G 1093 5.42 2.83 251 7.90 6.64 833 3.20 3.27 -0.63 0.53
2 rs3770111 182090561 A 1093 0.07 2.53 251 -4.71 6.59 833 1.37 2.81 0.85 0.40
2 rs2690751 190763511 A 1092 -2.60 1.89 251 -1.25 4.59 832 -3.41 2.15 -0.43 0.67
2 rs12467492 227127070 A 1092 -0.11 1.60 250 -2.46 4.23 833 0.60 1.76 0.67 0.50
3 rs1554328 118325495 A 1073 -4.34 2.46 248 -10.12 6.26 816 -3.46 2.77 0.97 0.33
3 rs938111 118330571 C 1092 -1.20 2.36 250 -5.04 5.77 833 -1.77 2.70 0.51 0.61
4 rs1394339 90492121 A 1093 -0.54 1.59 251 -3.21 4.10 833 0.02 1.78 0.72 0.47
5 rs1366331 110330169 A 1093 3.44 2.94 251 10.76 7.05 833 -2.53 3.36 -1.70 0.09
5 rs4836058 123375799 G 1093 0.18 1.62 251 5.62 4.36 833 -2.00 1.78 -1.62 0.11
5 rs1862404 123378142 G 1093 0.96 1.68 251 7.84 4.31 833 -1.31 1.87 -1.95 0.05
5 rs11949657 133897834 C 1093 -1.80 2.56 251 3.24 6.78 833 -5.34 2.82 -1.17 0.24
6 rs1498426 21116132 G 1092 -1.74 1.59 250 4.26 4.22 833 -2.58 1.75 -1.50 0.13
6 rs221749 165783026 G 1091 0.56 1.80 250 -4.54 4.84 832 1.85 1.98 1.22 0.22
6 rs17182135 169147239 G 1093 0.16 1.65 251 -4.96 4.34 833 0.19 1.82 1.09 0.27
6 rs12528430 169151607 A 1093 0.10 1.65 251 -4.79 4.38 833 0.19 1.82 1.05 0.29
7 rs4723295 33591734 G 1093 -3.88 2.40 251 -1.43 6.72 833 -4.19 2.61 -0.38 0.70
7 rs12667992 91183013 A 1093 2.44 2.64 251 -1.07 7.02 833 4.41 2.91 0.72 0.47
7 rs1916602 91199648 G 1093 1.96 2.53 251 -3.77 6.92 833 3.95 2.76 1.04 0.30
7 rs9791835 105324494 A 1092 -1.96 2.59 251 1.86 7.33 832 -4.41 2.81 -0.80 0.42
7 rs12705973 114100435 G 1092 -0.08 1.62 251 3.00 4.28 832 -1.99 1.79 -1.08 0.28
7 rs12671330 114121279 G 1092 -0.10 1.61 250 2.59 4.16 833 -2.00 1.78 -1.01 0.31
8 rs2458416 105420643 G 1092 0.39 2.69 250 2.63 7.07 833 0.10 2.98 -0.33 0.74
9 rs10962687 1690272 G 1093 0.36 3.52 251 3.59 8.19 833 -0.43 4.11 -0.44 0.66
9 rs10962689 1690460 G 1093 0.64 3.51 251 3.59 8.19 833 0.20 4.07 -0.37 0.71
12 rs4639992 43209601 G 1093 -3.32 2.30 251 -2.55 5.71 833 -3.76 2.61 -0.19 0.85
12 rs16946677 115386413 C 1093 0.92 2.48 251 4.61 6.54 833 -3.27 2.72 -1.11 0.27
17 rs2258367 18796532 C 1093 -2.51 2.52 251 -9.09 6.20 833 -1.49 2.84 1.12 0.26
20 rs6073768 43563560 G 1091 2.43 2.14 251 7.27 5.45 832 0.53 2.40 -1.13 0.26
20 rs1013562 43744158 G 1091 2.72 2.14 251 4.72 5.54 831 1.54 2.38 -0.53 0.60
20 rs6073862 43765119 G 1092 3.12 2.14 251 5.25 5.43 832 1.86 2.39 -0.57 0.57
21 rs13049780 19638152 G 1093 0.41 2.68 251 -2.29 6.77 833 3.02 3.01 0.72 0.47
21 rs2827251 22429921 A 1093 1.20 3.04 251 -1.92 9.23 833 1.35 3.24 0.33 0.74
BETA > 0 annual FEV
1
decline acceleration
BETA > 0 annual FEV
1
decline attenuation.
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Supplementary Table 2. Beta estimates in Doetinchem: whole cohort, >20 pack-years, <20 pack-years 
and GxE test




























1 rs2492321 59124034 A 1093 2.66 1.91 286 15.96 4.54 807 -0.87 2.16 -3.35 8.09-04
1 rs927743 59141535 A 1090 3.02 1.62 286 5.26 3.69 804 2.01 1.87 -0.78 0.43
1 rs6604558 216001829 A 1093 2.40 1.90 286 -1.11 4.13 807 3.81 2.23 1.05 0.30
1 rs6694862 216033717 G 1093 2.24 1.90 286 -1.18 4.09 807 3.58 2.24 1.02 0.31
1 rs11589174 240756312 C 1093 2.21 2.46 286 6.57 5.56 807 0.14 2.84 -1.03 0.30
1 rs12093170 240757607 C 1093 0.26 2.29 286 6.70 5.10 807 -2.14 2.67 -1.54 0.12
1 rs6677308 240763170 A 1091 2.32 2.40 286 8.28 5.24 805 -0.24 2.81 -1.43 0.15
2 rs892867 79218487 G 1093 -3.13 1.72 286 -2.61 3.99 807 -2.85 1.96 -0.05 0.96
2 rs10928087 141458573 G 1092 0.65 2.84 285 10.05 5.75 807 -3.97 3.42 -2.09 0.04
2 rs4664511 152522710 G 1093 5.42 2.83 286 13.58 6.11 807 1.78 3.32 -1.70 0.09
2 rs3770111 182090561 A 1093 0.07 2.53 286 4.05 5.57 807 -1.96 2.95 -0.95 0.34
2 rs2690751 190763511 A 1092 -2.60 1.89 286 -8.39 4.31 806 -0.40 2.18 1.66 0.10
2 rs12467492 227127070 A 1092 -0.11 1.60 285 -5.00 3.62 807 1.64 1.84 1.64 0.10
3 rs1554328 118325495 A 1073 -4.34 2.46 282 -5.35 5.20 791 -4.40 2.92 0.16 0.87
3 rs938111 118330571 C 1092 -1.20 2.36 285 0.84 4.99 807 -3.14 2.80 -0.70 0.49
4 rs1394339 90492121 A 1093 -0.54 1.59 286 -4.14 3.38 807 0.73 1.88 1.26 0.21
5 rs1366331 110330169 A 1093 3.44 2.94 286 8.43 7.45 807 0.45 3.29 -0.98 0.33
5 rs4836058 123375799 G 1093 0.18 1.62 286 1.04 3.59 807 -0.22 1.89 -0.31 0.76
5 rs1862404 123378142 G 1093 0.96 1.68 286 2.83 3.65 807 0.02 1.97 -0.68 0.50
5 rs11949657 133897834 C 1093 -1.80 2.56 286 -1.10 6.18 807 -3.37 2.89 -0.33 0.74
6 rs1498426 21116132 G 1092 -1.74 1.59 285 2.70 3.53 807 -2.50 1.85 -1.31 0.19
6 rs221749 165783026 G 1091 0.56 1.80 284 3.14 4.17 807 -0.18 2.06 -0.71 0.48
6 rs17182135 169147239 G 1093 0.16 1.65 286 1.64 3.62 807 -1.68 1.92 -0.81 0.42
6 rs12528430 169151607 A 1093 0.10 1.65 286 1.75 3.65 807 -1.68 1.92 -0.83 0.41
7 rs4723295 33591734 G 1093 -3.88 2.40 286 6.05 5.27 807 -8.50 2.78 -2.44 0.01
7 rs12667992 91183013 A 1093 2.44 2.64 286 2.59 5.97 807 2.59 3.05 0.00 1.00
7 rs1916602 91199648 G 1093 1.96 2.53 286 1.95 5.71 807 1.72 2.92 -0.04 0.97
7 rs9791835 105324494 A 1092 -1.96 2.59 285 -2.26 5.69 807 -2.95 3.01 -0.11 0.92
7 rs12705973 114100435 G 1092 -0.08 1.62 286 7.87 3.55 806 -3.56 1.89 -2.84 4.47-03
7 rs12671330 114121279 G 1092 -0.10 1.61 285 8.39 3.50 807 -3.74 1.87 -3.05 2.26-03
8 rs2458416 105420643 G 1092 0.39 2.69 286 -0.53 5.93 806 0.52 3.15 0.16 0.88
9 rs10962687 1690272 G 1093 0.36 3.52 286 2.44 6.89 807 -0.75 4.33 -0.39 0.69
9 rs10962689 1690460 G 1093 0.64 3.51 286 3.14 6.82 807 -0.54 4.33 -0.45 0.65
12 rs4639992 43209601 G 1093 -3.32 2.30 286 -5.98 4.92 807 -1.96 2.72 0.71 0.48
12 rs16946677 115386413 C 1093 0.92 2.48 286 -2.72 6.44 807 0.15 2.74 0.41 0.68
17 rs2258367 18796532 C 1093 -2.51 2.52 286 0.44 6.17 807 -3.36 2.83 -0.56 0.58
20 rs6073768 43563560 G 1091 2.43 2.14 286 -2.65 4.94 805 4.16 2.46 1.24 0.22
20 rs1013562 43744158 G 1091 2.72 2.14 286 -5.39 5.03 805 5.25 2.44 1.90 0.06
20 rs6073862 43765119 G 1092 3.12 2.14 286 -4.69 4.94 806 5.71 2.45 1.89 0.06
21 rs13049780 19638152 G 1093 0.41 2.68 286 0.79 5.20 807 0.59 3.33 -0.03 0.97
21 rs2827251 22429921 A 1093 1.20 3.04 286 7.96 6.84 807 -2.18 3.51 -1.32 0.19
BETA > 0 annual FEV
1
decline acceleration
BETA > 0 annual FEV
1
decline attenuation.
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Supplementary table 3. Beta estimates in Vlagtwedde/Vlaardingen: whole cohort, >20 pack-years, <20 
pack-years and GxE test















































1 rs2492321 59124034 A 1056 -1.10 0.98 250 0.62 2.03 806 -2.02 1.39 -1.07 0.28
1 rs927743 59141535 A 1053 -0.97 0.82 248 0.49 1.87 805 -1.11 1.12 -0.73 0.46
1 rs920307 188985655 A 1044 0.20 1.05 247 -2.82 2.18 797 1.02 1.49 1.46 0.15
1 rs6604558 216001829 A 1056 -0.03 0.95 250 0.37 2.11 806 -1.85 1.32 -0.89 0.37
1 rs6694862 216033717 G 1056 0.09 0.95 250 0.38 2.10 806 -1.61 1.32 -0.80 0.42
1 rs11589174 240756312 C 1049 -1.03 1.15 249 -1.55 2.31 800 -1.65 1.64 -0.03 0.97
1 rs12093170 240757607 C 1055 -0.50 1.08 250 1.83 2.20 805 -1.46 1.55 -1.22 0.22
1 rs6677308 240763170 A 1055 -1.54 1.16 250 -0.87 2.34 805 -1.73 1.67 -0.30 0.77
2 rs892867 79218487 G 1055 -0.56 0.84 250 -0.76 1.91 805 0.24 1.15 0.45 0.65
2 rs10928087 141458573 G 1056 0.20 1.51 250 -0.50 3.44 806 -0.96 2.08 -0.11 0.91
2 rs4664511 152522710 G 1056 1.22 1.36 250 2.10 3.05 806 0.46 1.87 -0.46 0.65
2 rs3770111 182090561 A 1056 -1.15 1.28 250 -2.98 2.52 806 2.54 1.85 1.77 0.08
2 rs2690751 190763511 A 1055 -0.56 0.96 250 0.85 2.19 805 -0.66 1.32 -0.59 0.55
2 rs12467492 227127070 A 1056 -1.43 0.77 250 0.73 1.65 806 -2.04 1.08 -1.40 0.16
3 rs1554328 118325495 A 1048 -0.05 1.23 249 -1.23 3.22 799 1.87 1.64 0.85 0.39
3 rs938111 118330571 C 1056 -0.09 1.18 250 0.85 2.87 806 0.16 1.60 -0.21 0.83
4 rs1394339 90492121 A 1056 -0.42 0.79 250 -1.02 1.70 806 -0.16 1.10 0.42 0.67
5 rs1366331 110330169 A 1056 0.18 1.46 250 1.35 3.43 806 0.82 1.99 -0.13 0.89
5 rs4836058 123375799 G 1056 2.13 0.80 250 3.16 1.86 806 1.34 1.10 -0.85 0.40
5 rs1862404 123378142 G 1056 2.63 0.84 250 4.13 1.96 806 1.27 1.15 -1.26 0.21
5 rs11949657 133897834 C 1056 2.49 1.18 250 2.10 2.71 806 4.01 1.62 0.60 0.55
6 rs1498426 21116132 G 1055 1.22 0.80 250 -0.26 1.71 805 1.01 1.12 0.62 0.53
6 rs221749 165783026 G 1055 -0.75 0.91 249 0.75 1.99 806 -0.94 1.27 -0.72 0.47
6 rs17182135 169147239 G 1055 -1.23 0.80 250 0.29 1.70 805 -0.95 1.13 -0.61 0.54
6 rs12528430 169151607 A 1055 -1.32 0.80 249 -0.18 1.68 806 -0.76 1.12 -0.29 0.77
7 rs4723295 33591734 G 1056 -0.42 1.18 250 -5.25 2.39 806 2.06 1.68 2.51 0.01
7 rs12667992 91183013 A 1056 2.03 1.43 250 2.85 3.05 806 0.57 2.02 -0.62 0.53
7 rs1916602 91199648 G 1056 1.28 1.31 250 3.25 2.80 806 -1.41 1.83 -1.40 0.16
7 rs9791835 105324494 A 1055 1.60 1.28 250 -0.13 2.82 805 2.53 1.77 0.80 0.42
7 rs12705973 114100435 G 1056 -1.04 0.80 250 -0.79 1.80 806 1.41 1.10 1.05 0.30
7 rs12671330 114121279 G 1054 -0.83 0.79 250 0.73 1.77 804 -1.51 1.09 -1.08 0.28
8 rs2458416 105420643 G 1056 1.53 1.32 250 -4.18 2.99 806 2.94 1.82 2.04 0.04
9 rs10962687 1690272 G 1056 -1.26 1.59 250 -3.25 4.78 806 0.24 2.08 0.67 0.50
9 rs10962689 1690460 G 1056 -1.16 1.55 250 -2.79 4.65 806 0.35 2.02 0.62 0.54
12 rs4639992 43209601 G 1056 1.31 1.13 250 -1.59 2.60 806 2.03 1.54 1.20 0.23
12 rs16946677 115386413 C 1056 -1.10 1.18 250 2.23 2.92 806 -1.05 1.58 -0.99 0.32
15 rs7182547 29084964 A 1051 0.99 0.86 249 1.92 1.79 802 0.00 1.22 -0.89 0.37
17 rs2258367 18796532 C 1045 0.60 1.28 248 -2.88 2.79 797 0.65 1.79 1.06 0.29
20 rs6073768 43563560 G 1055 -0.65 1.00 250 -2.95 2.27 805 -0.86 1.37 0.79 0.43
20 rs1013562 43744158 G 1048 -1.28 0.99 247 -4.12 2.19 801 -1.04 1.37 1.19 0.23
20 rs6073862 43765119 G 1056 -1.09 0.97 250 -3.65 2.13 806 -1.09 1.36 1.02 0.31
21 rs13049780 19638152 G 1055 0.05 1.35 250 0.08 2.91 805 1.58 1.89 0.43 0.66
21 rs2827251 22429921 A 1055 0.85 1.54 250 3.39 3.52 805 1.18 2.12 -0.54 0.59
BETA > 0 annual FEV
1
decline acceleration
BETA > 0 annual FEV
1
decline attenuation.
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Abstract
Chronic obstructive pulmonary disease (COPD) is a complex disorder involving multiple genes. 
However, despite genome-wide association studies (GWAS) identifying many disease genes, 
we know a significant proportion of a trait’s heritability remains unexplained. We therefore 
performed the first genome-wide SNP-SNP interaction (epistasis) analysis in COPD, as we 
suspect epistasis holds the key to at least part of the missing heritability. We used the NELSON 
cohort as a discovery set, comprising 1,030 cases and 1,808 controls, and the LifeLines cohort 
as a replication set, with 711 cases and 3,013 controls. Our results show SNP-SNP interactions 
suggesting that cell adhesion and cell communication pathways could be involved in COPD 
development. SNPs involved in these interactions are annotated to genes that include SERPINB9, 
CNTN5, PTPRM and SIGLEC1, and which, except for CNTN5, were not previously associated 
with COPD. Our findings open up new avenues towards understanding the course of events 
leading to COPD, but they should be considered with caution, as genome-wide significance 
was not reached. Further replication is needed to confirm our findings. 
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 Chronic obstructive pulmonary disease (COPD, MIM 606963) is a respiratory disease 
caused by both genetic and environmental factors, including cigarette smoking and air pollution. 
The role of genetics was first seen in studies on families with early-onset COPD1. Linkage 
studies identified a locus on chromosome 2q that mapped to the SERPINE2 (MIM 177010) 
gene2. SERPINA1 (MIM 107400) is known to predispose to early onset emphysema, one of the 
phenotypes in COPD3. Candidate gene studies have focused mostly on three pathways that 
are involved in COPD: the inflammatory, anti-oxidant and protease-anti-protease pathways. 
They have identified the following genes: TNFA (MIM 191160), TGFB1 (MIM 190180), GSTP1 (MIM 
134660) and MMP9 (MIM 120361), and others, as associated with COPD (reviewed in Smolonska 
et al4). However, these associations have not yet been confirmed by genome-wide association 
studies (GWAS). GWAS have identified CHRNA3/5 (MIM 118503, 118505), HHIP (MIM 606178)5, 
FAM13A (MIM 613299)6 and BICD1 (MIM 602204)7 as loci associated with COPD, the last with 
emphysema in particular. Since COPD is a complex disorder, these variants are unlikely to explain 
all the “missing heritability” for COPD. However, gene-gene interactions (epistasis) have been 
proposed as a potential mechanism that might explain a large part of this missing heritability8; 
their contribution to COPD development has not yet been investigated. We aimed to perform 
the first genome-wide epistatic analysis, using 1,030 COPD cases and 1,808 controls (Patients 
characteristics in Table S1). 
 Samples were genotyped on the Illumina 610Quad BeadChip and the data was subjected 
to detailed quality control (Supplemental Material) that left 492,339 SNPs for the analysis. We 
used EpiBLASTER9, software enabling a full genome epistasis scan in a time-efficient manner. 
EpiBLASTER follows a two-stage approach. In the first stage, the difference in Pearson’s 
correlation coefficients between cases and controls for all possible SNP pairs are computed and 
the significance of this difference is indicated. Using an arbitrary p < 1*10-6 as a cut-off for the 
first stage, we ended up with 120,425 unique SNP pairs exceeding this threshold. In the second 
stage, full rank logistic regression was performed on the top 1,000 SNP pairs (arbitrary number) 
from the first stage to obtain the effect estimate and p-value for the interaction term. Next, we 
performed likelihood ratio tests to test if the effect estimates from logistic regression were 
significantly different from zero. To confirm our findings we performed a replication analysis of 
the same 1,000 SNP pairs using 711 COPD cases and 3,013 controls from the LifeLines cohort10. 
This cohort was genotyped using the Illumina Human CytoSNP. Imputation was performed with 
BEAGLE 3.0 software11 using HapMap 2 CEU population as a reference panel and, after imputation, 
SNPs with r2 < 0.3 were removed, leaving 764 SNP pairs of the top 1,000 SNPs for analysis. 
Fifteen SNP pairs were replicated with p < 0.05 (Table 1). P-values were combined using Fisher’s 
method. None of the SNP pairs exceeded the genome-wide significance threshold: 4.12*10-13 
(0.05/492,3392/2). However, taking into account that: (1) SNPs included in the epistatic analysis 
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were not pruned for linkage disequilibrium (LD) beforehand, hence the tests were not entirely 
independent, and (2) EpiBLASTER uses a two-stage approach, in which the first is a filtration 
step preventing some 120 billion tests from being performed, it did not seem justified to use 
a strict Bonferroni correction. We therefore applied the false discovery rate (FDR) method to 
account for multiple testing in the replication phase, but none of the 764 SNP pairs showed 
significant epistatic effect. This might be due to (1) a power issue, i.e. a much larger sample size 
is required to replicate interactions, rather than traditional genotypic associations, or (2) because 
the identified SNP pairs are false-positives. We should also highlight the fact that the replication 
cohort had imputed genotypes, which can give good approximations for single polymorphism 
analysis, but in epistatic analysis, where two genotypes are taken together, can give a much 
higher deviation from the actual distribution. The minor allele frequency (MAF) may well be under- 
or over-estimated. The differences can thus seem insignificant, yet the sum of frequencies of 
genotypes involved in epistatic effect differed by nearly 3% (F
epi
, Supplemental Material). We 
should therefore interpret both positive and negative findings with caution when using imputed 
genotypes for epistatic analysis.
 Since we were interested whether epistasis could identify plausible pathways, we 
performed annotations for the 30 SNPs with p < 0.05 for interaction in the replication phase 
using SCANdb12 (Table 1). Ten SNP pairs could not be translated into gene-gene interactions, 
because at least one of the SNPs was not annotated to a gene. Genes presented in Table 1 were 
used for gene enrichment analysis in GeneMANIA13 (Figure 1) and annotation with GATHER14. We 
observed a clear over-representation of genes involved in cell adhesion (GO:0007155) and cell 
communication (GO:0007154) pathways (p < 0.0001 for both). Cell adhesion plays a crucial role 
in epithelial barrier repair after tissue injury, abundantly present in COPD.
 One of the interesting gene pairs is SERPINB9 (MIM 601799) and CNTN5 (MIM 607219). 
SERPINB9 belongs to the serine inhibitor protein family, with two members already associated 
with COPD (SERPINA1 and SERPINE2). Furthermore, it specifically inhibits granzyme B15, a 
cytolytic enzyme released by lymphocytes during the inflammatory response initiating target 
cell apoptosis16. 
 Another interesting pair of genes is PTPRM (MIM 176888) and SIGLEC1 (MIM 600751), 
both with cell adhesion-related functions. PTPRM (protein tyrosine phosphatase receptor type M) 
levels have been shown to be reduced after injury of epithelial cells. Lower expression of PTPRM 
results in reduced adhesion of epithelial cells17. SIGLEC1 (sialoadhesin, sialic acid binding Ig-like 
lectin 1) is one of the few receptors that are expressed solely on the monocyte and macrophage 
surfaces18. Macrophages are key players in the development of COPD and are recruited to the lung 
upon cigarette smoke inhalation. Interestingly, the ligands of sialoadhesin are mainly expressed on 
neutrophils19, which also play an important role in the pathogenesis of COPD. 
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Figure 1. Gene enrichment in GeneMANIA based on top gene-gene interactions.
Black circles: query genes (from Table 2); Grey circles: genes enriched in GeneMANIA
We further investigated the regulatory potential of SNPs not in the direct proximity of a 
gene, using HaploReg20 (Table 2). Six out of 11 SNPs showed regulatory potential at least in 
one ENCODE21 experiment type: three SNPs cause an alteration in transcription factor binding 
sites, two SNPs are located in DNAse I footprints (which correlate with open-state chromatin 
and transcription factor binding sites) and one SNP is situated within an enhancer. One of the 
interesting findings is that rs2042416 alters the Foxo motif, where Forkhead box O (FOXO) 
transcription factors bind. FOXO transcription factors are crucial to all aspects of T-cell 
biology, immune response and oxidative stress22 and FOXO3 levels have been shown to be 
reduced in the lungs of smokers and COPD patients23. 
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 In summary, we describe the first complete, genome-wide epistatic analysis in 
COPD, without pre-selection of markers. We tested for SNP-SNP interactions and performed 
replication in an independent cohort. We replicated 15 SNP pairs associated with COPD (p < 
0.05) but none of the SNPs involved in these 15 interactions was even marginally associated 
with COPD on its own(data not shown). This is in line with the definition of epistasis. Annotation 
of these SNPs indicates cell adhesion and cell communication pathways, both plausible in COPD 
pathogenesis. The overall picture of COPD pathogenesis emerging from the genes involved in 
interactions, like SERPINB9, CNTN5, PTPRM and SIGLEC, opens new avenues for further research 
and may be crucial for understanding the course of events leading to clinical expression of 
COPD. Our results must be interpreted with caution because none of the SNP-pairs reached 
copd.indd   131 9/2/2013   11:06:56 AM
chapter SIX EPISTASIS IN COPD
132
genome-wide significance threshold, probably due to the limited replication sample size and 
use of imputed genotypes. Our findings should be replicated in a large COPD cohort with non-
imputed, genome-wide genotype data.
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Supplemental Material
Quality control of genome-wide genotyping data.
SNPs with a call rate <95%, minor allele frequency <5% and SNPs deviating from Hardy-
Weinberg equilibrium (HWE; p<0.0001) were removed. Samples were removed if 5% or more 
of the genotypes were missing, if they were duplicates, if they were derived from individuals 
related to another one in the dataset or if they were ethnic outliers (based on components 
from multidimensional scaling C1 and C2). These quality control steps were performed using 
PLINK1.
Effects of MAF underestimation on epistasis as a result of imputation
Imputed genotypes can be a good approximation in case of single polymorphism analysis but 
in epistatic analysis, where two genotypes are taken together, the deviation from the actual 
distribution can be much higher. It can happen that minor allele frequency (MAF) is under- or 
overestimated. If we assume SNP1 has MAF
1
=0.3 and SNP2 has MAF
2
=0.08 we will observe 
distributions as shown in Table S2A. However, if SNP1 is genotyped and MAF
1
 is not changed 
and SNP2 is imputed and underestimated MAF
2
 equals to 0.05 the distribution is different 
(Table S2B). Differences can seem insignificant, however the sum of frequencies of genotypes 
involved in epistatic effect differs by nearly 3%.




Cases Controls Cases Controls
N 1,030 844*+ 964a 711 3,013
Age [mean(sd)] 61.3 (5.6) 59.1 (5) 63.9 (5.7) 43.2 (8.6)
% male 100 100 51.9 43.6
Height (cm) [mean(sd)] 178.3 (6.4) 178.2 (6.6) 175.6 (8.9) 175.5 (9.2)
% current smoker 39.8 64.5 49.9 42.4
% former smoker 60.2 35.5 50.1 57.6
Pack-years smokingb 42.6 (17.9) 39.4 (16.9) 19.2 (13.8) 10.8 (9)
FEV1/FVC(%) [mean(sd)] 60.3 (8.5) 76.5 (4.9) 63.9 (5.7) 79.3 (4.9)
* Blood bank controls - no demographic data available
a Characteristics below for number of individuals in bold
b Calculated only within ever-smokers [mean(sd)]
COPD cases were defined as airway obstruction according to GOLD2 criteria (FEV
1
/FVC<0.7).
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Table S2 Effects of MAF underestimation on epistasis as a result of imputation.
A) Actual distribution of genotype combinations
 SNP1, MAF=0.3
SNP2, MAF=0.08 AA1 AB1 BB1
AA2 0.414736 0.355488 0.076176
AB2 0.072128 0.061824 0.013248
BB2 0.003136 0.002688 0.000576
Shaded cells – frequencies of genotype combinations involved in epistasis, F
epi
=0.078336
B) Distribution of genotype combinations when SNP2 is imputed and MAF is underestimated.
 SNP1, MAF=0.3
SNP2, MAF=0.05 AA1 AB1 BB1
AA2 0.442225 0.37905 0.081225
AB2 0.04655 0.0399 0.00855
BB2 0.001225 0.00105 0.000225




1.  Purcell S, Neale B, Todd-Brown K et al. PLINK: a tool set for whole-genome 
association and population-based linkage analyses. Am J Hum Genet 
2007;81:559-575.
2.  From the Global Strategy for the Diagnosis, Management and Prevention of 
COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD). http://
www.goldcopd.org/, 2011.
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Discussion
Genetics of respiratory phenotypes
The aim of this thesis was to gain insight into the genetic factors underlying COPD. 
Back in 2008 when this project started, little was known about these factors. There were many 
candidate gene studies reporting associations with COPD, but the results were inconsistent. We 
therefore started with a systematic review and meta-analysis of previous findings (Chapter 2). 
When the GWAS era started (in 2005), several studies were published on respiratory phenotypes, 




/VC), lung function decline, and COPD. The overview of 
findings from these studies and our own research is shown in Figure 1. 
Figure 1. Genetics of lung function level, lung function decline, and COPD – findings from previous 
studies and studies described in this thesis (bold). 
Since COPD is basically a disease of progressive lung function loss, we cannot discuss 
the genetics of COPD without discussing the genetics of lung function and its decline. Indeed, 
there are now indications from several studies that genes associated with these respiratory 
phenotypes show an overlap (Figure 1). This is also one of the reasons why we investigated the 
shared genetics of airway obstruction and emphysema (Chapter 3) and the shared genetics of 
asthma and COPD (Chapter 5). We thought that studying multiple aspects of a phenotype would 
yield more knowledge. However, we kept in mind that airway obstruction and emphysema 
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(Chapter 3) are separate entities and that lung function decline (Chapter 4) not only occurs in 
COPD patients, and we therefore studied the specific genetics of these phenotypes as well. 
We were the first to investigate gene-gene interactions and their contribution to COPD in a 
genome-wide, hypothesis-free manner (Chapter 6). We identified focal adhesion pathways 
(Chapter 3) and cell adhesion (Chapter 6) pathways by investigating the genetics of COPD 
using different approaches. This could be an indication that cell communication is important 
in COPD. Airway epithelium is known to be damaged in COPD patients and by exposure to 
smoke.1 Alterations in focal adhesion and cell adhesion pathways can interfere with wound 
repair in airway epithelium.2 However, these pathways can also be altered in other cell types and 
lead to COPD development. Adhesion is not only crucial for maintaining multicellular structures, 
like tissue, but it also plays a key role in cell-matrix and cell-cell boundaries and communication. 
However, it still needs to be established where exactly these pathways are altered and how 
they may lead to COPD. 
Complex genetics of complex disorders
 The genetics of complex disorders has indeed become very complex over the last 
few years. Genome-wide association studies (GWAS) have identified loci associated with 
many complex phenotypes. These loci differ in size and content: on the one hand, sometimes 
they are huge and harbor many genes, making it difficult to determine which gene is actually 
the causal one. On the other hand, sometimes these loci are so-called ‘gene deserts’, harboring 
no protein-encoding genes and thus increasing the difficulty of interpreting the results further. 
Especially in the light of recent advances by the ENCODE project, which so far has mapped 
80% of the genome to regulatory elements, like transcription factor binding sites, DNAseI 
hypersensitive sites, open chromatin, etc. and taking into account the linkage disequilibrium 
structure of the loci identified by GWAS, we can expect that most of the SNPs will be 
annotated to a regulatory element. This might also be the case for the SNPs that are annotated 
to the genes and it may turn out that the gene itself has nothing to do with the disease. So 
were the GWA studies helpful? Yes, they were. They helped us identify loci that would never 
have been discovered using a candidate gene approach. If we consider genetics as the map 
of a disease, GWA studies would be the grid of this map, composed of identified loci and 
pathways. Now we need to fill in the grid to complete the map, which will not be an easy task 
given the multiple levels of information required. One of the tools we can use for this are 
microarrays with a content specific for a particular disease group, like the a metabochip or 
immunochip for performing fine-mapping studies. The aim is to refine the association signal 
in the locus, which can help to narrow down the region of interest. Another tool that can 
be used is next-generation sequencing (NGS), a powerful technique to detect mutations in 
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the genome. NGS has been successfully applied in a small number of individuals to identify 
mutations leading to rare Mendelian disorders. But, contrary to its application in Mendelian 
disorders, in complex disorders, much larger numbers of individuals need to be sequenced, but 
with the falling price of NGS such studies are becoming feasible. Other omics techniques, like 
gene expression, proteomics and metabolomics will add an extra layer to this map, making it 
more comprehensive and easier to read. The exact route, however, will be drawn by functional 
studies, which will provide information on the exact course of events leading to disease and on 
the tissue and cell types in which these events actually take place. Another level of information 
will come from studying both gene-environment and gene-gene interaction.
Missing heritability, hidden heritability, phantom heritability, and epistasis
By now (April 2013), the GWAS era has yielded 9,872 SNPs associated with over 1,400 
traits and described in 1,563 publications in little more than five years. Despite this abundance, 
only a small proportion of heritability of many traits can so far be explained. Some time ago 
the scientific community had already started wondering how the remainder of the heritability 
could be found and where. In the beginning, copy number variations (CNV) and rare variants 
were thought to account for a substantial proportion of the missing heritability, but it was 
soon proven this was not the case.3 The concept of hidden heritability was born, as it was 
thought that some relevant variants are hidden below conservative genome-wide significance 
thresholds or because the variants are so rare that they cannot be captured with GWAS.4 The 
next suspect was epistasis, in other words gene-gene interaction. Epistasis is a phenomenon 
in which two genes together affect the phenotype, either by the masking of one or acting 
synergistically. Epistasis is frequent in all organisms, starting with yeast 5 and up to humans.6 It 
has been proposed that by not taking epistasis into account while calculating the proportion 
of explained heritability, so-called phantom heritability is created.7 In other words, the genetic 
variants identified in GWA studies could explain much more of the heritability, but not under 
the additive model assumptions. Therefore the statement that rare variants or even more 
common variants must underlie common diseases might not be valid. In fact, it is likely that, 
for many disorders, the major susceptibility loci have already been identified. 
For many years, studies on epistasis were restricted to a subset of genes, most 
frequently the candidate genes, or later to genes identified in GWAS. This restriction was 
due to a large number of possible interactions. If we want to test all the possible pair-wise 
interactions, assuming we genotyped 500,000 SNPs, we would have to test 1.25*109 SNP 
pairs for interaction. Such an analysis is exhaustive computationally, not to mention the time 
required to run it. Not so long ago there were basically no tools that could enable a whole 
genome epistatic analysis to be completed in less than a year! With the development of 
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graphical processing units (GPUs) this has become feasible and more studies describing 
epistasis in complex disorders have appeared recently. Full genome scans for epistasis has 
already been were performed in prostate cancer 8 and serum uric acid levels,9 for example. Both 
studies were underpowered to detect significant interactions, as the required sample size is 
much larger than for GWAS, or it could also be due to applying a strict Bonferroni correction. 
Therefore novel approaches need to be implemented to reduce the limitations of multiple 
testing, like a two-stage approach, as implemented in EpiBLASTER.10 
Complex genetics are getting more and more complex
Gene, pseudogene, gene desert, junk DNA: these are just a few terms for which 
the definitions have changed in the past few years. Genes used to be defined as DNA units 
composed of a sequence containing protein code. We now know that genes not only encode 
for proteins, but also for many sorts of RNA genes, including miRNAs (micro RNAs), siRNAs (small 
interfering RNA), lincRNAs (long intergenic non-coding RNAs), to name a few. Pseudogenes 
were thought to be an inactive copy of a parent gene but recently it was shown that some 
pseudogenes are not so ‘pseudo’ and are either expressed 11 or at least transcribed,12 and the 
transcript itself may have a profound biological function.13 Gene deserts have turned out not to 
be deserts at all, but harbor many newly discovered genes, not only for protein coding, but also 
regulatory elements, etc. The concept of junk DNA simply does not hold anymore, as proven 
by the ENCODE consortium.14
These definitions have changed and been improved with the time and effort put into 
many studies and, as a result, our understanding has increased somewhat. But they also mean 
genetics is much more complex than we thought. If we take a complex disorder and a change 
in SNP X that is associated with it, what does it mean? Let’s start from the SNP, which by 
definition a single letter in the genome composed of 3.2 billion such letters. There are many 
ways through which this single letter can lead to a phenotype, irrespective of its location 
(Figure 2). A minority of the SNPs identified for complex disorders are located within exons of 
protein-coding genes, which means that, for the remaining majority, the function cannot be 
inferred easily. And at the end, we have a phenotype, a complex disorder, which means that not 
only SNP X will be responsible for it, but also that there might be perhaps hundreds of other 
SNPs contributing to the phenotype. This is the case for height, for example. 
Future perspectives
The 21st century has already brought significant advancements in technologies that 
can be used to construct tools to enable scientists to make significant scientific progress. 
This holds for all disciplines, but starting from 2005, the field of genetics has exploded. GWA
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Figure 2. Possible ways through which SNPs can lead to a phenotype.
eQTL – expression quantitative trait locus, TFBS – transcription factor binding site
studies are just a grid for our map of complex disorders. Maybe we still need to create a few 
of them, for example, for COPD there are still some gaps to be filled. So far there have been no 
GWA studies on COPD patients who have never smoked and it would be extremely interesting 
to see if the same or a completely distinct set of genes is responsible for COPD development 
in this group. However, research resources are limited, and new cohorts take time, effort and 
money to collect and then to characterize. The near future will probably see fewer and fewer new 
GWA studies and only a few meta-analyses by consortia. Meta-analyses do have the potential to 
discover new loci, as shown by many studies, for example, for ulcerative colitis, where pooling 
six studies yielded 29 new loci.15 No large meta-analysis has yet been performed for COPD. 
COPD remains a chronic and disabling disease affecting millions of people worldwide. 
The more genetic studies can shed light on its origin and development, the more likely we are 
to discover leads towards better prognoses and treatment. Many questions about COPD are 
left to be answered. GWAS era generated many hypotheses that need to be proven or refuted. 
In the end, finding a gene is just a beginning.
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The work described in this thesis was done within the framework of the COPACETIC consortium, 
which was established to determine the genetic background of chronic obstructive pulmonary 
disease (COPD) and lung function decline. We started with genome-wide screening that 
yielded dense genotype information. 
Chapter 3 describes the main outcome of the consortium, which are genome-wide association 
(GWA) studies on airway obstruction and emphysema, as well as an attempt to identify shared 
genetic components. These GWA studies did not yield any genome-wide significant findings, 
despite large sized replication cohorts (especially in airway obstruction), which might have 
been due to phenotype heterogeneity and limited  power in the discovery cohort. The overlap 
between airway obstruction and emphysema was difficult to study, due to use of a single 
discovery cohort. Using two different approaches we were able to point to the same pathway 
which was focal adhesion pathway, known to be crucial in epithelial repair mechanisms. 
In Chapter 4 we investigated the so-called ’Dutch hypothesis’ on a genome-wide level. Briefly, 
the Dutch hypothesis stated, that asthma and COPD are different manifestations of the same 
disease unit, hence share genetic background and environmental factors. Only the timing and 
specific interplay between genetics and environment will determine the final phenotype. To 
prove or refute this hypothesis we performed meta-analysis using asthma and COPD GWA 
studies. We found three loci associated with both phenotypes. The genes located in these 
three loci, COMMD10 and DDX1, point towards NFκβ which mediates inflammatory process in 
both, asthma and COPD. These processes are different, but could be mediated by COMMD10 
and DDX1 in both diseases, implying that the Dutch hypothesis can be valid. At this stage the 
Dutch hypothesis can not be proven or refuted with certainty. 
Chapter 5 describes GWA study on lung function decline. Our discovery cohort was a 
population of heavy smokers and our replication cohorts were population-based. What 
we noticed immediately were differences of the decline extent itself and genetic effects 
sizes. Heavy-smokers displayed much larger lung function decline per year, compared to the 
general population and we were not able to replicate the findings from the GWA study in 
the population-based replication cohorts. However, we performed some additional gene-
environment interaction analyses in two out of three replication cohorts, which strongly 
suggested that the genetic effects are diluted in the replication cohorts due to heterogeneity 
of the phenotypes that were present. We have shown, that if the replication sample is restricted 
to heavy smokers with COPD, the genetic effects are much more alike the discovery cohort 
(heavy-smokers, 50% of them with COPD). However, this restriction reduced the sample size 
significantly therefore the conclusion is that more phenotype-specific cohorts are needed to 
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perform proper lung function decline GWA studies.
So far three GWA studies have been published on COPD, however the number of loci identified 
is much lower than in other phenotypes. There is a debate ongoing on so-called ’missing 
heritability’ or ‘hidden heritability’ phenomena. Most likely, genetic associations will not explain 
the entire heritability of a phenotype. Therefore in Chapter 6 we performed the first genome-
wide gene-gene interaction analysis in COPD. Due to large number of tests performed our 
results did not reach genome-wide significance. 
We observed a clear over-representation of genes involved in cell adhesion and cell 
communication pathways. Cell adhesion plays a crucial role in epithelial barrier repair after 
tissue injury, abundantly present in COPD. These results should be further validated in a large 
COPD cohort.
In summary, this thesis is an investigation of several phenotypes of COPD: airway obstruction, 
emphysema, lung function decline. We were interested not only in these phenotypes, but also 
their shared genetic background. Airway obstruction and emphysema can occur together, 
asthma and COPD despite being separate diseases share many features, and therefore we 
searched for common genes underlying these phenotypes. GWA studies were the main tools 
used, but we also looked beyond GWA studies and used other tools, like analysis of epistasis. 
The pathways that emerge from our findings are worth investigating further, as not all of them 
were considered to be  involved in COPD before. 
 




Het in deze thesis gepresenteerde werk is uitgevoerd binnen het COPACETIC consortium, welke 
opgericht is om de genetische achtergrond van chronische obstructieve longaandoeningen 
(chronic obstructive pulmonary disease, COPD) en het verval van longfunctie te onderzoeken. 
We zijn gestart met genoomwijde genotyperingen, welke uitgebreide genotype informatie 
opleverden.
Hoofdstuk 3 beschrijft de voornaamste uitkomst van het consortium. Dit zijn genoomwijde 
associatie (GWA) studies op luchtwegobstructie en emfyseem, evenals een poging om gedeelde 
genetische componenten te identificeren. In de GWA studies werden geen genoomwijd 
significant geassocieerde bevindingen gedaan, ondanks het gebruik van een groot replicatie 
cohort (vooral voor luchtwegobstructie). Dit wordt waarschijnlijk veroorzaakt door een grote 
heterogeniteit in de fenotypes en een gebrek aan statistische power in het initiële cohort. 
De overlap tussen luchtwegobstructie en emfyseem was moeilijk te bestuderen, aangezien 
het initiële cohort hetzelfde was voor beide studies. Door middel van twee verschillende 
methoden konden we gezamelijke pathway aanwijzen, het focale adhesie pathway, bekend 
om zijn cruciale rol in epitheliale herstel mechanismen.
In hoofdstuk 4 hebben we de validiteit van de zogenaamde “Nederlandse hypothese” op een 
genoomwijde niveau getest. De Nederlandse hypothese gaat er van uit dat astma en COPD twee 
verschillende manifestaties zijn van eenzelfde ziekte, en daardoor een genetische achtergrond 
en omgevingsfactoren delen. De timing en specifieke interacties tussen genetische factoren 
en de omgeving bepalen het  uiteindelijke  fenotype. Om deze hypothese te bewijzen, dan wel 
te verwerpen, hebben we een meta-analyse verricht op astma en COPD studies. We vonden 
drie loci die met beide fenotypes geassocieerd zijn. Echter, we konden deze bevindingen niet 
repliceren in populatie gebaseerde cohorten met een minder sterk uitgesproken fenotype. De 
genen in deze loci, COMMD10 en DDX1 wijzen richting NFkB, welke imflammatoire processen 
in zowel astma en COPD reguleert. De onderliggende processen zijn verschillend in beide 
aandoeningen, maar kunnen in beide aandoeningen gereguleerd worden door COMMD10 en 
DDX1, wat er op wijst dat de Nederlandse hypothese waar zou kunnen zijn. Op dit moment is 
het echter nog onmogelijk de Nederlandse hypothese definitief te bewijzen of te verwerpen.
Hoofdstuk 5 beschrijft een GWA studie op verval van longfunctie. Ons initiële cohort  is 
een  van  zware rokers en de replicatie cohorten zijn populatie gebaseerd. Wat ons direct 
opviel waren de verschillen in de ernst van het verval en de effect grootte van de genetische 
varianten. Zware rokers laten per jaar een sterker verval in longfunctie zien ten opzichte van de 
algehele bevolking. Daardoor is het niet verrassend dat we de bevindingen van de GWA studie 
niet konden repliceren. 
Daarnaast hebben we ook gen-omgeving interactie analyses uitgevoerd in twee van de drie 
replicatie cohorten. Deze suggereren dat de genetische effecten in de replicatie cohorten 
worden afgezwakt doordat er een grote variatie is in fenotypes. We toonden aan dat, als we 
alleen zware rokers met COPD voor de replicatie  gebruikenn, de genetische effecten veel 
meer lijken op die gevonden in het initiële cohort (zware rokers, 50% heeft COPD). Echter, 
dat vermindert de grootte van het cohort sterk, en daardoor concluderen we dat er meer 
fenotype-specifieke cohorten nodig zijn om goede GWA studies op verval van longfunctie 
uit te voeren. 
Tot nu toe zijn er drie GWA studies op COPD gepubliceerd. Het aantal gevonden loci is echter 
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veel lager wanneer we dit vergelijken met andere fenotypes. Er is een discussie gaande over het 
zogenoemde fenomeen “missende erfelijkheid” of “verborgen erfelijkheid”. Zeer waarschijnlijk 
zullen genetische associaties niet de gehele erfelijkheid van een fenotype kunnen verklaren. 
Daarom hebben we in hoofdstuk 6 de eerste genoomwijde gen-gen interactie analyse in 
COPD uitgevoerd. Door het grote aantal uitgevoerde testen konden onze resultaten niet de 
grens van genoomwijde significantie bereiken. Het feit dat we geïmputeerde genotypes 
hebben gebruikt in het replicatie cohort kan ook het resultaat hebben beïnvloed. Echter, we 
vonden wel een duidelijke overrepresentatie van genen die betrokken zijn bij cel adhesie en 
cel communicatie pathways. Cel adhesie speelt een cruciale rol in epitheliale barriere herstel 
na weefselschade, hetgeen veel aanwezig is in COPD. Deze resultaten moeten nog verder 
gevalideerd worden in een groot COPD cohort. 
Samenvattend vormt deze thesis een onderzoek van vele fenotypes van COPD: 
luchtwegobstructie, emfyseem en verval van longfunctie. We waren niet alleen in deze fenotypes 
geïnteresseerd, maar ook in hun gedeelde genetische achtergrond. Luchtwegobstructie en 
emfyseem kunnen samen voorkomen en ondanks dat astma en COPD aparte aandoeningen 
zijn, delen ze toch vele karakteristieken. Daarom hebben we gezocht naar gemeenschappelijke 
genen die ten grondslag liggen aan deze fenotypes. We hebben vooral gebruikt gemaakt 
van GWA studies, maar we hebben ook verder gekeken middels epistase analyse. Het is van 
belang  de  gevonden pathways verder te onderzoeken, aangezien deze eerder nog niet waren 
aangemerkt als relevant voor COPD.




Praca przedstawiona w niniejszym manuskrypcie została wykonana w ramach konsorcjum 
COPACETIC, które powstało w celu odkrycia podłoża genetycznego przewlekłej 
obturacyjnej choroby płuc (POChP, z ang. Chronic obstructive pulmonary disease, COPD) oraz 
spadku funkcji płuc. Rozpoczęliśmy od genotypowania całego genomu, które dostarczyło 
szczegółowych informacji o genotypach w dużej rozdzielczości.
Rozdział 3 opisuje główne wyniki prac konsorcjum, którymi są genomowe badania asocjacyjne 
na fenotypach obstrukcji dróg oddechowych i rozedmy oraz próbę identyfikacji wspólnych 
dla tych fenotypów czynników genetycznych. Oba genomowe badania asocjacyjne nie 
wykazały żadnych istotnych statystycznie wyników, pomimo replikacji wyników w dużych 
kohortach (szczególnie w przypadku obstrukcji dróg oddechowych), co może wynikać z 
różnorodności fenotypów oraz ograniczonej mocy głównej kohorty. Badanie wspólnych 
czynników genetycznych dla obu fenotypów było trudne, wobec faktu użycia jednej kohorty. 
Z użyciem dwóch różnych metod udało nam się wskazać na tą samą ścieżkę metaboliczną, 
którą była adhezja fokalna, kluczowa w mechanizmach naprawy bariery nabłonkowej.
W Rozdziale 4 rozpatrywaliśmy tak zwaną “hipotezę holenderską” na poziomie całego genomu. W 
skrócie, hipoteza holnderska zakładała, że astma i POChP są różnymi manifestacjami tej samej 
jednostki chorobowej, a zatem mają wspólne podłoże genetyczne i czynniki środowiskowe. 
Jedynie czas i specyficzne oddziaływanie czynników genetycznych i środowiskowych 
determinuje ostateczny fenotyp. Aby udowodnić lub odrzucić tę hipotezę przeprowadziliśmy 
meta-analizę używając genomowch badań asocjacyjnych przeprowadzonych na astmi i 
POChP. Zidentyfikowaliśmy trzy loci zasocjowane z obydwoma fenotypami. Geny w tych 
loci, COMMD10 oraz DDX1, wskazują na NFκβ, który odpowiada za proces zapalny zarówno 
w astmie jak i w POChP. Procesy te różnią się, ale mogłyby zachodzić za pośrednictwem 
COMMD10 i DDX1 w obu chorobach, sugerując że hipoteza holenderska może być prawdziwa. 
Na tym etapie hipoteza ta nie może zostać ani potwierdzona ani odrzucona z pewnością.
Rozdział 5 opisuje genomowe badanie asocjacyjne zaniku funkcji płuc. Główną kohortą 
była populacja nałogowych palaczy a kohorty replikacyjne składały się z przedstawicieli 
populacji ogólnej. Co dało zauważyć się natychmiast, to różnice w skali zaniku funkcji płuc 
oraz efektów czynników genetycznych. Palacze wykazywali znacznie większy zanik funkcji 
płuc w ciągu roku, w porównaniu do populacji ogólnych i nie byliśmy w stanie zreplikować 
wyników genomowego badania asocjacyjnego. Jednakże przeprowadziliśmy dodatkowe 
analizy interakcji czynników genetycznych i środowiskowych w dwóch spośród trzech 
kohort replikacyjnych, które sugerowały „rozmycie” efektów genetycznych w kohortach 
replikacyjnych z powodu heterogenności fenotypów. Pokazaliśmy, że ograniczenie próby 
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replikacyjnej do palaczy chorych na PoChP pozwala uzyskać efekty genetyczne podobne do 
tych z kohorty głównej (palacze, 50% chorych na PoChP). Jednakże, taki zabieg znacząco 
redukuje liczebność kohorty, zatem naszym wnioskiem jest, że potrzebnych jest więcej 
kohort specyficznych dla tego fenotypu aby przeprowadzić prawidłowe genomowe badanie 
asocjacyjne zaniku funkcji płuc.
Dotychczas opublikowane został trzy genomowe badania asocjacyjne dla POChP, jednakże 
liczba odkrytych loci jest znacznie niższa w porównaniu z innymi fenotypami. Trwa debata na 
temat tak zwanej „brakującej dziedziczności” lub „ukrytej dziedziczności”. Najprawdopodobniej 
asocjacje genetyczne nie wyjaśnią całkowitej dziedziczności fenotypu. Wobec tego w 
Rozdziale 6 opisaliśmy pierwszą genomową analizę interakcji czynników genetycznych. Z 
powodu dużej liczby przeprowadzonych testów, żaden z wyników nie osiągnął istotności 
statystycznej.
Zaobserwowaliśmy zdecydowaną przewagę genów związanych z adhezją komórkową 
i komunikacją komórkową. Adhezja komórkowa odgrywa istotną rolę w naprawie bariery 
nabłonkowej po uszkodzeniu tkanki, która obficie występuje u chorych na POChP. Te wyniki 
powinny zostać potwierdzone w dużej kohorcie POChP.
Podsumowując, niniejsza praca rozpatruje kilka fenotypów POChP: obstrukcję dróg 
oddechowych, rozedmę oraz zanik funkcji płuc. Interesowały nas nie tylko same fenotypy, ale 
również ich wspólne podłoże genetyczne. Obstrukcja dróg oddechowych i rozedma mogą 
występować jednocześnie, astma i POChP mimo iż są osobnymi chorobami dzielą wiele cech, 
wobec czego poszukiwaliśmy wspólnych genów stanowiących podłoże tych fenotypów. 
Genomowe badania asocjacyjne były głównym narzędziem używanym w niniejszej pracy, 
używaliśmy również innych narzędzi, jak analiza epistazy. Ścieżki metaboliczne, które wyłaniają 
się na podstawie naszych wyników powinny być rozpatrywane w przyszłości, jako że nie 
wszystkie z nich były brane pod uwagę w kontekście POChP. 
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Thank you/Dziękuję!
Before I start listing All of You, I want to thank you All, and if by any chance your name 
is not there, please forgive me. 
Dear Supervisors, thank you for your time and effort you invested to make me a with a 
PhD degree.
Cisca, thank you for learning me to question things and to be critical. Marike, thank you 
for always being so calm, even when my adrenaline levels were sky high ;-) and for 
going with me through all my heart attacks, and we know there were quite a few of them.
Dear People from the COPACETIC consortium, without your contribution and effort it would 
not be possible to do this project. It was always very nice to meet you in Amsterdam!
Dirkje, thank you for all the warm words during all the meetings we had, your input in all 
the papers we have written together and your patience. 
Pieter, without you our COPACETIC meetings, both in Groningen and in Amsterdam would 
not be the same. I always smiled seeing your A4-sized emails, whatever was the subject 
:-)
Dear Borge, Marianne, Sune and Morten, thank you for hosting me and Mathieu in your 
Department in Herlev Hospital, we both enjoyed it and I fell in love with Kobenhavn :-) 
It was a real pleasure to work with you all the way through my PhD. 
Dear Jorgen, thank you for your invaluable input in the COPACETIC project, I always 
enjoyed your presentations.
Dear Kerrie, Morten and Kristina, the Astra-Zeneca people J it was a real pleasure to 
work with you, thank you for all the efforts to genotype samples.
Dear Hans, Ulrike, Monika, Michael and Suzanne, thank you for all your hard work you put 
to have samples and measurements ready. 
Dear Ewa, Paweł and Filip, thank you for your contribution to this project, it is nice that I 
was not the only Polish accent in it. Dear Ewa, special thank you for all the nice talks we 
had during COPACETIC meetings and for bringing sweets from Poland :-)
Dear Firdaus, you were the First to defend with COPACETIC project, congratulations and 
good luck in your future carreer. It was nice to work with you.
Dear Akkelies, thank you for always trying to cheer me up, when I was down a bit quite 
frequently :-), for your patience with me and your sense of humor. Good luck with 
everything!
Dear People from Genetica, I am not sure where to start, as there are so many of you! 
Some of you became my friends and thanks to you I will have some nice memories as 
well.
First I met you Mathieu, my dearest Grandpa J I will never forget our awesome time in the 
lab, all the evil things we did together ]:-)and all the fun we had! You were the one to 
introduce me to everyone, to show me the lab and to teach me how to do the GWAS from 
the basics! We were the dream team when it comes to Illumina assays J Further, I always 
enjoyed teasing you and I will continue doing that :-D It was also a lot of fun to visit your 
home, you have a great wife and cool kids :-)Good luck Grandpa :*
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Dear Soesie J, you are a real superstar in this department! I admire your high-heel 
walking skills. I always enjoyed our chit-chats, more or less serious conversations and 
of course dancing together under the supervision of Justyn :D Good luck with everything, 
especially with your two cute little heart-breakers ;-)
Dear Astrid, thank you for your involvement in everything! 
Dearest Secretaries, Helene, Bote, Joke and Mentje, thank you for your invaluable help in 
everything else than science, so in real life J Helene, thank you for reminding me about 
all the meetings that I forgot. Bote, thanks for all your help with Agata's books, it was a 
real drama, but we did it ;)
Dear Hayo, thank you for all nice talks we had in vicinity of the coffee machine and for 
your everyday smile :-)
Dear Marina, thank you for your patience in explaining mysteries of a Dutch bureaucracy.
Dear Jackie, thank you for all your help, not only the editorial one and for all the talks 
we had.
Dear Gerard, thank you for explaining statistical mysteries to me so well, that I was 
leaving your office always convinced that I understand and know what to do. Later it 
turned out I did not, but anyway: thank you! Also for reminding me frequently that 
smoking and piercing are bad for me :-)
My Dear, countless room mates, I had four offices in genetics, so if you were not my room 
mate, please move to the next section, as this one will be rather long.
My First office room mates, Paul and Annemike, it was nice sharing an office with 
you. I think Paul, you enjoyed it as much as I did, hence you moved to the second office 
with me ;) Annemike, we were both newbees back then, sharing fears and some problems. 
I enjoyed our lunch time together later on :-) Good luck with your PhD, I am sure you 
will be done soon, and your further scientific career.
My Second office room mates, Paul, Mats, Gosia, Jihane, Agata, Lude. Paul, it was 
a real fun, I enjoyed your jokes and sense of humor. Mats, you sure talk a lot, but it was 
still a pleasure :-)good luck in Sweden! Gosia, I hated your squirrel or whatever that shit 
was :-D Thanks for all the help with GWAS/Linux and good luck in Boston. Jiji, thanks for 
everything! You were there when I cried, when I laughed, always trying to calm me down 
when necessary. I will always remember you walking with your awesome hair, shining in 
the sun, with one of your countless bags and sunglasses of course! Gosia and Jiji, thanks 
for printing your books with Eikon, that was foundation for my company!
Agata, as a room mate I nearly hated you, and you already know that, so find yourself 
in the next section, as in this one I have nothing nice to say ;-P
My third office room mates, Yun-cute, Rodrigo, Senapati, Mitja, Rajendra and 
Omid. Guys, I had fun sharing this office with you, I think I helped each of you with 
something, so in fact you should consider yourselves lucky to have me there ;-D Rodrigo: 
pills!
Yunia, my Yun-cute, you were always looking for recipes exactly when I was hungry, recipes 
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with pictures of course, to make me suffer even more :-D But even though I enjoyed 
sharing the office with you :D Good luck in Rotterdam and further, wherever you go!
My fourth and last office room mates, Barbara, Pumpkin and Cleo, you had this 
bad luck of sharing an office with me when the time was the most difficult - the end of my 
endless PhD. I thank you all and one by one for going through all the dramas with me, 
whether you wanted or not. You bravely dealt with all the swearing, tears, more swearing 
and more tears. 
B, you are, I think, one of the most positive persons I know. No matter what happens you 
always see the bright side and you don't worry that much, I would love to have this skill. So 
keep it this way as long as you can. STERKTE and GEOEDE luck with everything! 
Pumpkin, my Evil Pumpkin, I have no words to express how severely disturbed you are :-D 
You are the craziest person I have met in the Netherlands, you are unpredictable in both, 
your words and actions :-D But even with these minor [honestly, they are not so minor] 
flaws ;-) you are simply a good friend, who will listen, understand and help to find a 
solution. I will miss you Pumpkin! Take care of Shieldpad ;-)
Dear Shieldpad, thanks to you a ''Genius of the day'' trophy was born :-D It was 
always fun to go for lunch with you and Pumpkin and talk about all this more and less 
[mostly less] serious stuff :-)
Dear Isis, I am so proud of you! Thank you for participating in the Glamour Day, 
despite your disability to wear high heels :-) Supervising you in a non-scientific matters 
was a real pleasure. And you brought pigs for me, for which I will be grateful forever :-D
Anna P. thanks for all the delicious things you brought from Hungary and for 
your help when Marcin was arranging the stay in Budapest! Remember: Polak, Węgier dwa 
bratanki!
Dear Duco, you left to a different department, I blame Agata for that :-D it is a 
miracle that you have been able to stay in the same office with her + two other crazy girls 
for so long ;-) You are a really nice guy, thing I found uncommon in the Netherlands. 
So do not change! And good luck with your PhD!
Dear Helga, thank you for your LAUGH, whenever I heard it I was laughing myself, 
it is one of the most infectious laughs I have heard in my life :-D I like your mean and 
evil sense of humor, similar to mine :-D 
Dear Dineke, even though you think yoga is nothing, I still would like to thank you 
for discussions over lunch and all the fun associated with it od luck with your career, both, 
as a scientist and as a mom J
Dear Cleo, you are certainly the coolest post-doc I have ever met! I think I saw 
you angry only once during these five years, you take things with ease and do not make 
that much drama... Thanks for the positive energy!
I would also like to thank remaining people from the bright side of the corridor: 
Ettje, Javier, Olga, Alejandro, Anna D, Eva, Ellen, Helen, Rene, Wytske, Michiel. Thank you 
for nice time, I enjoyed eating and smoking with you :-D Also those who moved from 
Groningen already, Ana F, Maria and Kaushal all the best! Robert thank you for your 
jokes, smile and shirts.
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Dear People from the Dark Side of the Corridor :-D 
Dear George, always a pleasure talking to you about anything, thanks for all the 
help with EpiBLASTER, together with Marcel!
Juha! Thanks for your help with Lovebird 's web and for making the coolest contact 
form ever! I am also grateful you introduced me to climbing, it really helped me at the 
difficult period of the never-approaching end of my PhD ;-) 
Jing-yan! Thank you for always finding time to help me solve the mysteries of R 
and for translating the Chinese article for my review :-)
Freerk! Thanks for all the talks, those with sense and those with complete lack of 
it, and the nice trip to Berlin it was fun! Good luck with your career and see you at some 
festival one day I guess ;-)
Harm-Jan and Lude, thanks for all the help with imputations, eQTLs and other 
hard-core genetic stuff.
Alex and Despoina, thanks for your crazy sense of humor and huge distance to 
the surrounding reality!
Dear Epi people, 
Thank you for the nice atmosphere at the unit meetings, all your help and time, 
especially Judith and Marjan, Simona, Kim, Nienke and Despo, we had a lot of fun in 
Barcelona, I enjoyed it a lot, Niloofar, good luck with your thesis, I keep my fingers 
crossed. Petra, you were always very helpful and I think one of the most positive and 
optimistic people I have met in the Netherlands! Thanks for your everyday smile!
Salome, thanks for always listening to me, I could always talk to you about the 
dark sides of science and you understood it very well. I hope I was not too irritating 
visiting the ''Monster'' form time to time ;-)
Dear Jan, thank you for introducing me to the R world, for all your help, for many 
tea cups we had together and for your patience with me. 
Dear Marjolein, I would like to thank you for all the yoga classes, you have no idea how 
much they helped me to survive the hardest moments in the Netherlands. You introduced 
me to Ashtanga yoga, for which I will be grateful forever, as it became my real passion. 
Thank you for always trying to come up with something extra challenging for me! :-)
Dziękuję rodzicom, za ich wsparcie, za zawsze ciepłe powitanie przy krótkich 
powrotach do domu. Dziękuję Mamuś za tysiące pierogów i krokietów, które ulepiłaś dla 
mnie i dla innych, bo wiesz, że zawsze się dzielę! Tato, dziękuję za pomoc przy rowerze, przy 
innych sprawach, nie tylko technicznych i za sukienkę na obronę!
Pawełku, Garbiku, dziękuję, że zawsze odwoziłeś mnie z tobołami na lotnisko i 
odradzałeś powrót do Polski :-P wróciłam, bo się nie słucham młodszych!
 Bobki, dzięki za wszystkie przygody, te w Holandii, w Polsce i w innych miejscach 
na świecie! Dzięki za pomoc przy przeprowadzkach, wsparcie mentalne i po prostu piękną 
przyjaźń, której nawet pobyt w tym przebrzdłym kraju nie zniszczył!
Czubu i Lalu, Wy zawsze znalazłyście dla mnie czas, żeby spotkać się choć na 
chwilę. Dziękuję za wszystkie wieczory/noce przegadane do rana, za wysłuchiwanie moich 
narzekań, za zwalczanie mojej depresji!
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Dziękuję też innym, którzy zawsze umilali mi czas w Polsce. Aśka W ,teraz już 
S., dzięki że zawsze wpadałaś na piwo, dopóki mogłaś, że wysłuchałaś. Dziadu! U Ciebie 
zawsze czas jakoś inaczej płynie, wpada człowiek na chwilę, a tu noc go zastaje :-D Dzięki 
za powrót do dzieciństwa, czasu dinozaurów, Czarodziejki z Księżyca i innych! Michał, 
Krzwy, Natalia, Rychu, Grzesiek, Andrzej: dzięki za wszystkie wieczory z grami, hulankami 
i swawolami, sylwestry, woodstocki i inne :-)
Dziękuję rodzicom Marcina, Elżbiecie i Czesławowi, za to, że pozwolili mi porwać ich 
syna ;-) oraz całej rodzinie Kępińskich za akceptację, wsparcie i gościnę oraz za mile 
spędzony razem czas: Kasi, Mirkowi, Wojtkowi, Ewie i Bartkowi, cioci Ani i wujkowi Jankowi 
oraz babci Józefie. 
Justyn, dzięki za wspólne mieszkanie, narzekanie oraz znoszenie mojego 
narzekania, którego było zawsze najwięcej :-D, za rysowanie, razem miałyśmy ten jakże 
owocny ''okres holenderski''w twórczości :-D i za Reggeaton i za break dance i za wszystkie 
kawy i fajki na przerwach. Tonka! Tobie również dzięki za wspólne mieszkanie, za poranne 
dyskusje, wiem, że czasem było ciężko ;-) ale dałyśmy radę, Pamiętaj, że masz przepiękne 
włosy! Fajnie było poznać Twoich rodziców i posłuchać opowieści o Chorwacji! Przy okazji 
pozdrowienia!
Gosia, dzięki za wspólnie spędzony czas, czy to w NL czy to w PL, zawsze fajnie wyjść 
razem na piwko :-)Dbaj o naszą Babcię Snoepcię, łooohohohoho.
Albert, Dimer and Remco, thanks for all the biertjes, parties, dinners, concerts 
and stuff! It was always a lot of fun. Albert, thanks for teaching me the basics of HTML and 
CSS and for rescuing the computer in Epi :-)
Anno! Zawsze miło było zjeść z Tobą lunch i pogadać o dramatach większych 
i mniejszych :-)przebrnęłyśmy przez ten doktorancki koszmar! Dzięki też za druk z 
Lovebird! Zaszalałyśmy z groszkami! 
Sąsiedzi! Paulina i Łukasz, Ciocia i Wujek samo zło! Dzięki za wszystkie imprezy 
spędzone razem, te niezliczone ilości alkoholu wypite i te przetańczone na macie godziny 
:-D zawsze był z Wami ubaw, mam nadzieję, że będziemy kontynuować w Polsce. Wspólne 
narzekanie i naśmiewanie się z holendrów było czystą przyjemnością! Złośliwce :-P 
Paulinko, Tobie szczególnie dziękuję za rycie mi beretu podczas jazdy rowerem! nie prędko 
Ci to zapomnę :-P
 Mahdo i Lamusie, although we met in fact few times, I always enjoyed it and had 
a lot of fun with you, Good luck my sweetest Lamusy! Kisses :*
 Snoepje, moja Ty wielokrotnie invited speaker, moja Ty Noblistko, mój Ty Człowieku-
Ekierko! nie wiem co Ci mam tu pisać, wszystko wiesz już dawno, a może lepiej nie pisać tu 
nic, żebyś mi później nie pier$%#nęła tą książką w twarz :-D a napiszę, co mi tam! Jesteś 
najbardziej porytą osobą jaką znam :-D I za to Cię uwielbiam! Twój fazowy śmiech zawsze 
doprowadza mnie do łez :-D 
Canard, despite the fact that you are Frunch, I always enjoyed quacking with you 
:-D I think I have never talked about so much bullshit with anyone else :-D it was like 
therapy! I hope one day you will make friends with email or other means of contacting 
people and that we can be in touch! How is Lulu? :P , 
Valentin, thanks for taking care of Agata, I know this is not so easy sometimes 
;-) I really like your sense of humor, your passion for bigos and your elephantness :-D 
Thanks for driving with me this summer and for really nice holidays!
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Agata, Habibąku! Tobie to osobny rozdział musiałabym chyba poświęcić, żeby Ci 
podziękować za wszystko. Przede wszystkim dziękuję, za znoszenie moich szlochów, ile łez 
Ci ja przed Koleżanką wylałam! Za słuchanie o patologiach mego życia i umysłu, za 
wsparcie, za opieprzanie kiedy trzeba, a trzeba było parę razy :-P Za wszystkie wieczory 
z ''pazgnokciami'' :-D za ziółka, za zupę z pieca, za Twoją dysleksję Ci nawet dziękuję, bo 
niejednokrotnie ubawiła mnie do łez. Dziękuję za wspólne trwonienie pieniędzy jak były :-D 
za wszystkie koncerty, za wszystkie wypady, za sesje edukacyjne o chorobach przenoszonych 
drogą płciową, o drugiej wojnie światowej i wielu innych. Dziękuję po prostu za przyjaźń, za 
to, że zawsze jesteś i zawsze wysłuchasz. Mam nadzieję, że znajdziesz wkrótce wymarzoną 
pracę i że po prostu będzie dobrze, bo kiedyś musi być. 
Dziękuję również Zofii, za zrozumienie bez słów jeśli chodzi o Habibąkowe sprawy 
:-D I ogólny ubaw jaki zwykle razem mamy, Dziękuję Małgorzacie, mamie Agaty, za zawsze 
mile spędzony czas i gościnę i Krzysztofowi, za miłe rozmowy na balkonie oraz cierpliwość 
podczas szukania Agaty na lotnisku!
Misiaku Mój :* Tobie dziękuję najbardziej ze wszystkich, bo to Ty pomogłeś mi 
przetrwać te pięć lat. Przede wszystkim dziękuję, że nie posłuchałeś mnie na imprezie w 
kinie i że znając mnie tak krótko zdecydowałeś się na przyjazd do Holandii ze mną, czego 
pewnie czasem żałowałeś.. Pamiętam początki, które nie były łatwe, ale daliśmy radę, 
jak ze wszystkim! Twoja cierpliwość do mnie, mnie samą zadziwia. Dziękuję Ci za ciągłe 
wsparcie, podnoszenie mnie na duchu i przywracanie wiary we własne siły i umiejętności, 
za Twój optymizm zwalczający mój skrajny realizm zwany potocznie pesymizmem. Dziękuję, 
za to, że dbasz o mnie (ą), że pozwalasz zabrać całą kołdrę i że jesteś taki, a nie inny. 
Uwielbiam Cię najbardziej na świecie! :*
I would like to make special thanks for everyone who helped me with my company, 
Lovebird design & printing solutions and all the people who decided to print their books 
with me! 
Dziękuję drukarni Eikon Plus za owocną współpracę, zwłaszcza Dominikowi Sieńko, 
za wprowadzenie mnie w tajniki druku oraz Pawłowi Gietce, za cierpliwość i odpowiadanie na 
moje niezliczone pytania, zawsze ogromne wsparcie przy realizacji moich nieszablonowych 
pomysłów (udało się tylko z wizytówką ;-P), a także za ubaw na Skype :-)
Nobody else seems to do that, but I would also like to thank myself, for being 
stubborn or stupid enough (time will show) to finish this PhD. 
Once again, thank you all, do not take it personally if you are not listed here.
Dziękuję, Dank je, Gracias, etc.
Asia
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